BINDING DOMAINS FROM PLASMODIUM VIVAX AND PLASMODIUM FALCIPARUM ERYTHROCYTE BINDING PROTEINS

Abstract: The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the DBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.

Description: BIMDIBIG DOMAINS FROM PLASMODIUM VIVAX Mto PLASMODIUM FALCIPARUM ERYTHROCYTE BINDING PROTEINS BACKGROUND OF THE INVENTION Malaria infects 200 - 400 million people each year causing 1-2 million deaths, thus remaining one of the most important infectious diseases in the world. Approximately 25 percent of all deaths of children in rural Africa between the ages of one and four years are caused by malaria. Due to the importance of the disease as a worldwide health problem, considerable effort is being expended to identify and develop malaria vaccines. Malaria in humans is caused by four species of the parasite Plasmodiυm: P. falciparum, P. vivax, P. knowlesi and P. malariae. The major cause of malaria in humans is P. falciparum which infects 200 million to 400 million people every year, killing 1 to 4 million. Duffy Antigen Binding Protein (DABP) and Sialic Acid Binding Protein (SABP) are soluble proteins that appear in the culture supernatant after infected erythrocytes release merozoites. Immunochemical data indicate that DABP and SABP which are the respective ligands for the P. vivax and P. falciparum Duffy and sialic acid receptors on erythrocytes, possess specificities of binding which are identical either in soluble or membrane bound form. DABP is a 135 kDa protein which binds specifically to Duffy blood group determinants (Wertheimer et al., Exp. Parasitol. 69: 340-350 (1989); Barnwell, et al., J. Exp. Med. 169: 1795-1802 (1989)). Thus, binding of DABP is specific to human Duffy positive erythrocytes. There are four major Duffy phenotypes for human erythrocytes: Fy(a), Fy(b), Fy(ab) and Fy(negative), as defined by the anti-Fy a and anti-Fy b sera (Had*ey et al., In Red Cell Antigens and Antibodies, G. Garratty, ed. (Arlington, Va.:American Association of Blood Banks) pp. 17-33 (1986)). DABP binds equally to both Fy(a) and Fy(b) erythrocytes which are equally susceptible to invasion by P. vivax; but not to Fy(negative) erythrocytes. In the case of SABP, a 175kDa protein, binding is specific to the glycophorin sialic acid residues on erythrocytes (Camus and Hadley, Science 230:553-556 (1985); Orlaπdi, et al., J. Cell Biol. 116:901-909 (1992)). Thus, neuraminidase treatment (which cleaves off sialic acid residues) render erythrocytes immune to P. falciparui. invasion. The specificities of binding and correlation to invasion by the parasite thus indicate that DABP and SABP are the proteins of P. vivax and P. falciparum which interact with sialic acids and the Duffy antigen on the erythrocyte. The genes encoding both proteins have been cloned and .the DNA and predicted protein sequences have been determined (B. Kim Lee Sim, et al., J. Cell Biol. 111: 1877-1884 (1990); Fang, X.. et al., Mol. Biochem Parasitol. 44: 125-132 (1991)). Despite considerable research efforts worldwide, because of the complexity of the Plasmodium parasite and its interaction with its host, it has not been possible to discover a satisfactory solution for prevention or abatement of the blood stage of malaria. Because malaria is a such a large worldwide health problem, there is a need for methods that abate the impact of this disease. The present invention provides effective preventive and therapeutic measures against Plasmodium invasion. -2- SUMMARY OF THE INVENTION The present invention provides compositions comprising an isolated DABP binding domain polypeptides and/or isolated SABP binding domain polypeptides. The DABP binding domain polypeptides preferably comprise between about 200 and about 300 amino acid residues while the SABP binding domain polypeptides preferably comprises between about 200 and about 600 amino acid residues. A preferred DABP binding domain polypeptide has about 325 residues of the amino acid sequence found in SEQ ID N0:2. A preferred SABP binding domain polypeptide has about 616 residues of the amino acid sequence of SEQ ID N0:4, encoded by the DNA sequence of SEQ ID NO: 3. The preferred DABP binding domain and SABP binding domain include the cysteine-rich portions of the proteins shown in Figure 1. The present invention also includes pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an isolated DABP binding domain polypeptide in an amount sufficient to induce a protective immune response to Plasmodium vivax merozoites in an organism. In addition, isolated SABP binding domain polypeptide in an amount sufficient to induce a protective immune response to Plasmodium falciparum may be added to the pharmaceutical composition. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an isolated SABP binding domain polypeptide in an amount sufficient to induce a protective immune response to Plasmodium falciparum merozoites in an organism. In addition, isolated DABP binding domain polypeptide in an amount sufficient to induce a protective immune response to Plasmodium vivax may be added to the pharmaceutical composition. Isolated polynucleotides which encode a DABP binding domain polypeptides or SABP binding domain polypeptides are also disclosed. In addition, the present invention includes a recombinant cell comprising the polynucleotide encoding the DABP binding domain polypeptide. The current invention further includes methods of inducing a protective immune response to Plasmodium merozoites in a patient. The methods comprise administering to the patient an immunologically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated DABP binding domain polypeptide, an SABP binding domain polypeptide or a combination thereof. The present disclosure also provides DNA sequences from additional P. falciparum genes in the Duffy-binding like (DBL) family that have regions conserved with the P. falciparum 175 kD and P. vivax 135 kD binding proteins. DEFINITIONS As used herein a "DABP binding domain polypeptide" or a "SABP binding domain polypeptide" are polypeptides substantially identical (as defined below) to a sequence from the cysteine-rich, amino-terminal region of the Duffy antigen binding protein (DABP) or sialic acid binding protein (SABP), respectively. Such polypeptides are capable of binding either the Duffy antigen or sialic acid residues on glycophorin. In particular, DABP binding domain polypeptides consist of amino acid residues substantially similar to a sequence of SABP within a binding domain coπtaining the cysteine-rich sequence shown in Figure 1. SABP binding domain polypeptides consist of residues substantially similar to a sequence of DABP within a binding domain containing the cysteine-rich sequence shown in Figure 1. The binding domain polypeptides encoded by the genes of the DBL family consist of those residues substantially identical to the sequence of the binding domains of DABP and SABP as defined above. The DBL family comprises sequences with substantial similarity to the conserved regions of the DABP and SABP. These include those sequences reported here as ebl-1 (SEQ ID N0:5 and SEQ ID N0:6), E31a (SEQ ID N0:7 and SEQ ID N0:8), var- 7 (SEQ. ID. N0:13 and SEQ. ID. N0:14, GenBank Accession No. L42636) and var l (SEQ. ID. N0:15 and SEQ ID N0:16, GenBank Accession No. L40608). The sequence ebl-2, (SEQ ID N0:9 and SEQ ID N0:10) represents the binding domains of var-7, and Proj3 (SEQ ID N0:11 and SEQ ID N0:12) is the binding domain of var l. The DBL family also includes two other members var-2 and var-3 (GenBank Accession No. L40609). The polypeptides of the invention can consist of the full length binding domain or a fragment thereof. Typically DABP binding domain polypeptides will consist of from about 50 to about 325 residues, preferably between about 75 and 300, more preferably between about 100 and about 250 residues. SABP binding domain polypeptides will consist of from about 50 to about 616 residues, preferably between about 75 and 300, more preferably between about 100 and about 250 residues. Particularly preferred polypeptides of the invention are those within the binding domain that are conserved between SABP and the DBL family. Residues within these conserved domains are shown in Figure 1, below. Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues in the two sequences is the same when aligned for maximum correspondence. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Adv. Appl. Math. 2: 482 (1981 ), by the homology alignment algorithm of Needlemaπ and Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection. The term "substantial identity" means that a polypeptide comprises a sequence that has at least 80% sequence identity, preferably 90%, more preferably 95% or more, compared to a reference sequence over a comparison window of about 20 residues to about 600 residues-- typically about 50 to about 500 residues usually about 250 to 300 residues. The values of percent identity are determined using the programs above. Particularly preferred peptides of the present invention comprise a sequence in which at least 70% of the cysteine residues conserved in DABP and SABP are present. Additionally, the peptide will comprise a sequence in which at least 50% of the tryptophan residues conserved in DABP and SABP are present. The term substantial similarity is also specifically defined here with respect to those amino acid residues found to be conserved between DABP, SABP and the sequences of the DBL family. These conserved amino acids consist prominently of tryptophan and cysteine residues conserved among all sequences reported here. In addition the conserved amino acid residues include phenylalanine residues which may be substituted with tyrosine. These amino acid residues may be determined to be conserved after the sequences have been aligned using methods outlined above by someone skilled in the art. Another indication that polypeptide sequences are substantially identical is if one protein is immunologically reactive with antibodies raised against the other protein. Thus, the polypeptides of the invention include polypeptides immunologically reactive with antibodies raised against the SABP binding domain, the DABP binding domain or raised against the conserved regions of the DBL family. Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5° C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent conditions will be those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 60°C. Nucleotide sequences are also substantially identical for purposes of this application when the polypeptides which they encode are substantially identical. Thus, where one nucleic acid sequence encodes essentially the same polypeptide as a second nucleic acid sequence, the two nucleic acid sequences are substantially identical, even if they would not hybridize under stringent conditions due to silent substitutions permitted by the genetic code (see, Darnell et al. (1990) Molecular Cell Biology, Second Edition Scientific American Books, W.H. Freeman and Company, New York, NY, for an explanation of codon degeneracy and the genetic code). The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the binding domain polypeptides of this invention do not contain materials normally associated with their in situ environment, e.g., other proteins from a merozoite membrane. Typically, isolated proteins of the invention are at least about 80% pure, usually at least about 90%, and preferrably at least about 95% as measured by band intensity on a silver stained gel. Protein purity or homogeneity may be indicated by a number of means well known in the art, such as polyacryla ide gel electrophoresis of a protein sample, followed by visualization upon staining. For certain purposes high resolution will be needed and HPLC or a similar means for purification utilized. The term "residue" refers to an amino acid (D or L) or amino acid mimetic incorporated in a oligopeptide by an amide bond or amide bond mimetic. An amide bond mimetic of the invention includes peptide backbone modifications well known to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 represents an alignment of the predicted amino acid sequences of the DABP binding domain (Vivax) (SEQ ID N0:25), the two homologous SABP domains (SABP F1 (SEQ ID N0.:26) and SABP F2 (SEQ ID N0:27)) and the sequenced members of the DBL gene family (ebl-1 (SEQ ID N0:28), E31 a (SEQ ID N0:29), EBL-2 (SEQ ID N0:30)) and the three homologous Proj3 domains (F1 (SEQ ID N0:31), F2 (SEQ ID N0:32) and F3 (SEQ ID N0:33». Figure 2 represents a schematic of the pRE4 cloning vector. Figure 3 shows primers useful for isolating sequences encoding the conserved motifs of the invention. Primers UNIEBP5 (SEQ ID N0:35) and UNIEBP5A (SEQ ID N0:36) encode the amino acid sequence of SEQ ID N0:34; primers UNIEBP5B (SEQ ID N0:38) and UNIEBP5C (SEQ ID N0.39) encode the amino acid sequence of SEQ ID N0:37; primers UNIEBP3 (SEQ ID N0:41) and UNIEBP3A (SEQ ID N0.42) encode the amino acid sequence of SEQ ID N0:40; and primers UNIEBP3B (SEQ ID N0:44) and UNIEBP3C (SEQ ID N0:45) encode the amino acid sequence of SEQ ID N0:43. Figure 4 shows the relative position of the E31 a ORF on chromosome 7. Figure 5 shows a map of a var gene cluster on chromosome 7. Relative positions of four YACs (PfYEF2, PfYFE6, PfYKFδ, PfYED9) are indicated under the chromosome 7 line at the top of the figure. YACs PfYFE6 and PfYKFδ lie entirely within a segment linked to CQR in a genetic cross, whereas YACs PfYED9 and PfYEF2 extend beyond sites (identified by pE53a and pH270.5) that are dissociated from the chloroquine response. The var cluster extends over a region of 100-150 kb in PfYED9. Exons and introns of the var l, var-2 and var-3 genes within the sequenced 40 kb segment are represented by solid and dotted lines, respectively; arrows show the coding direction. Two more var elements outside of the sequenced region, identified by conserved restriction sites and cross- hybridization, are indicated by dashed-lines (var-2c and var-3c). Bold letters mark repeated restriction sites that suggest a duplication in the var-2/var-3 and var-2c/var-3c segments. Enzyme recognition sites: A, ApaV, B, BgΛ; C, ClaV, D, HinάWV, E, HaeWV, H, BssWV, K, KpnV, M, BamWV, P, HpaV, S, Sma\. Hinά\\\ and HaeWl sites outside of the sequenced region were not mapped. Positions and sizes of inserts from the Dd2 subsegment library are indicated: a, pE280b; b, pB20.3; c, pB600; d, pE21b; e, pB20.24; f, pE32b; h, pE241 a; i, pE240a/51d; j, pE33a; k, pB20.23; I, IL17BA6; m, pB20.26; n, pB20SU.27; o, p15J2J3. Inserts from the PfYED9 34 kb Apa\ Sma\ fragment library: r, pB3; s, p3G11; t, pJVs; u, p2E10; v, plG3; w, p2E3; x, p2B6; y, PE10; z, pJYr; α, pC5; β, p1A3; y, p1 F6; δ, p3C3; e, pA2; ζ, p2A9; η, p3C4; θ, pJZn; K, p3D8. DESCRIPTION OF THE PREFERRED EMBODIMENT The binding of merozoites and schizonts to erythrocytes is mediated by specific binding proteins on the surface of the merozoite or schizont and is necessary for erythrocyte invasion. In the case of P. falciparum, this binding involves specific interaction between sialic acid glycophorin residues on the erythrocyte and the sialic acid binding protein (SABP) on the surface of the merozoite or schizont. The ability of purified SABP to bind erythrocytes with chemically or enzymatically altered sialic acid residues paralleled the ability of P. falciparum to invade these erythrocytes. Furthermore, sialic acid deficient erythrocytes neither bind SABP nor support invasion by P. falciparum. The DNA encoding SABP from P. falciparum has also been cloned and sequenced. Iπ P. vivax, specific binding to the erythrocytes involves interaction between the Duffy blood group antigen on the erythrocyte and the Duffy antigen binding protein (DABP) on the merozoite. Duffy binding proteins were defined biologically as those soluble proteins that appear in the culture supematant after the infected erythrocytes release merozoites which bind to human Duffy positive, but not to human Duffy negative erythrocytes. It has been shown that binding of the P. vivax DABP protein to Duffy positive erythrocytes is blocked by antisera to the Duffy blood group determinants. Purified Duffy blood group antigens also block the binding to erythrocytes. DABP has also been shown to bind Duffy blood group determinants on Western blots. Duffy positive blood group determinants on human erythrocytes are essential for invasion of human erythrocytes by Plasmodium vivax. Both attachment and reorientation of P. vivax merozoites occur equally well on Duffy positive and negative erythrocytes. A junction then forms between the apical end of the merozoite and the Duffy-positive erythrocyte, followed by vacuole formation and entry of the merozoite into the vacuole. Junction formation and merozoite entry into the erythrocyte do not occur on Duffy negative cells, suggesting that the receptor specific for the Duffy determinant is involved in apical junction formation but not initial attachment. The DNA sequences encoding the DABP from P. vivax and P. knowlesi have been cloned and sequenced. P. vivax red cell invasion has an absolute requirement for the Duffy blood group antigen. Isolates of P. falciparum, however, vary in their dependency on sialic acid for invasion. Certain P. falciparum clones have been developed which invade sialic acid deficient erythrocytes at normal rates. This suggests that certain strains of P. falciparum can interact with other ligands on the erythrocyte and so may possess multiple erythrocyte binding proteins with differing specificities. A basis for the present invention is the discovery of the binding domains in both DABP and SABP. Comparison of the predicted protein sequences of DABP and SABP reveals an amino-terminal, cysteine-rich region in both proteins with a high degree of similarity between the two proteins. The amino-terminal, cysteine-rich region of DABP contains about 325 amino acids, whereas the amino-terminal, cysteine-rich region of SABP contains about 616 amino acids. This is due to an apparent duplication of the amino-terminal, cysteine-rich region in the SABP protein. The cysteine residues are conserved between the two regions of SABP and DABP, as are the amino acids surrounding the cysteine residues and a number of aromatic amino acid residues in this region. The amino-terminal cysteine rich region and another cysteine-rich region near the carboxyl-terminus show the most similarity between the DABP and SABP proteins. The region of the amino acid sequence between these two cysteine-rich regions show only limited similarity between DABP and SABP. Other P. falciparum open reading frames and genes with regions that have substantial identity to binding domains of SABP and DABP have been identified. Multiple copies of these sequences exist in the parasite genome, indicating their important activity in host-parasite interactions. A family of these sequences (the DBL family) have been cloned from chromosome 7 subsegment libraries that were constructed during genetic studies of the chloroquine resistance locus (Wellems et. al., PNAS 88: 3382-3386 (1991)). Certain of these transcripts are known to be from the var family of genes that modulate cytoadherence and antigenic variation of P. falciparum- infected erythrocytes (see, Example 3, below). Genes of the P. falciparum var family encode 200-350 kD variant surface molecules that determine antigenic and adhesive properties of parasitized erythrocytes. The large repertoire of var genes (50-150 copies, having sufficient DNA to account for 2-6% of the haploid genome), the dramatic sequence variation among the gene copies, their variable expression in different parasite lines, the ready detection of DNA rearrangements, and the receptor binding features of the encoded extracellular domains all implicate var genes as the major determinants of antigenic variation and cytoadherence in P. falciparum malaria. A second class of ZrøZ-encoding transcripts includes single-copy genes such as ebl-1. Genetic linkage studies have placed this gene within a region of chromosome 13 that affects invasion of malarial parasites in human red blood cells (Wellems et al., Cell 49:633-642 (1987)). Both SABP and ebl-1 show restriction patterns that are well conserved among different parasite isolates. This conservation of gene structure and the sequence relationships between the ebl l and SABP domains suggest that ebl l encodes a novel erythrocyte binding molecule having receptor properties distinct from those of SABP. Southern hybridization experiments using probes from these open reading frames have indicated that additional copies of these conserved sequences are located elsewhere in the genome. The largest of the open reading frames on chromosome 7 is 8 kilobases and contains four tandem repeats homologous to the N-terminal, cysteine-rich unit of SABP and DABP. Figure 1 represents an alignment of the DBL family with the DABP binding domain and two homologous regions of SABP (F*| and F 2 ). The DBL family is divided into two sub-families to achieve optimal alignment. Conserved cysteine residues are shown in bold face and conserved aromatic residues are underlined. The polypeptides of the invention can be used to raise monoclonal antibodies specific for the binding domains of SABP, DABP or the conserved regions in the DBL gene family. The antibodies can be used for diagnosis of malarial infection or as therapeutic agents to inhibit binding of merozoites to erythrocytes. The production of monoclonal antibodies against a desired antigen is well known to those of skill in the art and is not reviewed in detail here. The multitude of techniques available to those skilled in the art for production and manipulation of various immunoglobulin molecules can thus be readily applied to inhibit binding. As used herein, the terms "immunoglobulin" and "antibody" refer to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. Immunoglobulins may exist in a variety of forms besides antibodies, including for example, Fv, Fab, and F(ab) 2 , as well as in single chains. For a general review of immunoglobulin structure and function see, Fundamental Immunology, 2d Ed., W.E. Paul ed., Ravens Press, N.Y., (1989). Antibodies which bind polypeptides of the invention may be produced by a variety of means. The production of non-human monoclonal antibodies, e.g., murine, lagomorpha, equine, etc., is well known and may be accomplished by, for example, immunizing the animal with a preparation containing the polypeptide. Antibody-producing cells obtained from the immunized animals are immortalized and screened, or screened first for the production of antibody which inhibits binding between and meroxoites and erythrocytes and then immortalized. For a discussion of general procedures of monoclonal antibody production see Harlow and Lane, Antibodies, A Laboratory Manual Cold Spring Harbor Publications, N.Y. (1988). Thus, the present invention allows targeting of protective immune responses or monoclonal antibodies to sequences in the binding domains that are conserved between SABP, DABP and encoded regions of the DBL family. Identification of the binding regions of these proteins facilitates vaccine development because it allows for a focus of effort upon the functional elements of the large molecules. The particular sequences within the binding regions refine the target to critical regions that have been conserved during evolution, and are thus preferred for use as vaccines against the parasite. The genes of the DBL family (which have not previously been sequenced) can be used as markers to detect the presence of the P. falciparum parasite in patients. This can be accomplished by means well known to practitioners in the art using tissue or blood from symptomatic patients in PCR reactions with oligonucleotides complementary to portions of the genes of the DBL family. Furthermore, sequencing the DBL family provides a means for skilled practitioners to generate defined probes to be used as genetic markers in a variety of applications. Additionally, the present invention defines a conserved motif present in, but not restricted to other members of the subphylum Apicompiexa which participates in host parasite interaction. This motif can be identified in Plasmodium species and other parasitic protozoa by the polymerase chain reaction using the synthetic oligonucleotide primers shown in Figure 3. PCR methods are described in detail below. These primers are designed from regions in the conserved motif showing the highest degree of conservation among DABP, SABP and the DBL family. Figure 3 shows these regions and the consensus amino acid sequences derived from them. A. General Methods Much of the nomenclature and general laboratory procedures required in this application can be found in Sambrook, et al., Molecular Cloning A Laboratory Manual, 2nd Ed., Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989. The manual is hereinafter referred to as "Sambrook, et al., 1989." The practice of this invention involves the construction of recombinant nucleic acids and the expression of genes in transfected cells. Molecular cloning techniques to achieve these ends are known in the art. A wide variety of cloning and in vitro amplification methods suitable for the construction of recombinant nucleic acids are well-known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 Academic Press, Inc., San Diego, CA (Berger); and Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel). Examples of techniques sufficient to direct persons of skill through in vitro amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q ?-replicase amplification and other RNA polymerase mediated techniques are found in Berger, Sambrook et al., 1989, and Ausubel, as well as Mullis et al., (1987) U.S. Patent No. 4,683,202; PCR Protocols A Guide to Methods and Applications (Innis et al. eds). Academic Press Inc., San Diego, CA, 1990) ("Innis"); Arnheim & Levinson (October 1, 1990) C&EN 36-47; The Journal Of NIH Research (1991) 3, 81-94; Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86, 1173; Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87, 1874; Lomell et al. (1989) J. Clin. Chem 35, 1826; Landegren et al., (1988) Science 241, 1077-1080; Van Brunt (1990) Biotechnology %, 291-294; Wu and Wallace, (1989) Gene 4, 560; and Barriπger et al. (1990) Gene 89, 117. Improved methods of cloning in vitro amplified nucleic acids are described in Wallace et al., U.S. Pat. No. 5,426,039. The culture of cells used in the present invention, including cell lines and cultured cells from tissue or blood samples is well known in the art. Freshπey (Culture of Animal Cells, a Manual of Basic Technique, third ed., Wiley-Liss, New York, NY (1994)) and the references cited therein provides a general guide to the culture of cells. DBL genes are optionally bound by antibodies in one of the embodiments of the present invention. Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press, NY; Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975) Nature 256: 495-497. Other suitable techniques for antibody preparation include selection of libraries of recombinant antibodies in phage or similar vectors. See, Huse et al. (1989) Science 246: 1275-1281; and Ward, et al. (1989) Nature 341: 544-546. Specific Monoclonal and polyclonal antibodies will usually bind with a KD of at least about .1 mM, more usually at least about 1 μM, and most preferably at least about .1 μM or better. B. Methods for isolating DNA encoding SABP, DABP and DBL binding regions The nucleic acid compositions of this invention, whether RNA, cDNA, genomic DNA, or a hybrid of the various combinations, may be isolated from natural sources or may be synthesized in vitro. The nucleic acids claimed may be present in transformed or transfected whole cells, in a transformed or transfected cell lysate, or in a partially purified or substantially pure form. Techniques for nucleic acid manipulation of genes encoding the binding domains of the invention, such as subcioning nucleic acid sequences encoding polypeptides into expression vectors, labelling probes, DNA hybridization, and the like are described generally in Sambrook et al, 1989. Recombinant DNA techniques can be used to produce the binding domain polypeptides. In general, the DNA encoding the SABP and DABP binding domains are first cloned or isolated in a form suitable for ligation into an expression vector. After ligation, the vectors containing the DNA fragments or inserts are introduced into a suitable host cell for expression of the recombinant binding domains. The polypeptides are then isolated from the host cells. There are various methods of isolating the DNA sequences encoding the SABP, DABP and DBL binding domains. Typically, the DNA is isolated from a genomic or cDNA library using labelled oligonucleotide probes specific for sequences in the DNA. Restriction endonuclease digestion of genomic DNA or cDNA containing the appropriate genes can be used to isolate the DNA encoding the binding domains of these proteins. Since the DNA sequences of the SABP and DABP genes are known, a panel of restriction endonucleases can be constructed to give cleavage of the DNA in the desired regions. After restriction endonuclease digestion, DNA encoding SABP binding domain or DABP binding domain is identified by its ability to hybridize with nucleic acid probes, for example on Southern blots, and these DNA regions are isolated by standard methods familiar to those of skill in the art. See Sambrook, et al, 1989. The polymerase chain reaction can also be used to prepare DABP, SABP DBL binding domain DNA. Polymerase chain reaction technology (PCR) is used to amplify nucleic acid sequences of the DABP and SABP binding domains directly from mRNA, from cDNA, and from genomic libraries or cDNA libraries. The primers shown in Figure 3 are particularly preferred for this process. Appropriate primers and probes for amplifying the SABP and DABP binding region DNA's are generated from analysis of the DNA sequences. In brief, oligonucleotide primers complementary to the two 3' borders of the DNA region to be amplified are synthesized. The polymerase chain reaction is then carried out using the two primers. See PCR Protocols: A Guide to Methods and Applications. (Innis, M, Gelfand, D., Sninsky, J. and White, T., (eds.), Academic Press, San Diego, CA (1990). Primers can be selected to amplify the entire DABP regions or to amplify smaller segments of the DABP and SABP binding domains, as desired. Oligonucleotides for use as probes are chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage, S.L. and Caruthers, M.H., 1981, Tetrahedron Letts., 22(20):1859-1862 using an automated synthesizer, as described in Needham-VanDevanter, D.R., et al. 1984, Nucleic Acids Res., 12:6159-6168. Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson, J.D. and Regnier, F.E., 1983, J. Chrom., 255:137-149. The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Maxam, A.M. and Gilbert, 1980, in W., Grossman, L. and Moldave, D., eds. Academic Press, New York, NY, Methods in Enzymology 65:499-560. Other methods known to those of skill in the art may also be used to isolate DNA encoding all or part of the SABP or DABP binding domains. See Sambrook, et al., 1989. C. Expression of DABP, SABP and DBL Binding Domain Polypeptides Once binding domain DNAs are isolated and cloned, one may express the desired polypeptides in a recombinantly engineered cell such as bacteria, yeast, insect (especially employing baculoviral vectors), and mammalian cells. It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of the DNA encoding the DABP and SABP binding domains. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made. In brief summary, the expression of natural or synthetic nucleic acids encoding binding domains will typically be achieved by operably linking the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding the binding domains. To obtain high level expression of a cloned gene, it is desirable to construct expression plasmids which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. 1. Expression in Prokaryotes Examples of regulatory regions suitable for this purpose in £ coli are the promoter and operator region of the £ coli tryptophan biosynthetic pathway as described by Yanofsky, C, 1984, J. Bacteriol., 158:1018-1024 and the leftward promoter of phage lambda (P L ) as described by Herskowitz, I. and Hagen, D., 1980, Ann. Rev. Genet., 14:399-445. The inclusion of selection markers in DNA vectors transformed in £ coli is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol. See Sambrook et ai, 1989, for details concerning selection markers for use in £ coli. The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector DNA. Expression systems for expressing the DABP and SABP binding domains are available using £ coli, Bacillus sp. (Palva, I et al., 1983, Gene 22:229-235; Mosbach, K. et al. Nature, 302:543-545 and Salmonella. £ coli systems are preferred. The binding domain polypeptides produced by prokaryote cells may not necessarily fold properly. During purification from £ coli, the expressed polypeptides may first be denatured and then renatured. This can be accomplished by solubilizing the bacterially produced proteins in a chaotropic agent such as guanidine HCl and reducing all the cysteine residues with a reducing agent such as beta-mercaptoethanol. The polypeptides are then renatured, either by slow dialysis or by gel filtration. U.S. Patent No. 4,511,503. Detection of the expressed antigen is achieved by methods known in the art as radioimmunoassays, Western blotting techniques or immunoprecipitation. Purification from £ coli can be achieved following procedures described in U.S. Patent No. 4,511,503. 2. Synthesis of SABP, DABP and DBL Binding Domains in Eukaryotes A variety of eukaryotic expression systems such as yeast, insect cell lines and mammalian cells, are known to those of skill in the art. As explained briefly below, the DABP and SABP binding domains may also be expressed in these eukaryotic systems. a. Expression in Yeast Synthesis of heterologous proteins in yeast is well known and described. Methods in Yeast Genetics, Sherman, F., et al., Cold Spring Harbor Laboratory, (1982) is a well recognized work describing the various methods available to produce the binding domains in yeast. Examples of promoters for use in yeast include GAL1.10 (Johnson, M., and Davies, R.W., 1984, Mol. and Cell. Biol., 4:1440-1448) ADH2 (Russell, D., et al. 1983, J. Biol. Chem., 258:2674-2682), PH05 (EMBO J. 6:675-680, 1982), and MFσl (Herskowitz, I. and Oshima, Y., 1982, in The Molecular Biology of the Yeast Saccharomyces, (eds. Strathern, J.N. Jones, E.W., and Broach, J.R., Cold Spring Harbor Lab., Cold Spring Harbor, N.Y., pp. 181-209. A multicopy plasmid with a selective marker such as Leu-2, URA-3, Trp-1, and His-3 is also desirable. A number of yeast expression plasmids like YEp6, YEp13, YEp4 can be used as vectors. A gene of interest can be fused to any of the promoters in various yeast vectors. The above-mentioned plasmids have been fully described in the literature (Botstein, et al, 1979, Gene, 8:17-24; Broach, et al, 1979, Gene, 8:121-133). Two procedures are used in transforming yeast cells. In one case, yeast cells are first converted into protoplasts using zymolyase, lyticase or glusulase, followed by addition of DNA and polyethylene glycol (PEG). The PEG-treated protoplasts are then regenerated in a 3% agar medium under selective conditions. Details of this procedure are given in the papers by J.D. Beggs, 1978, Nature (London), 275:104-109; and Hiπnen, A., et al., 1978, Proc. Natl. Acad. Sci. USA, 75:1929-1933. The second procedure does not involve removal of the cell wall. Instead the cells are treated with lithium chloride or acetate and PEG and put on selective plates (Ito, H., et al, 1983, J. Bact., 153:163-168). The binding domains can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot techniques or radioimmunoassays of other standard immunoassay techniques. b. Expression in Mammalian and Insect Cell Cultures Illustrative of cell cultures useful for the production of the binding domains are cells of insect or mammalian origin. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. Illustrative examples of mammalian cell lines include VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, W138, BHK, Cos-7 or MDCK cell lines. As indicated above, the vector, e. g., a plasmid, which is used to transform the host cell, preferably contains DNA sequences to initiate transcription and sequences to control the translation of the antigen gene sequence. These sequences are referred to as expression control sequences. When the host cell is of insect or mammalian origin illustrative expression control sequences are obtained from the SV-40 promoter (Science, 222:524-527, 1983), the CMV I.E. Promoter (Proc. Natl. Acad. Sci. 81:659-663, 1984) or the metallothionein promoter (Nature 296:39-42, 1982). The cloning vector containing the expression control sequences is cleaved using restriction enzymes and adjusted in size as necessary or desirable and ligated with DNA coding for the SABP or DABP polypeptides by means well known in the art. As with yeast, when higher animal host cells are employed, polyadenlyation or transcription terminator sequences from known mammalian genes need to be incorporated into the vector. An example of a terminator sequence is the polyadenlyation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VPI intron from SV40 (Sprague, J. et al., 1983, J. Virol. 45: 773-781). Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., 1985, "Bovine Papilloma virus -13- DNA a Eukaryotic Cloning Vector" in DNA Cloning Vol. II a Practical Approach Ed. D.M. Glover, IRL Press, Arlington, Virginia pp. 213-238. The host cells are competent or rendered competent for transformation by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, electroporation and micro-injection of the DNA directly into the cells. The transformed cells are cultured by means well known'in the art. Biochemical Methods in Cell Culture and Virology, Kuchler, R.J., Dowden, Hutchinson and Ross, Inc., (1977). The expressed DABP and SABP binding domain polypeptides are isolated from cells grown as suspensions or as monolayers. The latter are recovered by well known mechanical, chemical or enzymatic means. c. Expression in recombinant vaccinia virus- or adenovirus infected cells In addition to use in recombinant expression systems, the isolated binding domain DNA sequences can also be used to transform viruses that transfect host cells in the patient. Live attenuated viruses, such as vaccinia or adenovirus, are convenient alternatives for vaccines because they are inexpensive to produce and are easily transported and administered. Vaccinia vectors and methods useful in immunization protocols are described, for example, in U.S. Patent No. 4,722,848. Suitable viruses for use in the present invention include, but are not limited to, pox viruses, such as canarypox and cowpox viruses, and vaccinia viruses, alpha viruses, adeπoviruses, and other animal viruses. The recombinant viruses can be produced by methods well known in the art, for example, using homologous recombination or ligating two plasmids. A recombinant canarypox or cowpox virus can be made, for example, by inserting the DNA's encoding the DABP and SABP binding domain polypeptides into plasmids so that they are flanked by viral sequences on both sides. The DNA's encoding the binding domains are then inserted into the virus genome through homologous recombination. A recombinant adenovirus can be produced, for example, by ligating together two plasmids each containing about 50% of the viral sequence and the DNA sequence encoding erythrocyte binding domain polypeptide. Recombinant RNA viruses such as the alpha virus can be made via a cDNA intermediate using methods known in the art. In the case of vaccinia virus (for example, strain WR), the DNA sequence encoding the binding domains can be inserted in the genome by a number of methods including homologous recombination using a transfer vector, pTKgpt-OFIS as described in Kaslow, et al., Science 252:1310-1313 (1991). Alternately the DNA encoding the SABP and DABP binding domains may be inserted into another plasmid designed for producing recombinant vaccinia, such as pGS62, Langford, C.L., et al., 1986, Mol. Cell. Biol. 6:3191-3199. This plasmid consists of a cloning site for insertion of foreign genes, the P7.5 promoter of vaccinia to direct synthesis of the inserted gene, and the vaccinia TK gene flanking both ends of the foreign gene. Confirmation of production of recombinant virus can be achieved by DNA hybridization using cDNA encoding the DABP and SABP binding domain polypeptides and by immunodetection techniques using antibodies specific for the expressed binding domain polypeptides. Virus stocks may be prepared by infection of cells such as HELA S3 spinner cells and harvesting of virus progeny. The recombinant virus of the present invention can be used to induce anti-SABP and anti-DABP binding domain antibodies in mammals, such as mice or humans. In addition, the recombinant virus can be used to produce the SABP and DABP binding domains by infecting host cells in vitro, which in turn express the polypeptide (see section on expression of SABP and DABP binding domains in eukaryotic cells, above). The present invention also relates to host cells infected with the recombinant virus. The host cells of the present invention are preferably mammalian, such as BSC-1 cells. Host cells infected with the recombinant virus express the DABP and SABP binding domains on their cell surfaces. In addition, membrane extracts of the infected cells induce protective antibodies when used to inoculate or boost previously inoculated mammals. D. Purification of the SABP. DABP and DBL Binding Domain Polypeptides The binding domain polypeptides produced by recombinant DNA technology may be purified by standard techniques well known to those of skill in the art. Recombinantly produced binding domain polypeptides can be directly expressed or expressed as a fusion protein. The protein is then purified by a combination of cell lysis (e. g., sonication) and affinity chromatography. For fusion products, subsequent digestion of the fusion protein with an appropriate proteolytic enzyme release the desired SABP and DABP binding domains. The polypeptides of this invention may be purified to substantial purity by standard techniques well known in the art, including selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, for instance, R. Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York, NY (1982). E. Production of Binding Domains by protein chemistrv techπigues The polypeptides of the invention can be synthetically prepared in a wide variety of ways. For instance polypeptides of relatively short size, can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co. (1984). Alternatively, purified and isolated SABP, DABP or DBL family proteins may be treated with proteolytic enzymes in order to produce the binding domain polypeptides. For example, recombinant DABP and SABP proteins may be used for this purpose. The DABP and SABP protein sequence may then be analyzed to select proteolytic enzymes to be used to generate polypeptides containing desired regions of the DABP and SABP binding domain. The desired polypeptides are then purified by using standard techniques for protein and peptide purification. For a review of standard techniques see. Methods in Enzymology, "Guide to Protein Purification", M. Deutscher, ed. Vol. 182 (1990), pages 619-626. F. Modification of nucleic acid and polypeptide sequences The nucleotide sequences used to transfect the host cells used for production of recombinant binding domain polypeptides can be modified according to standard techniques to yield binding domain polypeptides, with a variety of desired properties. The binding domain polypeptides of the present invention can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the binding domain polypeptides can vary from the naturally-occurring sequence at the primary structure level by amino acid insertions, substitutions, deletions, and the like. These modifications can be used in a number of combinations to produce the final modified protein chain. The amino acid sequence variants can be prepared with various objectives in mind, including facilitating purification and preparation of the recombinant polypeptides. The modified polypeptides are also useful for modifying plasma half-life, improving therapeutic efficacy, and lessening the severity or occurrence of side effects during therapeutic use. The amino acid sequence variants are usually predetermined variants not found in nature but exhibit the same immunogenic activity as naturally occurring polypeptides. For instance, polypeptide fragments comprising only a portion (usually at least about 60-80%, typically 90-95%) of the primary structure may be produced. For use as vaccines, polypeptide fragments are typically preferred so long as at least one epitope capable of eliciting production of blocking antibodies remains. In general, modifications of the sequences encoding the binding domain polypeptides may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see, Giliman and Smith, Gene 8:81-97 (1979) and Roberts, S. et ai, Nature 328:731-734 (1987)). One of ordinary skill will appreciate that the effect of many mutations is difficult to predict. Thus, most modifications are evaluated by routine screening in a suitable assay for the desired characteristic. For instance, changes in the immunological character of the polypeptide can be detected by an appropriate competitive binding assay. Modifications of other properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolysis, or the tendency to aggregate are all assayed according to standard techniques. G. Diagnostic and Screening Assays The polypeptides and πucelic acids of the invention can be used in diagnostic applications for the detection of merozoites or nucleic acids in a biological sample. The presence of parasites can be detected using several well recognized specific binding assays based on immunological results. (See U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For instance, labeled monoclonal antibodies to polypeptides of the invention can be used to detect merozoites in a biological sample. Alternatively, labelled polypeptides of the invention can be used to detect the presence of antibodies to SABP or DABP in a biological sample. For a review of the general procedures in diagnostic immunoassays, see also Basic and Clinical Immunology 7th Edition (D. Stites and A. Terr ed.) 1991. In addition, modified polypeptides, antibodies or other compounds capable of inhibiting the interaction between SABP or DABP and erythrocytes can be assayed for biological activity. For instance, polypeptides can be recombinantly expressed on the surface of cells and the ability of the cells to bind erythrocytes can be measured as described below. Alternatively, peptides or antibodies can tested for the ability to inhibit binding between erythrocytes and merozoites or SABP and DABP. Cell-free assays can also be used to measure binding of DABP or SABP polypeptides to isolated Duffy antigen or glycophorin polypeptides. For instance, the erythrocyte proteins can be immobilized on a solid surface and binding of labelled SABP or DABP polypeptides can be measured. Many assay formats employ labelled assay components. The labelling systems can be in a variety of forms. The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. A wide variety of labels may be used. The component may be labelled by any one of several methods. The most common method of detection is the use of autoradiography with H, 125 l, 35 S, 14 C, or 32 P labelled compounds or the like. Non radioactive labels include ligands which bind to labelled antibodies, fiuorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labelled ligand. The choice of label depends on sensitivity required, ease of conjugation with the compound, stability requirements, and available instrumentation. In addition, the polypeptides of the invention can be assayed using animal models, well known to those of skill in the art. For P falciparum the in vivo models include Aotus sp. monkeys or chimpanzees; for P. vivax the in vivo models include Saimiri monkeys. In the case of the use nucleic acids for diagnostic purposes, standard nucleic hybridization techniques can be used to detect the presence of the genes identified here (e.g., members of the DBL family). If desired, nucleic acids in the sample may first be amplified using standard procedures such as PCR. Diagnostic kits comprising the appropriate primers and probes can also be prepared. H. DBL Targeted Therepeutics DBL polypeptides are expressed on the surface of Plasmodiυm-m ' iecteά erythrocytes. As such, they present ideal targets for therepeutics which target infected erythrocytes. In one preferred embodiement of the present invention, cytotoxic antibodies or antibody fusion proteins with cytotoxic agents are targeted against DBL proteins, killing infected erythrocytes and inhibiting the reproduciton of Plasmodium in an infected host. The procedure for attaching a cytotoxic agent to an antibody will vary according to the chemical structure of the agent. Antibodies and cytotoxic agents are typically bound together chemically or, where the antibody and cytotoxic agents are both polypeptides, are optionally synthesized recombinantly as a fusion protein. Polypeptides typically contain variety of functional groups; e.g., carboxylic acid (COOH) or free amine (-NH 2 ) groups, which are available for reaction with a suitable functional group on either the antibody or the cytotoxic agent. Alternatively, antibodies or cytotoxic agents are derivitized to attach additional reactive functional groups. The derivatization optionally involves attachment of linker molecules such as those available from Pierce Chemical Company, Rockford Illinois. A "linker", as used herein, is a molecule that is used to join the nucleic acid binding molecule to the receptor ligand. The linker is capable of forming covalent bonds to both the antibody and the cytotoxic agent. Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. Where the antibody and the cytotoxic agent are polypeptides, the linkers are joined to the constituent amino acids through their side groups (e.g., through a disulfide linkage to cysteine) or to the alpha carbon amino and carboxyl groups of the terminal amino acids. A bifunctional linker having one functional group reactive with a group on a particular ligand, and another group reactive with a nucleic acid binding molecule, can be used to form the desired conjugate. Alternatively, derivatization can proceed through chemical treatment of the ligand or nucleic acid binding molecule, e.g., glycol cleavage of the sugar moiety of a glycoprotein with periodate to generate free aldehyde groups. The free aldehyde groups on the glycoprotein may be reacted with free amine or hydrazine groups on an agent to bind the agent thereto (See, e.g., U.S. Patent No. 4,671,958). Procedures for generation of free sulfhydryl groups on polypeptides, are known (See, e.g., U.S. Pat. No. 4,659,839). Many procedures and linker molecules for attachment of various compounds to proteins are known. See, for example, European Patent Application No. 188,256; U.S. Patent Nos. 4,671,958, 4,659,839, 4,414,148, 4,699,784; 4,680,338; 4,569,789; and 4,589,071; and Borlinghaus et al. Cancer Res. 47: 4071-4075 (1987). In particular, production of various antibody conjugates is well-known within the art and can be found, for example in Thorpe et ai. Monoclonal Antibodies in Clinical Medicine, Academic Press, pp. 168-190 (1982), Waldmann, Science, 252: 1657 (1991), and U.S. Patent Nos. 4,545,985 and 4,894,443. A number of antibodies which bind cell surface receptors have been converted to form suitable for incorporation into fusion proteins, and similar strategies are used to create fusion-protein antibodies which bind DBR polypeptides. see Batra et al., Mol. Cell. Biol, 11: 2200-2205 (1991); Batra et al, Proc. Natl. Acad. Sci. USA, 89: 5867-5871 (1992); Brinkmann, et al. Proc. Natl. Acad. Sci. USA, 88: 8616-8620 (1991); Brinkmann et al, Proc. Natl. Acad. Sci. USA, 90: 547-551 (1993); Chaudhary et al, Proc. Natl. Acad. Sci. USA, 87: 1066-1070 (1990); Friedman et ai. Cancer Res. 53: 334-339 (1993); Kreitman et al, J. Immunol., 149: 2810-2815 (1992); Nicholls et al, J. Biol. Chem., 268: 5302-5308 (1993); and Wells, et al. Cancer Res., 52: 6310-6317 (1992), respectively). B. Production of Fusion Proteins Where the antibody fragment and/or the cytotoxic agents are relatively short polypeptides (i.e., less than about 50 amino acids) they are often synthesized using standard chemical peptide synthesis techniques. Where both molecules are relatively short, a chimeric molecule is optionally synthesized as a single contiguous polypeptide. Alternatively, the ligand and the nucleic acid binding molecule can be synthesized separately and then fused chemically. Solid phase synthesis in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is a preferred method for the chemical synthesis of the ligands of this invention. Techniques for solid phase synthesis are described by Barany and Merrifield, Solid-Phase Peptide Synthesis; pp. 3-284 in The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods in Peptide Synthesis, Part A., Merrifield, et al., J. Am. Chem. Soc, 85: 2149-2156 (1963), and Stewart et al, Solid Phase Peptide Synthesis, 2nd ed. Pierce Chem. Co., Rockford, III. (1984). In a preferred embodiment, the fusion molecules of the invention are synthesized using recombinant nucleic acid methodology. Generally this involves creating a nucleic acid sequence that encodes the receptor-targeted fusion molecule, placing the nucleic acid in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the expressed protein and, if required, renaturing the protein. Techniques sufficient to guide one of skill through such procedures are found in, e.g., Berger, Sambrook, Ausubel, Innis, and Freshney (all supra). While the two molecules are often joined directly together, one of skill will appreciate that the molecules may be separated by a peptide spacer consisting of one or more amino acids. Generally the spacer will have no specific biological activity other than to join the proteins or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. Once expressed, recombinant fusion proteins can be purified according to standard procedures, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, Protein Purification, Springer-Verlag, N.Y. (1982), Deutscher, Methods in Enzymology Vol. 182: Guide to Protein Purification., Academic Press, Inc. N.Y. (1990)). Substantially pure compositions of about 50 to 95% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therepeutic agents. One of skill in the art will recognize that after chemical synthesis, biological expression, or purification, the fusion molecule may possess a conformation substantially different than the native conformations of the constituent polypeptides. In this case, it is often necessary to denature and reduce the polypeptide and then to cause the polypeptide to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art (See, Debinski et at. J. Biol. Chem., 268: 14065- 14070 (1993); Kreitman and Pastan, Bioconjug. Chem., 4: 581-585 (1993); and Buchner, et al, Anal. Biochem., 205: 263-270 (1992). I. Pharmaceutical compositions comprising binding domain polypeptides The polypeptides of the invention are useful in therapeutic and prophylactic applications for the treatment of malaria. Pharmaceutical compositions of the invention are suitable for use in a variety of drug delivery systems. Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). For a brief review of methods for drug delivery, see, Langer, Science 249:1 527-1533 (1990). The polypeptides of the present invention can be used in pharmaceutical and vaccine compositions that are useful for administration to mammals, particularly humans. The polypeptides can be administered together in certain circumstances, e.g. where infection by both P. falciparum and P. vivax is likely. Thus, a single pharmaceutical composition can be used for the treatment or prophylaxis of malaria caused by both parasites. The compositions are suitable for single administrations or a series of administrations. When given as a series, inoculations subsequent to the initial administration are given to boost the immune response and are typically referred to as booster inoculations. The pharmaceutical compositions of the invention are intended for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral -19- administration that comprise a solution of the agents described above dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine, hyaluroπic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient and more preferably at a concentration of 25%-75%. For aerosol administration, the polypeptides are preferably supplied in finely divided form along with a surfactant and propellant. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery. In certain embodiments patients with malaria may be treated with SABP or DABP polypeptides or other specific blocking agents (e.g. monoclonal antibodies) that prevent binding of Plasmodium merozoites and schizonts to the erythrocyte surface. The amount administered to the patient will vary depending upon what is being administered, the state of the patient and the manner of administration. In therapeutic applications, compositions are administered to a patient already suffering from malaria in an amount sufficient to inhibit spread of the parasite through erythrocytes and thus cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on the severity of the disease, the particular composition, and the weight and general state of the patient. Generally, the dose will be in the range of about 1mg to about 5gm per day, preferably about 100 mg per day, for a 70 kg patient. Alternatively, the polypeptides of the invention can be used prophylactically as vaccines. The vaccines of the invention contain as an active ingredient an immunogenically effective amount of the binding domain polypeptide or of a recombinant virus as described herein. The immune response may include the generation of antibodies; activation of cytotoxic T lymphocytes (CTL) against cells presenting peptides derived from the peptides encoded by the SABP, DABP or DBL sequences of the present invention, or other mechanisms well known in the art. See e.g. Paul Fundamental Immunology, Second Edition (Raven Press, New York, NY) for a description of immune response. Useful carriers are well known in the art, and include, for example, thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(D-lysine:D-glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are materials well known in the art. The DNA or RNA encoding the SABP or DABP binding domains and the DBL gene family motifs may be introduced into patients to obtain an immune response to the polypeptides which the nucleic acid encodes. Wolff et. al., Science 247: 1465-1468 (1990) which is describes the use of nucleic acids to produce expression of the genes which the nucleic acids encode. Vaccine compositions containing the polypeptides, nucleic acids or viruses of the invention are administered to a patient to elicit a protective immune response against the polypeptide. A "protective immune response" is one which prevents or inhibits the spread of the parasite through erythrocytes and thus at least partially prevent the symptoms of the disease and its complications. An amount sufficient to accomplish this is defined as an "immunogenically effective dose." Amounts effective for this use will depend on the composition, the manner of administration, the weight and general state of health of the patient, and the judgment of the prescribing physician. For peptide compositions, the general range for the initial immunization (that is for therapeutic or prophylactic administration) is from about 100 μg to about 1 gm of peptide for a 70 kg patient, followed by boosting dosages of from about 100 μg to about 1 gm of the polypeptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition e.g. by measuring levels of parasite in the patient's blood. For nucleic acids, typically 30-1000ug of nucleic acid is injected into a 70kg patient, more typically about 50-150ug of nucleic acid is injected into a 70kg patient followed by boosting doses as appropriate. The following examples illustrate preferred embodiments of the invention. EXAMPLE 1: Identification of the amino-terminal. cysteine-rich region of SABP and DABP as binding domains for erythrocytes 1. Expression of the SABP binding domain polypeptide on the surface of Cos cells. To demonstrate that the amino-terminal, cysteine-rich region of the SABP protein is the sialic acid binding region, this region of the protein was expressed on the surface of mammalian Cos cells in vitro. This DNA sequence is from position 1 to position 1848 of the SABP DNA sequence (SEQ ID No 3). Polymerase chain reaction technology (PCR) was used to amplify this region of the SABP DNA directly from the cloned gene. Sequences corresponding to restriction endonuclease sites for Pvull or Apal were incorporated into the oligonucleotide sequence of the probes used in PCR amplification in order to facilitate insertion of the PCR-amplified regions into the pRE4 vector (see below). The specific oligonucleotides, 5'-ATCGATCAGCTGGGAAGAAATACTTCATCT-3 * (SEQID N0:17) and 5'-ATCGATGGGCCCCGAAGTTTGTTCATTATT-3' (SEQ ID N0:18) were synthesized. These oligonucleotides were used as primers to PCR-amplify the region of the DNA sequence encoding the cysteine-rich amino terminal region of the SABP protein. PCR conditions were based on the standard described in Saiki, et al. Science 239: 487-491 (1988). Template DNA was provided from cloned fragments of the gene encoding SABP which had been spliced and re-cloned as a single open-reading frame piece. The vector, pRE4, used for expression in Cos cells is shown in Figure 2. The vector has an SV40 origin of replication, an ampicillin resistance marker and the Herpes simplex virus glycoprotein D gene (HSV glyd) cloned downstream of the Rous sarcoma virus long terminal repeats (RSV LTR). Part of the extracellular domain of the HSV glyd gene was excised using the Pvull and Apal sites in HSV glyd. As described above, the PCR oligonucleotide primers contained the Pvull or Apal restriction sites. The PCR-amplified DNA fragments obtained above were digested with the restriction enzymes Pvull and Apal and cloned into the Pvull and Apal sites of the vector pRE4. These constructs were designed to express regions of the SABP protein as chimeric proteins with the signal sequence of HSV glyd at the N-terminal end and the transmembrane and cytoplasmic domain of HSV glyd at the C-terminal end. The signal sequence of HSV glyd targets these chimeric proteins to the surface of Cos cells and the transmembrane segment of HSV glyd anchors these chimeric proteins to the Cos cell surface. Mammalian Cos cells were transfected with the pRE4 constructs containing the PCR-amplified SABP DNA regions, by calcium phosphate precipitation according to standard techniques. 2. Expression of the DABP binding domain polypeptide on the surface of Cos cells. To demonstrate that the amino-terminal, cysteine-rich region of the DABP protein is the binding domain, this region was expressed on the surface of Cos cells. This region of the DNA sequence from position 1-975 was first PCR-amplified (SEQ ID No 1 ). Sequences corresponding to restriction endonuclease sites for Pvull or Apal were incorporated into the oligonucleotide probes used for PCR amplification in order to facilitate subsequent insertion of the amplified DNA into the pRE4 vector, as described above. The oligonucleotides, 5'-TCTCGTCAGCTGACGATCTCTAGTGCTATT-3' (SEQ ID NO: 19) and 5'-ACGAGTGGGCCCTGTCACAACTTCCTGAGT-3' (SEQ ID N0:20) were synthesized. These oligonucleotides were used as primers to amplify the region of the DABP DNA sequence encoding the cysteine-rich, amino-terminal region of the DABP protein directly from the cloned DABP gene, using the same conditions described above. The same pRE4 vector described above in the section on expression of SABP regions in Cos cells was also used as a vector for the DABP DNA regions. 3. Binding studies with erythrocytes. To demonstrate their ability to bind human erythrocytes, the transfected Cos cells expressing binding domains from DABP and SABP were incubated with erythrocytes for two hours at 37°C in culture media (DMEM/10% FBS). The non-adherent erythrocytes were removed with five washes of phosphate-buffered saline and the bound erythrocytes were observed by light microscopy. Cos cells expressing the amino terminal, cysteine-rich SABP polypeptides on their surface bound untreated human erythrocytes, but did not bind neura inidase treated erythrocytes, that is, erythrocytes which lack sialic acid residues on their surface. Cos cells expressing other regions of the SABP protein on their surface did not bind human erythrocytes. These results identified the amino-terminal, cysteine-rich region of SABP as the erythrocyte binding domain and indicated that the binding of Cos cells expressing these regions to human erythrocytes is specific. Furthermore, the binding of the expressed region to erythrocytes is identical to the binding pattern seen for the authentic SABP- 175 molecule upon binding to erythrocytes. Similarly, Cos cells expressing the amino-terminal cysteine-rich region of DABP on their surface bound Duffy-positive human erythrocytes, but did not bind Duffy-negative human erythrocytes, that is erythrocytes which lack the Duffy blood group antigen. Cos cells expressing other regions of the DABP protein on their surface did not bind human erythrocytes. These results identified the amino-terminal cysteine rich region of DABP as the erythrocyte binding domain and indicated that the binding of the Cos cells was specific. EXAMPLE 2: Isolation of polynucleotide sequences in the DBL family P.falciparum clones and cell line used include the following. P. falciparum clones 3D7, D10, LF4/1, Camp/A 1, SL/D6, HB3, 7G8, V1/S, T2/C6, KMWII, HG2F6, FCR3/A2 and Dd2 have been previously tabulated (Dolan, et al. (1993), Mol. Biochem. Parasitol. 61, 137-142). Line Dd2/NM1 was selected from clone Dd2 for invasion via a sialic acid-independent pathway (Dolan, et al. (1990), J. Clin. Invest. 86, 618-624). All parasites were maintained in vitro by standard methods (Trager, et al. (1976), Science 193, 673-675). DNA and RNA Isolation and Analysis. DNA was extracted as described (Peterson, et al. (1990), Proc. Natl. Acad. Sci. USA 87, 3018-3022). Endonuclease digestion, agarose gel electrophoresis, and filter hybridizations were performed by standard methods (Sambrook, et al, 1989). All hybridizations were at 56°C (Sambrook, et al, 1989). Blots were washed for 2 min. at room temperature in 2x standard saline/phosphate/EDTA (SSPE) with 0.5% SDS, followed by two higher stringency washes at 50°C in 0.3xSSPE with 0.5% SDS. Parasite chromosomes were embedded in agarose blocks and separated by pulsed field gel electrophoresis (Dolan, et al. (1993), Methods. Mol. Biol. 21, 319-332). RNA was isolated from cultured parasites by LiC1 extraction of Catrimox-14-precipitated RNA (Dahie, et al. (1993), BioTechniques 15, 1102-1105). Agarose gel electrophoresis of total RNA and filter hybridizations were performed by standard methods (Sambrook, et ai, (1989). Oligonucleotide Primers and PCR. Primers specific for E31a used in a RT-PCR to test for expression of this sequence were E31 aT2 (5'-AGA-CCT-CAA-TTT-CTA-AG-3'l (SEQ ID N0:21) and E31 aRev1 (5'-AAT-CGC-GAG-CAT-CAT-CTG-3 F ) (SEQ ID N0:22). Two primers were used to amplify additional sequences from genes encoding DBL domains. These were designed from conserved amino acids encoded in the DBL domain of the eba-175 and E31a sequences. After adaptation to incorporate the most frequently-used P. falciparum codons, forward primer UNIEBP5' [5'-CC(A/G)-AG(G/A)-AG(G/A)-CAA-(G/A)AA-(C/T)TA-TG-3'] (SEQ ID N0:23), based upon the amino acid sequence PRRQKLC, and reverse primer UNIEBP3' [5'-CCA-(A/T)C(T/G)-(T/G)A(A/G) (A/G)AA-πG-(A/T)GG-3'] (SEQ ID N0:24), based upon the amino acid sequence PQFLRW, were synthesized. RT-PCR amplifications were performed as described (Kawasaki, et al (1990), PCR Protocols, A Guide to Methods and Applications, eds. Innis, M.A., Gelfand, D.H., Sπiπsku, J.J. & White, T.J. (Academic, San Diego), pp. 21-27). In brief, 0.5 to 1 mg of total RNA was treated with RQ1 DNAse (Promega), phenol/chloroform extracted, and ethanol precipitated. The RNA was then annealed with random oligonucleotide primers and extended with Superscript reverse transcriptase (GIBCO/BRL). PCR cycling conditions were 94°C for 10 sec, 45°C for 15 sec, and 72°C for 45 sec, for 30 cycles. All PCRs were performed in an Idaho Technology air thermal cycler using buffer containing 2 mM Mg2+. PCR amplification products were separated by use of PCR Purity Plus gels and protocols (AT Biochem, Malvern, PA). DNA Clones and Hybridization Probes. Clone pE31a was isolated from a genomic library prepared from the region of chromosome 7 linked to chloroquine resistance Walker-Jonah, et ai (1992), Mol. Biochem. Parasitol. 51, 313-320. Clone pS31H (GenBank accession no. L38454), containing an insert encompassing that of pE31a, was cloned from a size-selected Hind III restriction digest of Dd2 genomic DNA. Clone pEBLel was cloned from a RT-PCR of Dd2 cDNA after amplification with primers UNIEBP5' (SEQ ID N0:23) and UNIEBP3' (SEQ ID N0:24). Clone pEBP1.2 (GenBank accession no. L38450), containing an insert encompassing that of pEBLel, was isolated from a Dd2 cDNA library probed with pEBLel. Zrø/ encoding sequences of db/nml-4 (GenBank accession no. L38455) and dbl-nml-5 (GenBank accession no. L38453) were amplified by RT-PCR from first strand cDNA of line Dd2/NM using primers UNIEBP5' and UNIEBP3'. Sequencing was performed on double stranded DNA templates by standard protocols for the dideoxynucleotide method. (Sequenase; U.S. Biochemicals). Sequences related to the E31a sequence were detected with the 3005 bp insert of clone pS31H. The eba-175 gene was detected with a PCR amplified probe consisting of the first 1825 bp of the coding sequence. ebl l sequences were detected with the 2098 bp insert of clone pEBP1.2. All probes were comparable in organization, each containing a region encoding at least one DBL domain and varying amounts of flanking sequence. Homology searches and alignments. Homology searches were performed with BLAST and the Genetics Computer Group program FASTA (Altschul, et al. (1990), J. Mol. Biol. 215, 403-410; Devereux, et al. (1984), Nucleic Acids. Res. 12(1 Pt 1, 387-395). Optimized alignments were produced with MACAW sequence alignment software (Schuler, et al. (1991), Proteins. 9, 180-190). Multiple P. falciparum sequences encode DBL domains. Positional cloning experiments directed to P. falciparum chromosome 7 identified an ORF (E31 a) encoding a DBL domain that is homologous to the domains found in the P. vivax and P. knowlesi DABPs and the P. falciparum SABP. Figure 4 shows the realtive position of the E31a ORF on chromosome 7. The homology between the DBL domains of E31a and the erythrocyte-binding proteins is due to the presence of short motifs of highly conserved amino acids. These well-conserved stretches are separated by non-homologous sequences and by deletions and insertions that vary the size of the domain by greater than 60 aa. The typical DBL domain contains 12 or more cysteine residues and has 7 conserved tryptophan residues. Additional well conserved amino acids include 4 arginines, 3 aspartates, 9 positions with aliphatic residues (alanine, isoleucine, leucine, or valine) and 4 with aromatic amino acids (tryptophan, phenylalanine, or tyrosine). Probes spanning the sequence that encodes the E31a DBL domain hybridized to multiple fragments within a single restriction digest and yielded bands that varied among parasite lines. The numerous distinct bands from a selection of different parasite DNAs indicated a large number of diverse but related elements. These multiple bands varied among different P. falciparum clones, in contrast to the well-conserved, single-copy signal obtained with the eba- 175 probe. Because of the numerous cross-hybridizing sequences, it seemed likely that many of these related sequences would be on different chromosomes of the parasite. PFG electrophoresis of P. falciparum Dd2 chromosomes and hybridization with the E31a probe identified a number of cross-hybridizing sequences on multiple chromosomes. A control hybridization with the eba-175 probe under identical conditions yielded a single band of hybridization from chromosome 7. RNA Analysis of DBL Elements. Sequences from E31 a (pS31 H insert) were used to probe RNA blots for corresponding transcripts. No hybridization was detected. Because it was still possible that a message of low abundance was not being detected on the RNA blot, RT-PCR was used as a means of more sensitive detection. For this purpose, cDNA was generated by RT from random primers annealed to DNAse-treated total RNA. E31a-specific oligonucleotides were then used to test for amplification from the cDNA. No amplification of the E31a sequence was obtained, while genomic DNA controls and amplification from cDNA by dihydrofolate reductase/thymidylate synthetase-specific primers yielded the expected bands. A screen of a cDNA library with E31a specific probes also failed to detect any clones hybridizing with the ORF. These results indicate that E31a is either a pseudogene, or is expressed in parasite strains or stages not examined in this work. A PCR Method to Isolate Sequences Encoding DBL Domains. The identification of short conserved motifs in DBL domains that otherwise have extreme diversity led to a PCR strategy using degenerate oligonucleotide primers designed from conserved amino acid sequences in the DBL domains. Sequences PRRQKLC and PQFLRW were judged most suitable for minimizing degeneracy while allowing amplification of expressed DBL sequences. After these considerations and adjustment for P. falciparum codon usage, primers UNIEBP5' and UNIEBP3' were synthesized. While some P. falciparum lines yielded similar patterns of amplified bands (e. g. Dd2 and MCamp; FCR3/A2 and K-1), no two separate isolates showed identical patterns, reflecting the diversity of the DBL domains in the parasite lines. A few bands of the same apparent size were present in many isolates. These included a consistent 490 bp product that was determined to be the eba-175 gene by its expected size and hybridization to a gene-specific probe. The number of discernible bands probably underestimates the number of amplifiable sequences because of overlapping products of the same size and possible preferential amplification of some sequences over others. Nevertheless, the parasite-specific patterns in the amplified bands may provide a means to quickly type isolates and serves as a measure of parasite diversity in field samples. To identify DBL -encoding sequences in RNA transcripts, the UNIEBP primers were used to amplify first-strand cDNAs generated from DNAse-treated RNA preparations. Amplified products from Dd2, 3D7, HB3 and MCAMP cDNAs had diverse sizes ranging from 400 bp to nearly 1 kb. These included a band at 480-500 bp that was determined to be eba-175 from its expected size and cross-hybridization to an øfø-775-specific probe. Other bands were from amplification of different transcripts encoding DBL domains. Dd2-NM1 RNA, for example, yielded bands above the eba-175 product that included two related sequences (dbl-nm1-4,dbl-nm1-5). These bands were found to be isolate-specific and to have features consistent with the var genes described in Example 3, below. Probes that detect dblnm1-4 and dbl-nml-5 hybridized to multiple chromosomes and aligned more closely with E31a than with EBA-175 or DABP. The RT-PCR amplifications also yielded a consistent band that encoded a novel DBL domain distinct from eba-175. A cDNA clone corresponding to this product was isolated by screening a Λgt10 Dd2 cDNA library with a radiolabeled ebl-1 probe. Sequence from this and additional overlapping cDNA clones confirmed the conserved motifs of the DBL domain. The alignment of the predicted amino acid sequences showed that the DBL domain of ebl-1 is more similar to eba-175 than to the multicopy genes. There was, however, extensive divergence from eba-175 and other known genes outside of the amplified region. In contrast to the multicopy hybridization patterns of dbl-nml-4 and db/nml-5, the ebl-1 sequence, like that of eba-175, was found to have hybridization patterns consistent with a conserved single-copy gene. Probes specific for ebl l hybridized only to chromosome 13, and restriction analysis with the enzymes Cla I, £cσRI, Hinά\\\, Hin\ I, Nsi I, Rsa I, and Spe I, all yielded bands expected from a single copy sequence. RNA blots probed with eΛ/- /-specific sequences showed several bands of hybridization, however, corresponding to 8-9.5 kb transcripts in mRNA from the Dd2 and 3D7 parasites. The transcripts of different size may result from alternative start and termination points or from incompletely processed species containing introns. EXAMPLE 3: Isolation of var genes Parasite clones. DNA analysis and Chromosome Mapping. Parasite clones were cultivated by the methods of (Trager, et al. (1976), Science 193, 673-675). DNA was extracted from parasite cultures as described (Peterson, et ai (1988), Proc. Natl. Acad. Sci. USA 85, 9114-9118) except that the DNA was as recoverd by ethanol precipitation rather than spooling. Fingerprint analysis with the pC4.H32 probe was used to confirm DNA preparations (Dolan, et ai (1993), Mol. Biochem. Parasitol 61, 137-142). Southern blotting to Nytran membranes was recommended by the manufacturer (Schleicher & Schuell, Keene, NH). PFG separation of the 14 P. falciparum chromosomes and chromosome mapping were performed as described (Wellems, et at. (1987), Cell 3, 633-642; Sinnis, et al. (1988); Genomics 3, 287-295). RNA isolation. Parasites from 200 ml mixed stage cultures (5-10% parasitemia) were released by saponin lysis as for DNA preparations except that the procedures were performed with ice-cold solutions. RNA was immediately isolated from the parasite pellet by guanidine thiocyanate/phenol-chloroform methods, recovered and treated with RNAase-free DNAse (Creedon, et al. (1994), J. Biol Chem. 269, 16364-16370. RNA in H 2 0 was combined with 2 vol 100% ETOH, distributed into 2 ml vials and frozen as stock at -70°C. RNA was recovered by precipitation with 0.1 vol 3M NaOAc. RNA blots were generated and probed as described (Creedon, et al. (1994), J. Biol. Chem. 269, 16364-16370). YAC isolation, chromosome-segment libraries and cDNA libraries. Overlapping YACs spanning the 300 kb segment of chromosome 7 that contains the CQR locus were obtained from a YAC library of a CQR FCR3 parasite line de Bruin, et al. (1992), Genomics 14, 332-339) by the procedures of Lanzer, et al. (1993), Nature 361, 654-657. Orientation of the YACs and their overlaps were identified with probes obtained from the YAC ends by inverted PCR. Attempts to construct cosmid libraries and large insert ( — 10 kb) λ libraries from high molecular weight P. falciparum genomic DNA yielded only rearranged clones. An alternative approach was therefore taken in which chromosome-segment libraries were constructed that contained small (0.5-5 kb) inserts in plasmid vectors. Plasmid libraries containing Alu\, HinW, Rsa\ and Ssp\ inserts in pCDNAIi were constructed from Dd2 chromosome 7 restriction fragments purified by pulsed-field gel (PFG) electrophoresis (Wellems, et al. (1991), Proc. Natl. Acad. Sci. USA 88, 3382-3386). A plasmid library from a 34 kb Apa\ Sma\ restriction fragment of YAC PfYED9 was constructed by the same methods. Inserts in the plasmid libraries were generally 0.5-4 kb. The Igt10 Dd2 cDNA library was prepared under contract by CloneTech Laboratories Inc. (Palo Alto, CA) from the DNAse-treated, poly A + fraction of Dd2 RNA. The cDNA was generated in two separate reactions using oligodT primers or random primers. Products of these reactions were combined, processed and cloned into the EcoRI site of Λgt10. 1.6 x 10 independent recombinaπts were obtained and amplified. Isolation of overlapping clones and DNA sequencing. Plasmid clones from the chromosome-segment and YAC-segment libraries were picked at random and their locations were established by restriction mapping. After sequence data from these clones were generated, overlapping clones were isolated in a process of "chromosome walking" by rescreening the libraries with oligonucleotide probes near the ends of sequenced inserts. Sufficient divergence was present among repetitive elements in the sequences to allow distinction of clones and unambiguous assignment of overlaps (generally 50-200 bp). Sequencing reactions with single-strand M13 DNA (1 μg) and double-strand plasmid DNA (2-5 μg) were performed in 96-well polyvinyl chloride U-bottom microassay plates using a Sequenase protocol recommended by United States Biochemical Corp. (Cleveland, OH). Reactions were separated by 8M urea-6% polyacrylamide sequencing gels and exposed to Kodak BioMax MR film. Sequence data from some clones were also obtained by use of an ABI 373A automated DNA sequencer (Applied Biosystems Inc., Foster City, CA). Cycle sequencing reactions were performed using the ABI PRISM DyeDeoxy system. DNA sequence editing, analyses and display were performed with MacVector software (International Biotechnologies Inc., New HaVen, CT), BLAST (Altschul, et al. (1990), J. Mol. Biol. 215, 403-410), Genetics Computer Group programs (Devereux, et al. (1984), Nucleic Acids Res. 12, 387-395) and the DNADRAW package (Shapiro, et al. (1986), Nucleic Acids Res. 14, 65-73) maintained at the National Institutes of Health. Identification of a large hvpervariable region within a chromosome 7 segment linked to chloroguine resistance. Four overlapping yeast artificial chromosomes from the P. falciparum FCR3 line were obtained that span the 300 kb chromosome segment linked to CQR, a segment located 300-600 kb from the telomere of chromosome 7. Figure 5 shows the positions of these YACs (PfYEF2, PfYFE6, PfYKFδ, PfYED9) relative to the chromosome map. In order to define the structure of this 300 kb segment, we performed comparative hybridizations to search for polymorphisms between parasite lines. Clones were randomly picked from chromosome segment-specific plasmid libraries and their inserts were hybridized against restriction digests of the YAC and parasite DNAS. Over thirty inserts were identified that recognized PfYEF2, PfYFE6 or PfYKFδ and showed a predonderance of single copy sequences with few polymorphisms (AM, Hinf\, Rsa\ and Ssp\ digests), consistent with prior findings that chromosome internal regions are largely conserved and contain a preponderance of single copy sequences. However, fifteen other inserts that recognized PfYED9 showed highly polymorphic sets of repetitive elements in the parasite DNAs. Southern analysis indicated that these polymorphic elements were part of a chromosome hypervariable region contained within the PfYED9 clone. Mapping and DNA seguencing of the hypervariable region spanned bv YAC PfYED9. Single copy sequences detected by pE45b and pH270.5 flank the hypervariable region spanned by PfYED9 (Figure 5). The pE45b and pH270.5 probes were therefore used to assign large restriction fragments on the PfYED9 map and establish enzyme recognition sites as reference points. A detailed restriction map of the PfYED9 hypervariable region was then developed. Fifteen overlapping clones ("a"-"f and "h"-"o" in Figure 5) were isolated by a chromosome walking approach from Dd2 chromosome subsegment libraries (Wellems et al, supra) The inserts yielded 19.1 kb of continuous Dd2 sequence having predicted enzyme recognition sites in perfect accord with the PfYED9 restriction map. Such agreement indicates that the Dd2 and FCR3 sequences in this part of the chromosome are very similar, despite differences elsewhere in the genome that are evident by restriction analysis. We also obtained genomic sequence data from the 34 kb Apa\ Sma\ fragment of PfYED9. Purified PfYED9 DNA was cut with Sma\ to yield a 110 kb fragment, which was then isolated by PFG electrophoresis and digested with Apal The resulting 34 kb Apa\ Sma\ band was purified by PFG electrophoresis, digested in four separate reactions by AM, Hint], Rsa\ or Ssp\ and incorporated into a plasmid (PCDNAII) library. Cloned inserts from the library were checked for hybridization to the PfYED9 34 kb fragment, assigned to the PfYED9 map and sequenced (Figure 5). Overlapping inserts were obtained by the chromosome walking approach except for three gaps ("t", "z", "θ" in Figure 5) which were closed by PCR amplification of PfYED9 DNA using primers from flanking sequences. The clones from PfYED9 (V-YVV", V and "α"+ n β" in Figure 5) yielded 22.2 kb of continuous DNA sequence that overlaps the Dd2 sequence at the "f"/"/?" junction and has predicted restriction sites that match the PfYED9 map perfectly. The composite sequence from the Dd2 and PfYED9 segments is 40,171 kb. Structure of a var gene cluster and comparative analysis of predicted amino acid seguences. The 40,171 bp sequence contains three 10-12 kb regions that have related sequences and structure. Each of these regions harbors a pair of ORFS. The first ORF in each pair begins with a consensus ATG start codon preceded by typical P. falciparum non-coding sequence of abundant A+T content. The ORFs of each pair are separated by an intervening AT-rich and non-coding sequence of 0.9 kb to 1.1 kb. Presence of consensus intron-exon splice junction sequences at either end of these intervening sequences and lack of a consistent translation start site in the 3' ORF indicate that the each pair of ORFs belongs to an individual gene having a two exon structure. This has been verified by comparison of the genomic sequences to the cDNA sequence of an expressed gene (var- 7; see subsequent section). The three 10 kb to 12 kb regions thus contain members of a variant gene family which have coding regions of 9.23kb (var-1), 7.99 kb (var-2) and 9.01 kb (var-3). Predicted molecular weights of the encoded proteins are 350 kD, 302 kD and 344 kD. respectively. The var genes are flanked by additional members of the var family in PfYED9. Restriction analysis identified two additional genes that are 12-35 kb upstream of the sequenced region and are closely related to var-2 and var-3 (var-2c and Var-3c, Figure 5). The var genes thus have a clustered arrangement in which many individual members are organized in head-to-tail fashion. Between var-1 and var-2 is a 5 kb DNA sequence that harbors a short ORF homologous to that of a repetitive element (rij) suggested to be a transposable element in P. falciparum. The deduced protein sequences of the var genes are highly diverse, yet all contain certain conserved motifs and common structural features. Database searches identified 2 to 4 domains within each var sequence that are homologous to cysteine-rich domains of SABP and DABP. In the var sequences, the first domain near the amiπo-terminus (DBL domain 1) is the most conserved of the DBL domains and has amino acid signatures that differentiate it from subsequent domains (e.g. consensus peptide sequences GAcAp[Y/F]rrL, CTxLARsfadlgdIVrgrdLYLG and VPTYFDYVpqylrwF). Between DBL domains 1 and 2 is another type of conserved domain, a cysteine-rich interdomain region (CIDR) of 300-400 amino acids. The CIDR does not have all the motifs of a DBL domain, but it does have a region at the 3'end which is homologous to the end of the Fl DBL domain in SABP. The conservation evident in the sequences of DBL domain I and the CIDR suggest that these regions maintain important structures in the head of the variant molecule. DBL domains 2, 3 and 4 (numbering is according to var- 1, the first sequence completed) have less discriminating signatures than domain 1, and show features of cross-alignment and variation in number that suggest these domains can undergo shuffling and deletion. DBL domain 4 is followed by a segment of variable length and a hydrophobic region that is encoded at the end of the first exon (exon 1). In all var sequences this hydrophobic region fits the criteria of a transmembrane segment. The second exon (exon II) encodes a large (45-55 kD) conserved C-terminal sequence that has an acid character (predicted pi - 4.5, vs. 5.9 for the part of the protein upstream of the splice junction) and a cysteine content of < 1 % (vs. > 4% upstream). The position of this C-terminal sequence downstream of a single transmembrane segment suggests that it has a cytoplasmic location. No consensus signal sequence was detected in the NH 2 -terminal region of the predicted var ORFs. We note the presence of several motifs in the protein sequences that are known to act as ligands and receptors in the integrin family. These include RGD (var-1 codons 886-88, 1992-94) and DGEA (var- 1 codons 2111-14). Not all of these motifs occur in each protein sequence and, when they do occur, their positions vary. Identification of var transcripts and chromosome expression sites. To identify transcribed var sequences we screened a Λgt10 Dd2 cDNA library with iw-coπtaining BssWW restriction fragments that had been purified from PfYED9 and radiolabeled by random hexamer priming. This screening yielded 18 clones with inserts that hybridized back to PfYED9. By cross-hybridization studies and DNA sequence analysis the inserts fell into two groups: group I inserts that aligned with sequences of var exon I (ΛT240, ΛT242, ΛT244, ΛT2δ4, ΪT287, ΛT288, ΛT295, ΛT296); and group II inserts that aligned with sequences of var exon II (ΛT140, ΛT141, ΛT142, ΛT145, ΛT147, > 4T148, ΛTI50, ΛT152). The full ORF of an expressed var gene (varl) was determined from ΛT242 and overlapping cDNA clones that were obtained by a PCR-based walking strategy. The sequence showed that varl has a 6.6 kb ORF containing two DBL domains, a hydrophobic transmembrane sequence and carboxy-terminal region typical of var genes (predicted molecular weight 249 kD). Comparison of varl with the varl sequence demonstrated continuity of the alignments at the predicted splice junction between the ORFs of exons I and II. PCR amplification of Dd2 genomic DNA was also performed with primers derived from the two varl exons. Sequence of this varl PCR product confirmed consensus splice sites and a 1 kb intron typical of the var genes. Transcription of varl was detected as a 7.5 kb band by RNA blot analysis. Chromosome mapping experiments with a ιw-7-specific probe localized the varl gene to a region that is 600 kb from one end of Dd2 chromosome 12 (chromosome 12 has a length of 2600 kb). No hybridization of the varl probe was detected to any other Dd2 chromosome nor to any chromosomes of the HB3, 3D7 or A4 parasites. Other cDNA inserts from the group I clones were also sequenced and examined for chromosome hybridization signals. The ΛT240 cDNA insert mapped to the var-Mvar-2lvar-3 cluster on Dd2 chromosome 7 and its sequence matched that of var-3. The ΛT244, ΛT284, ΛT2δ7, ΛT2δδ, ΛT295 and ΛT296 inserts all showed overlapping sequences and yielded the same hybridization patterns. Chromosome sites recognized by these inserts included regions within two Sma\ fragments from Dd2 chromosome 7 and another from chromosome 9. We note that loss of a cytoadherence phenotype has been correlated with a chromosome 9 deletion in certain P. falciparum lines. 1.8 kb to 2.4 kb RNA transcripts related to var exon II. In addition to the 7.5 kb varl band, a broad 1.8 kb to 2.4 kb band was detected on RNA blots after hybridization with a probe that recognizes var exon II. Sequences of eight group II cDNA inserts homologous to exon II were therefore determined and aligned against the var genes. Comparative analysis of the insert sequences showed that all differed from one another in regions of overlap, indicating that transcription of the corresponding RNAs was from different loci. Three of the cDNA sequences ( IT 140, ΛTI41 and ΛTI48) aligned downstream of the intron/exon II splice junction. However, five other cDNA inserts (ΛT142, ΛT145, ΛT147, ΛT150 and ΛT152) had sequences that aligned upstream of the var intron/exon II splice site and included regions homologous to var intron sequences. In the vicinity of the splice junction, consensus splice sites occurred in three of the cDNA sequences (ΛT142, ΛTI47, ΛT150) while a fourth sequence (ΛT145) showed the required AG dinucleotide but not the expected pyrimidine tract of the splice consensus. The part of the fifth sequence (ΛT152) that aligned with the var intron extended upstream only to the TAG of the splice sequence. All five sequences lacked a consensus start codon preceded by A+T-rich non-coding DNA that is typical of P. falciparum translation start sites. Isolate-specific var sequences and evidence for DNA recombination in cultivated parasite clones. The diversity of var forms expressed by P. falciparum parasites reflects a tremendous repertoire in the var gene family. This repertoire is evident in the patterns of restriction polymorphism detected by var probes as well as in the detection of røΛ-specific sequences that hybridize to some parasite DNAs but not to others. The var- 7 gene expressed by Dd2, for example, is not present in the HB3, 3D7 or A4 genomes. Such var diversity suggests that frequent DNA rearrangements underlie the production of antigenically variant types in different parasite strains. To test for DNA rearrangements in parasites cultivated in vitro, we used var sequences to probe restricted DNAs from Dd2 lines adapted to neuraminidase-treated erythrocytes. In one rearrangement a novel 35 kb BgΛ fragment is seen in NM1 DNA probed with the ΛT142 (group II) insert. In another rearrangement a deletion of a 20 kb Pst\ band is evident in NM8 DNA probed with a varl sequence. Deletion of this 20 kb band was also detected in the Dd2/R8 subclone obtained before neuraminidase selection, indicating that the DNA rearrangement was not produced by selection in neuraminidase-treated erythrocytes. The above examples are provided to illustrate the invention and other variants of the invention encompassed by the claims will be readily apparent to one of ordinary skill in the art. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: The United States, As Represented by the Secretary, Department of Health and Human Services (ii) TITLE OF INVENTION: BINDING DOMAINS FROM PLASMODIUM VIVAX AND PLASMODIUM FALCIPARUM ERYTHROCYTE BINDING PROTEINS Iiii) NUMBER OF SEQUENCES: 45 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Knobbe Martens Olson & Bear (B) STREET: 620 Newport Center Drive 16th Floor (C) CITY: Newport Beach (D) STATE: California (E) COUNTRY: US (F) ZIP: 92660 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA (A) APPLICATION NUMBER: US08/487826 (B) FILING DATE: 07-JUN-1996 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Israelsen, Ned (B) REGISTRATION NUMBER: 29,655 (C) REFERENCE/DOCKET NUMBER: NIH121.001QPC (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (619) 235-8550 (B) TELEFAX: (619) 235-0176 (2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4084 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium vivax (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: AAGCTTTTAA AAATAGCAAC AAAATTTCGA AACATTGCCA CAAAAATTTT ATGTTTTACA 60 TATATTTAGATTCATACAAT TTAGGTGTAC CCTGTTTTTT GATATATGCG CTTAAATTTT 120 TTTTTCGCTCATATGTTTAGTTATATGTGTAGAACAACTTGCTGAATAAATTACGTACAC 180 TTTCTGTTCT GAATAATATTACCACATACATTTAATTTTAAATACTATGAAAGGAAAAAA 240 CCGCTCTTTATTTGTTCTCCTAGTTTTATTATTGTTACACAAGGTATCATATAAGGATGA 300 TTTTTCTATCACACTAATAAATTATCATGAAGGAAAAAAATATTTAATTATACTAAAAAG 360 AAAATTAGAAAAAGCTAATAATCGTGATGT TTGCAATTTT TTTCTTCATT TCTCTCAGGT 420 AAATAATGTATTATTAGAAC GAACAATTGAAACCCTTCTAGAATGCAAAAATGAATATGT 480 GAAAGGTGAAAATGGTTATAAATTAGCTAAAGGACACCAC TGTGTTGAGGAAGATAACTT 540 AGAACGATGG TTACAAGGAACCAATGAAAGAAGAAGTGAGGAAAATATAAAATATAAATA 600 TGGAGTAACG GAACTAAAAATAAAGTATGC GCAAATGAAT GGAAAAAGAAGCAGCCGCAT 660 TTTGAAGGAATCAATTTACGGGGCGCATAA CTTTGGAGGCAACAGTTACATGGAGGGAAA 720 AGATGGAGGAGATAAAACTG GGGAGGAAAAAGATGGAGAA CATAAAACTGATAGTAAAAC 780 TGATAACGGGAAAGGTGCAAACAATTTGGTAATGTTAGAT TATGAGACAT CTAGCAATGG 840 CCAGCCAGCG GGAACCCTTGATAATGTTCT TGAATTTGTGACTGGGCATGAGGGAAATTC 900 TCGTAAAAAT TCCTCGAATG GTGGCAATCC TTACGATATT GATCATAAGAAAACGATCTC 960 TAGTGCTATT ATAAATCATG CTTTTCTTCA AAATACTGTA ATGAAAAACT GTAATTATAA 1020 GAGAAAACGT CGGGAAAGAG ATTGGGACTG TAACACTAAG AAGGATGTTT GTATACCAGA 1080 TCGAAGATAT CAATTATGTA TGAAGGAACT TACGAATTTG GTAAATAATA CAGACACAAA 1140 TTTTCATAGG GATATAACAT TTCGAAAATT ATATTTGAAA AGGAAACTTA TTTATGATGC 1200 TGCAGTAGAG GGCGATTTAT TACTTAAGTT GAATAACTAC AGATATAACA AAGACTTTTG 1260 CAAGGATATA AGATGGAGTT TGGGAGATTT TGGAGATATA ATTATGGGAA CGGATATGGA 1320 AGGCATCGGA TATTCCAAAG TAGTGGAAAA TAATTTGCGC AGCATCTTTG GAACTGATGA 1380 AAAGGCCCAA CAGCGTCGTA AACAGTGGTG GAATGAATCT AAAGCACAAA TTTGGACAGC 1440 AATGATGTAC TCAGTTAAAA AAAGATTAAA GGGGAATTTT ATATGGATTT GTAAATTAAA 1500 TGTTGCGGTA AATATAGAAC CGCAGATATA TAGATGGATT CGAGAATGGG GAAGGGATTA 1560 CGTGTCAGAA TTGCCCACAG AAGTGCAAAA ACTGAAAGAA AAATGTGATG GAAAAATCAA 1620 TTATACTGAT AAAAAAGTAT GTAAGGTACC ACCATGTCAA AATGCGTGTA AATCATATGA 1680 TCAATGGATA ACCAGAAAAA AAAATCAATG GGATGTTCTG TCAAATAAAT TCATAAGTGT 1740 AAAAAACGCA GAAAAGGTTC AGACGGCAGG TATCGTAACT CCTTATGATA TACTAAAACA 1800 GGAGTTAGAT GAATTTAACG AGGTGGCTTT TGAGAATGAA ATTAACAAAC GTGATGGTGC 1860 ATATATTGAG TTATGCGTTT GTTCCGTTGA AGAGGCTAAA AAAAATACTC AGGAAGTTGT 1920 GACAAATGTG GACAATGCTG CTAAATCTCA GGCCACCAAT TCAAATCCGA TAAGTCAGCC 1980 TGTAGATAGT AGTAAAGCGG AGAAGGTTCC AGGAGATTCT ACGCATGGAA ATGTTAACAG 2040 TGGCCAAGAT AGTTCTACCA CAGGTAAAGC TGTTACGGGG GATGGTCAAA ATGGAAATCA 2100 GACACCTGCA GAAAGCGATG TACAGCGAAG TGATATTGCC GAAAGTGTAA GTGCTAAAAA 2160 TGTTGATCCG CAGAAATCTG TAAGTAAAAG AAGTGACGAC ACTGCAAGCG TTACAGGTAT 2220 TGCCGAAGCT GGAAAGGAAA ACTTAGGCGC ATCAAATAGT CGACCTTCTG AGTCCACCGT 2280 TGAAGCAAAT AGCCCAGGTG ATGATACTGT GAACAGTGCA TCTATACCTG TAGTGAGTGG 2340 TGAAAACCCA TTGGTAACCC CCTATAATGG TTTGAGGCAT TCGAAAGACA ATAGTGATAG 2400 CGATGGACCT GCGGAATCAA TGGCGAATCC TGATTCAAAT AGTAAAGGTG AGACGGGAAA 2460 GGGGCAAGAT AATGATATGG CGAAGGCTAC TAAAGATAGT AGTAATAGTT CAGATGGTAC 2520 CAGCTCTGCT ACGGGTGATA CTACTGATGC AGTTGATAGG GAAATTAATA AAGGTGTTCC 2580 TGAGGATAGG GATAAAACTG TAGGAAGTAA AGATGGAGGG GGGGAAGATA ACTCTGCAAA 2640 TAAGGATGCA GCGACTGTAG TTGGTGAGGA TAGAATTCGT GAGAACAGCG CTGGTGGTAG 2700 CACTAATGAT AGATCAAAAA ATGACACGGA AAAGAACGGG GCCTCTACCC CTGACAGTAA 2760 ACAAAGTGAG GATGCAACTG CGCTAAGTAA AACCGAAAGT TTAGAATCAA CAGAAAGTGG 2820 AGATAGAACT ACTAATGATA CAACTAACAG TTTAGAAAAT AAAAATGGAG GAAAAGAAAA 2880 GGATTTACAA AAGCATGATT TTAAAAGTAA TGATACGCCG AATGAAGAAC CAAATTCTGA 2940 TCAAACTACA GATGCAGAAG GACATGACAG GGATAGCATC AAAAATGATA AAGCAGAAAG 3000 GAGAAAGCAT ATGAATAAAG ATACTTTTAC GAAAAATACA AATAGTCACC ATTTAAATAG 3060 TAATAATAAT TTGAGTAATG GAAAATTAGA TATAAAAGAA TACAAATACA GAGATGTCAA 3120 AGCAACAAGG GAAGATATTA TATTAATGTC TTCAGTACGC AAGTGCAACA ATAATATTTC 3180 TTTAGAGTAC TGTAACTCTG TAGAGGACAA AATATCATCG AATACTTGTT CTAGAGAGAA 3240 AAGTAAAAAT TTATGTTGCT CAATATCGGA TTTTTGTTTG AACTATTTTG ACGTGTATTC 3300 TTATGAGTAT CTTAGCTGCA TGAAAAAGGA ATTTGAAGAT CCATCCTACA AGTGCTTTAC 3360 GAAAGGGGGC TTTAAAGGTA TGCAGAAAAA GATGCTGAAT AGAGAAAGGT GTTGAGTAAA 3420 TTAAAAAGGA ATTAATTTTA GGAATGTTAT AAACATTTTT GTACCCAAAA TTCTTTTTGC 3480 AGACAAGACT TACTTTGCCG CGGCGGGAGC GTTGCTGATA CTGCTGTTGT TAATTGCTTC 3540 AAGGAAGATG ATCAAAAATG AGTAACCAGA AAATAAAATA AAATAACATA AAATAAAATA 3600 AAAACTAGAA TAACAATTAA AATAAAATAA AATGAGAAAT GCCTGTTAAT GCACAGTTAA 3660 TTCTAACGAT TCCATTTGTG AAGTTTTAAA GAGAGCACAA ATGCATAGTC ATTATGTCCA 3720 TGCATATATA CACATATATG TACGTATATA TAATAAACGC ACACTTTCTT GTTCGTACAG 3780 TTCTGAAGAA GCTACATTTA ATGAGTTTGA AGAATACTGT GATAATATTC ACAGAATCCC 3840 TCTGATGCCT AACAGTAATT CAAATTTCAA GAGCAAAATT CCATTTAAAA AGAAATGTTA 3900 CATCATTTTG CGTTTTTCTT TTTTTCTTTT TTTTTTCTTT TTTAGATATT GAACACATGC 3960 AGCCATCAAC CCCCCTGGAT TATTCATGAT GCTACTTTGG TAAGTAAAAG CAATTCTGAT 4020 TGTAGTGCTG ATGTAATTTT AGTCATTTTG CTTGCTGCAA TAAACGAGAA AATATATCAA 4080 GCTT 4084 (2) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1115 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium vivax (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : Met Lys Gly Lys Asn Arg Ser Leu Phe Val Leu Leu Val Leu Leu Leu 1 5 10 15 Leu His Lys Val Ser Tyr Lys Asp Asp Phe Ser lie Thr Leu lie Asn 20 25 30 Tyr His Glu Gly Lys Lys Tyr Leu lie lie Leu Lys Arg Lys Leu Glu 35 40 45 Lys Ala Asn Asn Arg Asp Val Cys Asn Phe Phe Leu His Phe Ser Gin 50 55 60 Val Asn Asn Val Leu Leu Glu Arg Thr lie Glu Thr Leu Leu Glu Cys 65 70 75 80 Lys Asn Glu Tyr Val Lys Gly Glu Asn Gly Tyr Lys Leu Ala Lys Gly 85 90 95 His His Cys Val Glu Glu Asp Asn Leu Glu Arg Trp Leu Gin Gly Thr 100 105 110 Asn Glu Arg Arg Ser Glu Glu Asn lie Lys Tyr Lys Tyr Gly Val Thr 115 120 125 Glu Leu Lys lie Lys Tyr Ala Gin Met Asn Gly Lys Arg Ser Ser Arg 130 135 140 lie Leu Lys Glu Ser lie Tyr Gly Ala His Asn Phe Gly Gly Asn Ser 145 150 155 160 Tyr Met Glu Gly Lys Asp Gly Gly Asp Lys Thr Gly Glu Glu Lys Asp 165 170 175 Gly Glu His Lys Thr Asp Ser Lys Thr Asp Asn Gly Lys Gly Ala Asn 180 185 190 Asn Leu Val Met Leu Asp Tyr Glu Thr Ser Ser Asn Gly Gin Pro Ala 195 200 205 Gly Thr Leu Asp Asn Val Leu Glu Phe Val Thr Gly His Glu Gly Asn 210 215 220 Ser Arg Lys Asn Ser Ser Asn Gly Gly Asn Pro Tyr Asp lie Asp His 225 230 235 240 Lys Lys Thr lie Ser Ser Ala lie lie Asn His Ala Phe Leu Gin Asn 245 250 255 Thr Val Met Lys Asn Cys Asn Tyr Lys Arg Lys Arg Arg Glu Arg Asp 260 265 270 Trp Asp Cys Asn Thr Lys Lys Asp Val Cys lie Pro Asp Arg Arg Tyr 275 280 285 Gin Leu Cys Met Lys Glu Leu Thr Asn Leu Val Asn Asn Thr Asp Thr 290 295 300 Asn Phe His Arg Asp lie Thr Phe Arg Lys Leu Tyr Leu Lys Arg Lys 305 310 315 320 Leu lie Tyr Asp Ala Ala Val Glu Gly Asp Leu Leu Leu Lys Leu Asn 325 330 335 Asn Tyr Arg Tyr Asn Lys Asp Phe Cys Lys Asp lie Arg Trp Ser Leu -34- 340 345 350 Gly Asp Phe Gly Asp lie lie Met Gly Thr Asp Met Glu Gly lie Gly 355 360 365 Tyr Ser Lys Val Val Glu Asn Asn Leu Arg Ser lie Phe Gly Thr Asp 370 375 380 Glu Lys Ala Gin Gin Arg Arg Lys Gin Trp Trp Asn Glu Ser Lys Ala 385 390 395 400 Gin lie Trp Thr Ala Met Met Tyr Ser Val Lys Lys Arg Leu Lys Gly 405 410 415 Asn Phe lie Trp lie Cys Lys Leu Asn Val Ala Val Asn lie Glu Pro 420 425 430 Gin lie Tyr Arg Trp lie Arg Glu Trp Gly Arg Asp Tyr Val Ser Glu 435 440 445 Leu Pro Thr Glu Val Gin Lys Leu Lys Glu Lys Cys Asp Gly Lys lie 450 455 460 Asn Tyr Thr Asp Lys Lys Val Cys Lys Val Pro Pro Cys Gin Asn Ala 465 470 475 480 Cys Lys Ser Tyr Asp Gin Trp lie Thr Arg Lys Lys Asn Gin Trp Asp 485 490 495 Val Leu Ser Asn Lys Phe lie Ser Val Lys Asn Ala Glu Lys Val Gin 500 505 510 Thr Ala Gly lie Val Thr Pro Tyr Asp lie Leu Lys Gin Glu Leu Asp 515 520 525 Glu Phe Asn Glu Val Ala Phe Glu Asn Glu lie Asn Lys Arg Asp Gly 530 535 540 Ala Tyr lie Glu Leu Cys Val Cys Ser Val Glu Glu Ala Lys Lys Asn 545 550 555 560 Thr Gin Glu Val Val Thr Asn Val Asp Asn Ala Ala Lys Ser Gin Ala 565 570 575 Thr Asn Ser Asn Pro lie Ser Gin Pro Val Asp Ser Ser Lys Ala Glu 580 585 590 Lys Val Pro Gly Asp Ser Thr His Gly Asn Val Asn Ser Gly Gin Asp 595 600 605 Ser Ser Thr Thr Gly Lys Ala Val Thr Gly Asp Gly Gin Asn Gly Asn 610 615 620 Gin Thr Pro Ala Glu Ser Asp Val Gin Arg Ser Asp lie Ala Glu Ser 625 630 635 640 Val Ser Ala Lys Asn Val Asp Pro Gin Lys Ser Val Ser Lys Arg Ser 645 650 655 Asp Asp Thr Ala Ser Val Thr Gly lie Ala Glu Ala Gly Lys Glu Asn 660 665 670 Leu Gly Ala Ser Asn Ser Arg Pro Ser Glu Ser Thr Val Glu Ala Asn 675 680 685 Ser Pro Gly Asp Asp Thr Val Asn Ser Ala Ser lie Pro Val Val Ser 690 695 700 Gly Glu Asn Pro Leu Val Thr Pro Tyr Asn Gly Leu Arg His Ser Lys 705 710 715 720 Asp Asn Ser Asp Ser Asp Gly Pro Ala Glu Ser Met Ala Asn Pro Asp 725 730 735 Ser Asn Ser Lys Gly Glu Thr Gly Lys Gly Gin Asp Asn Asp Met Ala 740 745 750 Lys Ala Thr Lys Asp Ser Ser Asn Ser Ser Asp Gly Thr Ser Ser Ala 755 760 765 Thr Gly Asp Thr Thr Asp Ala Val Asp Arg Glu lie Asn Lys Gly Val 770 775 780 Pro Glu Asp Arg Asp Lys Thr Val Gly Ser Lys Asp Gly Gly Gly Glu 785 790 795 800 Asp Asn Ser Ala Asn Lys Asp Ala Ala Thr Val Val Gly Glu Asp Arg 805 810 815 lie Arg Glu Asn Ser Ala Gly Gly Ser Thr Asn Asp Arg Ser Lys Asn 820 825 830 Asp Thr Glu Lys Asn Gly Ala Ser Thr Pro Asp Ser Lys Gin Ser Glu 835 840 845 Asp Ala Thr Ala Leu Ser Lys Thr Glu Ser Leu Glu Ser Thr Glu Ser 850 855 860 Gly Asp Arg Thr Thr Asn Asp Thr Thr Asn Ser Leu Glu Asn Lys Asn 865 870 875 880 Gly Gly Lys Glu Lys Asp Leu Gin Lys His Asp Phe Lys Ser Asn Asp 885 890 895 Thr Pro Asn Glu Glu Pro Asn Ser Asp Gin Thr Thr Asp Ala Glu Gly 900 905 910 His Asp Arg Asp Ser lie Lys Asn Asp Lys Ala Glu Arg Arg Lys His 915 920 925 Met Asn Lys Asp Thr Phe Thr Lys Asn Thr Asn Ser His His Leu Asn 930 935 940 Ser Asn Asn Asn Leu Ser Asn Gly Lys Leu Asp lie Lys Glu Tyr Lys 945 950 955 960 Tyr Arg Asp Val Lys Ala Thr Arg Glu Asp lie lie Leu Met Ser Ser 965 970 975 Val Arg Lys Cys Asn Asn Asn lie Ser Leu Glu Tyr Cys Asn Ser Val 980 985 990 Glu Asp Lys lie Ser Ser Asn Thr Cys Ser Arg Glu Lys Ser Lys Asn 995 1000 1005 Leu Cys Cys Ser lie Ser Asp Phe Cys Leu Asn Tyr Phe Asp Val Tyr 1010 1015 1020 Ser Tyr Glu Tyr Leu Ser Cys Met Lys Lys Glu Phe Glu Asp Pro Ser 1025 1030 1035 1040 Tyr Lys Cys Phe Thr Lys Gly Gly Phe Lys lie Asp Lys Thr Tyr Phe 1045 1050 1055 Ala Ala Ala Gly Ala Leu Leu lie Leu Leu Leu lie Ala Ser Arg Lys 1060 1065 1070 Met lie Lys Asn Asp Ser Glu Glu Ala Thr Phe Asn Glu Phe Glu Glu 1075 1080 1085 Tyr Cys Asp Asn lie His Arg lie Pro Leu Met Pro Asn Asn lie Glu 1090 1095 1100 His Met Gin Pro Ser Thr Pro Leu Asp Tyr Ser 1105 1110 1115 (2) INFORMATION FOR SEQ ID NO:3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4507 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : ' TATATATATA TATATATATA GATAATAACA TATAAATATA TTCAATGTGC ATACAATGAA 60 ATGTAATATT AGTATATATT TTTTTGCTTC CTTCTTTGTG TTATATTTTG CAAAAGCTAG 120 GAATGAATAT GATATAAAAGAGAATGAAAAATTTTTAGAC GTGTATAAAGAAAAATTTAA 180 TGAATTAGATAAAAAGAAATATGGAAATGT TCAAAAAACT GATAAGAAAATATTTACTTT 240 TATAGAAAAT AAATTAGATATTTTAAATAA TTCAAAATTT AATAAAAGAT GGAAGAGTTA 300 TGGAACTCCA GATAATATAGATAAAAATAT GTCTTTAATAAATAAACATAATAATGAAGA 360 AATGTTTAACAACAATTATC AATCATTTTT ATCGACAAGT TCATTAATAAAGCAAAATAA 420 ATATGTTCCTATTAACGCTGTACGTGTGTC TAGGATATTAAGTTTCCTGGATTCTAGAAT 480 TAATAATGGAAGAAATACTT CATCTAATAA CGAAGTTTTAAGTAATTGTA GGGAAAAAAG 540 GAAAGGAATGAAATGGGATT GTAAAAAGAAAAATGATAGAAGCAACTATG TATGTATTCC 600 TGATCGTAGAATCCAATTAT GCATTGTTAA TCTTAGCATTATTAAAACATATACAAAAGA 660 GACCATGAAGGATCATTTCATTGAAGCCTC TAAAAAAGAATCTCAACTTT TGCTTAAAAA 720 AAATGATAAC AAATATAATT CTAAATTTTG TAATGATTTG AAGAATAGTT TTTTAGATTA 780 TGGACATCTT GCTATGGGAAATGATATGGATTTTGGAGGT TATTCAACTAAGGCAGAAAA 840 CAAAATTCAAGAAGTTTTTAAAGGGGCTCATGGGGAAATAAGTGAACATAAAATTAAAAA 900 TTTTAGAAAAGAATGGTGGAATGAATTTAGAGAGAAACTT TGGGAAGCTATGTTATCTGA 960 GCATAAAAAT AATATAAATA ATTGTAAAAA TATTCCCCAA GAAGAATTAC AAATTACTCA 1020 ATGGATAAAA GAATGGCATG GAGAATTTTT GCTTGAAAGA GATAATAGAT CAAAATTGCC 1080 AAAAAGTAAA TGTAAAAATA ATACATTATA TGAAGCATGT GAGAAGGAAT GTATTGATCC 1140 ATGTATGAAA TATAGAGATT GGATTATTAG AAGTAAATTT GAATGGCATA CGTTATCGAA 1200 AGAATATGAA ACTCAAAAAG TTCCAAAGGA AAATGCGGAA AATTATTTAA TCAAAATTTC 1260 AGAAAACAAG AATGATGCTA AAGTAAGTTT ATTATTGAAT AATTGTGATG CTGAATATTC 1320 AAAATATTGT GATTGTAAAC ATACTACTAC TCTCGTTAAA AGCGTTTTAA ATGGTAACGA 1380 CAATACAATT AAGGAAAAGC GTGAACATAT TGATTTAGAT GATTTTTCTA AATTTGGATG 1440 TGATAAAAAT TCCGTTGATA CAAACACAAA GGTGTGGGAA TGTAAAAACC CTTATATATT 1500 ATCCACTAAA GATGTATGTG TACCTCCGAG GAGGCAAGAA TTATGTCTTG GAAACATTGA 1560 TAGAATATAC GATAAAAACC TATTAATGAT AAAAGAGCAT ATTCTTGCTA TTGCAATATA 1620 TGAATCAAGA ATATTGAAAC GAAAATATAA GAATAAAGAT GATAAAGAAG TTTGTAAAAT 1680 CATAAATAAA ACTTTCGCTG ATATAAGAGA TATTATAGGA GGTACTGATT ATTGGAATGA 1740 TTTGAGCAAT AGAAAATTAG TAGGAAAAAT TAACACAAAT TCAAAATATG TTCACAGGAA 1800 TAAAAAAAAT GATAAGCTTT TTCGTGATGA GTGGTGGAAA GTTATTAAAA AAGATGTATG 1860 GAATGTGATA TCATGGGTAT TCAAGGATAA AACTGTTTGT AAAGAAGATG ATATTGAAAA 1920 TATACCACAA TTCTTCAGAT GGTTTAGTGA ATGGGGTGAT GATTATTGCC AGGATAAAAC 1980 AAAAATGATA GAGACTCTGA AGGTTGAATG CAAAGAAAAA CCTTGTGAAG ATGACAATTG 2040 TAAAAGTAAA TGTAATTCAT ATAAAGAATG GATATCAAAA AAAAAAGAAG AGTATAATAA 2100 ACAAGCCAAA CAATACCAAG AATATCAAAA AGGAAATAAT TACAAAATGT ATTCTGAATT 2160 TAAATCTATA AAACCAGAAG TTTATTTAAA GAAATACTCG GAAAAATGTT CTAACCTAAA 2220 TTTCGAAGAT GAATTTAAGG AAGAATTACA TTCAGATTAT AAAAATAAAT GTACGATGTG 2280 TCCAGAAGTA AAGGATGTAC CAATTTCTAT AATAAGAAAT AATGAACAAA CTTCGCAAGA 2340 AGCAGTTCCT GAGGAAAACA CTGAAATAGC ACACAGAACG GAAACTCCAT CTATCTCTGA 2400 AGGACCAAAA GGAAATGAAC AAAAAGAACG TGATGACGAT AGTTTGAGTA AAATAAGTGT 2460 ATCACCAGAA AATTCAAGAC CTGAAACTGA TGCTAAAGAT ACTTCTAACT TGTTAAAATT 2520 AAAAGGAGAT GTTGATATTA GTATGCCTAA AGCAGTTATT GGGAGCAGTC CTAATGATAA 2580 TATAAATGTT ACTGAACAAG GGGATAATAT TTCCGGGGTG AATTCTAAAC CTTTATCTGA 2640 TGATGTACGT CCAGATAAAA AGGAATTAGA AGATCAAAAT AGTGATGAAT CGGAAGAAAC 2700 TGTAGTAAAT CATATATCAA AAAGTCCATC TATAAATAAT GGAGATGATT CAGGCAGTGG 2760 AAGTGCAACA GTGAGTGAAT CTAGTAGTTC AAATACTGGA TTGTCTATTG ATGATGATAG 2820 AAATGGTGAT ACATTTGTTC GAACACAAGA TACAGCAAAT ACTGAAGATG TTATTAGAAA 2880 AGAAAATGCT GACAAGGATG AAGATGAAAA AGGCGCAGAT GAAGAAAGAC ATAGTACTTC 2940 TGAAAGCTTA AGTTCACCTG AAGAAAAAAT GTTAACTGAT AATGAAGGAG GAAATAGTTT 3000 AAATCATGAA GAGGTGAAAG AACATACTAG TAATTCTGAT AATGTTCAAC AGTCTGGAGG 3060 AATTGTTAAT ATGAATGTTG AGAAAGAACT AAAAGATACT TTAGAAAATC CTTCTAGTAG 3120 CTTGGATGAA GGAAAAGCAC ATGAAGAATT ATCAGAACCA AATCTAAGCA GTGACCAAGA 3180 TATGTCTAAT ACACCTGGAC CTTTGGATAA CACCAGTGAA GAAACTACAG AAAGAATTAG 3240 TAATAATGAA TATAAAGTTA ACGAGAGGGA AGATGAGAGA ACGCTTACTA AGGAATATGA 3300 AGATATTGTT TTGAAAAGTC ATATGAATAG AGAATCAGAC GATGGTGAAT TATATGACGA 3360 AAATTCAGAC TTATCTACTG TAAATGATGA ATCAGAAGAC GCTGAAGCAA AAATGAAAGG 3420 AAATGATACA TCTGAAATGT CGCATAATAG TAGTCAACAT ATTGAGAGTG ATCAACAGAA 3480 AAACGATATG AAAACTGTTG GTGATTTGGG AACCACACAT GTACAAAACG AAATTAGTGT 3540 TCCTGTTACA GGAGAAATTG ATGAAAAATT AAGGGAAAGT AAAGAATCAA AAATTCATAA 3600 GGCTGAAGAG GAAAGATTAA GTCATACAGA TATACATAAA ATTAATCCTG AAGATAGAAA 3660 TAGTAATACA TTACATTTAA AAGATATAAG AAATGAGGAA AACGAAAGAC ACTTAACTAA 3720 TCAAAACATT AATATTAGTC AAGAAAGGGA TTTGCAAAAA CATGGATTCC ATACCATGAA 3780 TAATCTACAT GGAGATGGAG TTTCCGAAAG AAGTCAAATT AATCATAGTC ATCATGGAAA 3840 CAGACAAGAT CGGGGGGGAA ATTCTGGGAA TGTTTTAAAT ATGAGATCTA ATAATAATAA 3900 TTTTAATAAT ATTCCAAGTA GATATAATTT ATATGATAAA AAATTAGATT TAGATCTTTA 3960 TGAAAACAGA AATGATAGTA CAACAAAAGA ATTAATAAAG AAATTAGCAG AAATAAATAA 4020 ATGTGAGAAC GAAATTTCTG TAAAATATTG TGACCATATG ATTCATGAAG AAATCCCATT 4080 AAAAACATGC ACTAAAGAAA AAACAAGAAA TCTGTGTTGT GCAGTATCAG ATTACTGTAT 4140 GAGCTATTTT ACATATGATT CAGAGGAATA TTATAATTGT ACGAAAAGGG AATTTGATGA 4200 TCCATCTTAT ACATGTTTCA GAAAGGAGGC TTTTTCAAGT ATGATATTCA AATTTTTAAT 4260 AACAAATAAA ATATATTATT ATTTTTATAC TTACAAAACT GCAAAAGTAA CAATAAAAAA 4320 AATTAATTTC TCATTAATTT TTTTTTTCTT TTTTTCTTTT TAGGTATGCC ATATTATGCA 4380 GGAGCAGGTG TGTTATTTAT TATATTGGTT ATTTTAGGTG CTTCACAAGC CAAATATCAA 4440 AGGTTAGAAA AAATAAATAA AAATAAAATT GAGAAGAATG TAAATTAAAT ATAGAATTCG 4500 AGCTCGG 4507 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1435 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 : Met Lys Cys Asn lie Ser lie Tyr Phe Phe Ala Ser Phe Phe Val Leu 1 5 10 15 Tyr Phe Ala Lys Ala Arg Asn Glu Tyr Asp lie Lys Glu Asn Glu Lys 20 25 30 Phe Leu Asp Val Tyr Lys Glu Lys Phe Asn Glu Leu Asp Lys Lys Lys 35 40 45 Tyr Gly Asn Val Gin Lys Thr Asp Lys Lys lie Phe Thr Phe lie Glu 50 55 60 Asn Lys Leu Asp lie Leu Asn Asn Ser Lys Phe Asn Lys Arg Trp Lys 65 70 75 80 Ser Tyr Gly Thr Pro Asp Asn lie Asp Lys Asn Met Ser Leu lie Asn 85 90 95 Lys His Asn Asn Glu Glu Met Phe Asn Asn Asn Tyr Gin Ser Phe Leu 100 105 110 Ser Thr Ser Ser Leu lie Lys Gin Asn Lys Tyr Val Pro lie Asn Ala 115 120 125 Val Arg Val Ser Arg lie Leu Ser Phe Leu Asp Ser Arg lie Asn Asn 130 135 140 Gly Arg Asn Thr Ser Ser Asn Asn Glu Val Leu Ser Asn Cys Arg Glu 145 150 155 160 Lys Arg Lys Gly Met Lys Trp Asp Cys Lys Lys Lys Asn Asp Arg Ser 165 170 175 Asn Tyr Val Cys lie Pro Asp Arg Arg lie Gin Leu Cys lie Val Asn 180 185 190 Leu Ser lie lie Lys Thr Tyr Thr Lys Glu Thr Met Lys Asp His Phe 195 200 205 lie Glu Ala Ser Lys Lys Glu Ser Gin Leu Leu Leu Lys Lys Asn Asp 210 215 220 Asn Lys Tyr Asn Ser Lys Phe Cys Asn Asp Leu Lys Asn Ser Phe Leu 225 230 235 240 Asp Tyr Gly His Leu Ala Met Gly Asn Asp Met Asp Phe Gly Gly Tyr 245 250 255 Ser Thr Lys Ala Glu Asn Lys He Gin Glu Val -Phe Lys Gly Ala His 260 265 270 Gly Glu He Ser Glu His Lys He Lys Asn Phe Arg Lys Glu Trp Trp 275 280 285 Asn Glu Phe Arg Glu Lys Leu Trp Glu Ala Met Leu Ser Glu His Lys 290 295 300 Asn Asn He Asn Asn Cys Lys Asn He Pro Gin Glu Glu Leu Gin He 305 310 315 320 Thr Gin Trp He Lys Glu Trp His Gly Glu Phe Leu Leu Glu Arg Asp 325 330 335 Asn Arg Ser Lys Leu Pro Lys Ser Lys Cys Lys Asn Asn Thr Leu Tyr 340 345 350 Glu Ala Cys Glu Lys Glu Cys He Asp Pro Cys Met Lys Tyr Arg Asp 355 360 365 Trp He He Arg Ser Lys Phe Glu Trp His Thr Leu Ser Lys Glu Tyr -38- 370 375 380 Glu Thr Gin Lys Val Pro Lys Glu Asn Ala Glu Asn Tyr Leu He Lys 385 390 395 400 He Ser Glu Asn Lys Asn Asp Ala Lys Val Ser Leu Leu Leu Asn Asn 405 410 415 Cys Asp Ala Glu Tyr Ser Lys Tyr Cys Asp Cys Lys His Thr Thr Thr 420 425 430 Leu Val Lys Ser Val Leu Asn Gly Asn Asp Asn Thr He Lys Glu Lys 435 440 445 Arg Glu His He Asp Leu Asp Asp Phe Ser Lys Phe Gly Cys Asp Lys 450 455 460 Asn Ser Val Asp Thr Asn Thr Lys Val Trp Glu Cys Lys Asn Pro Tyr 465 470 475 480 He Leu Ser Thr Lys Asp Val Cys Val Pro Pro Arg Arg Gin Glu Leu 485 490 495 Cys Leu Gly Asn He Asp Arg He Tyr Asp Lys Asn Leu Leu Met He 500 505 510 Lys Glu His He Leu Ala He Ala He Tyr Glu Ser Arg He Leu Lys 515 520 525 Arg Lys Tyr Lys Asn Lys Asp Asp Lys Glu Val Cys Lys He He Asn 530 535 540 Lys Thr Phe Ala Asp He Arg Asp He He Gly Gly Thr Asp Tyr Trp 545 550 555 560 Asn Asp Leu Ser Asn Arg Lys Leu Val Gly Lys He Asn Thr Asn Ser 565 570 575 Lys Tyr Val His Arg Asn Lys Lys Asn Asp Lys Leu Phe Arg Asp Glu 580 585 590 Trp Trp Lys Val He Lys Lys Asp Val Trp Asn Val He Ser Trp Val 595 600 605 Phe Lys Asp Lys Thr Val Cys Lys Glu Asp Asp He Glu Asn He Pro 610 615 620 Gin Phe Phe Arg Trp Phe Ser Glu Trp Gly Asp Asp Tyr Cys Gin Asp 625 630 635 640 Lys Thr Lys Met He Glu Thr Leu Lys Val Glu Cys Lys Glu Lys Pro 645 650 655 Cys Glu Asp Asp Asn Cys Lys Ser Lys Cys Asn Ser Tyr Lys Glu Trp 660 665 670 He Ser Lys Lys Lys Glu Glu Tyr Asn Lys Gin Ala Lys Gin Tyr Gin 675 680 685 Glu Tyr Gin Lys Gly Asn Asn Tyr Lys Met Tyr Ser Glu Phe Lys Ser 690 695 700 He Lys Pro Glu Val Tyr Leu Lys Lys Tyr Ser Glu Lys Cys Ser Asn 705 710 715 720 Leu Asn Phe Glu Asp Glu Phe Lys Glu Glu Leu His Ser Asp Tyr Lys 725 730 735 Asn Lys Cys Thr Met Cys Pro Glu Val Lys Asp Val Pro He Ser He 740 745 750 He Arg Asn Asn Glu Gin Thr Ser Gin Glu Ala Val Pro Glu Glu Asn 755 760 765 Thr Glu He Ala His Arg Thr Glu Thr Pro Ser He Ser Glu Gly Pro 770 775 780 Lys Gly Asn Glu Gin Lys Glu Arg Asp Asp Asp Ser Leu Ser Lys He 785 790 795 800 Ser Val Ser Pro Glu Asn Ser Arg Pro Glu Thr Asp Ala Lys Asp Thr 805 810 815 Ser Asn Leu Leu Lys Leu Lys Gly Asp Val Asp He Ser Met Pro Lys 820 825 830 Ala Val He Gly Ser Ser Pro Asn Asp Asn He Asn Val Thr Glu Gin 835 840 845 Gly Asp Asn He Ser Gly Val Asn Ser Lys Pro Leu Ser Asp Asp Val 850 855 860 Arg Pro Asp Lys Lys Glu Leu Glu Asp Gin Asn Ser Asp Glu Ser Glu 865 870 875 880 Glu Thr Val Val Asn His He Ser Lys Ser Pro Ser He Asn Asn Gly 885 890 895 Asp Asp Ser Gly Ser Gly Ser Ala Thr Val Ser Glu Ser Ser Ser Ser 900 905 910 Asn Thr Gly Leu Ser He Asp Asp Asp Arg Asn Gly Asp Thr Phe Val 915 920 925 Arg Thr Gin Asp Thr Ala Asn Thr Glu Asp Val He Arg Lys Glu Asn 930 935 940 Ala Asp Lys Asp Glu Asp Glu Lys Gly Ala Asp Glu Glu Arg His Ser 945 950 955 960 Thr Ser Glu Ser Leu Ser Ser Pro Glu Glu Lys Met Leu Thr Asp Asn 965 970 975 Glu Gly Gly Asn Ser Leu Asn His Glu Glu Val Lys Glu His Thr Ser 980 985 990 Asn Ser Asp Asn Val Gin Gin Ser Gly Gly He Val Asn Met Asn Val 995 1000 1005 Glu Lys Glu Leu Lys Asp Thr Leu Glu Asn Pro Ser Ser Ser Leu Asp 1010 1015 1020 Glu Gly Lys Ala His Glu Glu Leu Ser Glu Pro Asn Leu Ser Ser Asp 1025 1030 1035 1040 Gin Asp Met Ser Asn Thr Pro Gly Pro Leu Asp Asn Thr Ser Glu Glu 1045 1050 1055 Thr Thr Glu Arg He Ser Asn Asn Glu Tyr Lys Val Asn Glu Arg Glu 1060 1065 1070 Asp Glu Arg Thr Leu Thr Lys Glu Tyr Glu Asp He Val Leu Lys Ser 1075 1080 1085 His Met Asn Arg Glu Ser Asp Asp Gly Glu Leu Tyr Asp Glu Asn Ser 1090 1095 1100 Asp Leu Ser Thr Val Asn Asp Glu Ser Glu Asp Ala Glu Ala Lys Met 1105 1110 1115 1120 Lys Gly Asn Asp Thr Ser Glu Met Ser His Asn Ser Ser Gin His He 1125 1130 1135 Glu Ser Asp Gin Gin Lys Asn Asp Met Lys Thr Val Gly Asp Leu Gly 1140 1145 1150 Thr Thr His Val Gin Asn Glu He Ser Val Pro Val Thr Gly Glu He 1155 1160 1165 Asp Glu Lys Leu Arg Glu Ser Lys Glu Ser Lys He His Lys Ala Glu 1170 1175 1180 Glu Glu Arg Leu Ser His Thr Asp He His Lys He Asn Pro Glu Asp 1185 1190 1195 1200 Arg Asn Ser Asn Thr Leu His Leu Lys Asp He Arg Asn Glu Glu Asn 1205 1210 1215 Glu Arg His Leu Thr Asn Gin Asn He Asn He Ser Gin Glu Arg Asp 1220 1225 1230 Leu Gin Lys His Gly Phe His Thr Met Asn Asn Leu His Gly Asp Gly 1235 1240 1245 Val Ser Glu Arg Ser Gin He Asn His Ser His His Gly Asn Arg Gin 1250 1255 1260 Asp Arg Gly Gly Asn Ser Gly Asn Val Leu Asn Met Arg Ser Asn Asn 1265 1270 1275 1280 Asn Asn Phe Asn Asn He Pro Ser Arg Tyr Asn' Leu Tyr Asp Lys Lys 1285 1290 1295 Leu Asp Leu Asp Leu Tyr Glu Asn Arg Asn Asp Ser Thr Thr Lys Glu 1300 1305 1310 Leu He Lys Lys Leu Ala Glu He Asn Lys Cys Glu Asn Glu He Ser 1315 1320 1325 Val Lys Tyr Cys Asp His Met He His Glu Glu He Pro Leu Lys Thr 1330 1335 1340 Cys Thr Lys Glu Lys Thr Arg Asn Leu Cys Cys Ala Val Ser Asp Tyr 1345 1350 1355 1360 Cys Met Ser Tyr Phe Thr Tyr Asp Ser Glu Glu Tyr Tyr Asn Cys Thr 1365 1370 1375 Lys Arg Glu Phe Asp Asp Pro Ser Tyr Thr Cys Phe Arg Lys Glu Ala 1380 1385 1390 Phe Ser Ser Met He Phe Lys Phe Leu He Thr Asn Lys He Tyr Tyr 1395 1400 1405 Tyr Phe Tyr Thr Tyr Lys Thr Ala Lys Val Thr He Lys Lys He Asn 1410 1415 1420 Phe Ser Leu He Phe Phe Phe Phe Phe Ser Phe 1425 1430 1435 (2) INFORMATION FOR SEQ ID NO:5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2288 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 : CACTTTATGC TTCCGGCTCG TATGTTGTGT GGAATTGTGA GCGGATAACA ATTTCACACA 60 GGAAACAGCTATGACCATGATTACGCCAAG CTCTAATACGACTCACTATAGGGAAAGCTG 120 GTACGCCTGC AGGTCCGGTC CGGAATTCAA TAAAATATTT CCAGAAAGGAATGTGCAAAT 180 TCACATATCC AATATATTCAAGGAATATAAAGAAAATAAT GTAGATATCATATTTGGAAC 240 GTTGAATTAT GAATATAATAATTTCTGTAAAGAAAAACCT GAATTAGTAT CTGCTGCCAA 300 GTATAATCTGAAAGCTCCAAATGCTAAATC CCCTAGAATA TACAAATCTAAGGAGCATGA 360 AGAATCAAGT GTGTTTGGTT GCAAAACGAAAATCAGTAAA GTTAAAAAAAAATGGAATTG 420 TTATAGTAAT AATAAAGTAA CTAAACCTGAAGGTGTATGT GGACCACCAAGAAGGCAACA 480 ATTATGTCTT GGATATATAT TTTTGATTCG CGACGGTAAC GAGGAAGGAT TAAAAGATCA 540 TATTAATAAG GCAGCTAATT ATGAGGCAAT GCATTTAAAA GAGAAATATG AGAATGCTGG 600 TGGTGATAAAATTTGCAATG CTATATTGGGAAGTTATGCA GATATTGGAG ATATTGTAAG 660 AGGTTTGGAT GTTTGGAGGG ATATAAATAC TAATAAATTA TCAGAAAAAT TCCAAAAAAT 720 TTTTATGGGT GGTGGTAATT CTAGGAAAAAACAAAACGATAATAATGAAC GTAATAAATG 780 GTGGGAAAAA CAAAGGAATT TAATATGGTC TAGTATGGTAAAACACATTC CAAAAGGAAA 840 AACATGTAAA CGTCATAATAATTTTGAGAAAATTCCTCAA TTTTTGAGAT GGTTAAAAGA 900 ATGGGGTGAT GAATTTTGTGAGGAAATGGG TACGGAAGTCAAGCAATTAGAGAAAATATG 960 TGAAAATAAA AATTGTTCGG AAAAAAAATG TAAAAATGCA TGTAGTTCCT ATGAAAAATG 1020 GATAAAGGAA CGAAAAAATG AATATAATTT GCAATCAAAG AAATTTGATA GTGATAAAAA 1080 ATTAAATAAA AAAAACAATC TTTATAATAA ATTTGAGGAT TCTAAAGCTT ATTTAAGGAG 1140 TGAATCAAAA CAGTGCTCAA ATATAGAATT TAATGATGAA ACATTTACAT TTCCTAATAA 1200 ATATAAAGAG GCTTGTATGG TATGTGAAAA TCCTTCATCT TCGAAAGCTC TTAAACCTAT 1260 AAAAACGAAT GTGTTTCCTA TAGAGGAATC AAAAAAATCT GAGTTATCAA GTTTAACAGA 1320 TAAATCTAAG AATACTCCTA ATAGTTCTGG TGGGGGAAAT TATGGAGATA GACAAATATC 1380 AAAAAGAGAC GATGTTCATC ATGATGGTCC TAAGGAAGTG AAATCCGGAG AAAAAGAGGT 1440 ACCAAAAATA GATGCAGCTG TTAAAACAGA AAATGAATTT ACCTCTAATC GAAACGATAT 1500 TGAAGGAAAG GAAAAAAGTA AAGGTGATCA TTCTTCTCCT GTTCATTCTA AAGATATAAA 1560 AAATGAGGAA CCACAAAGGG TGGTGTCTGA AAATTTACCT AAAATTGAAG AGAAAATGGA 1620 ATCTTCTGAT TCTATACCAA TTACTCATAT AGAAGCTGAA AAGGGTCAGT CTTCTAATTC 1680 TAGCGATAAT GATCCTGCAG TAGTAAGTGG TAGAGAATCT AAAGATGTAA ATCTTCATAC 1740 TTCTGAAAGG ATTAAAGAAA ATGAAGAAGG TGTGATTAAA ACAGATGATA GTTCAAAAAG 1800 TATTGAAATT TCTAAAATAC CATCTGACCA AAATAATCAT AGTGATTTAT CACAGAATGC 1860 AAATGAGGAC TCTAATCAAG GGAATAAGGA AACAATAAAT CCTCCTTCTA CAGAAAAAAA 1920 TCTCAAAGAA ATTCATTATA AAACATCTGA TTCTGATGAT CATGGTTCTA AAATTAAAAG 1980 TGAAATTGAA CCAAAGGAGT TAACGGAGGA ATCACCTCTT ACTGATAAAA AAACTGAAAG 2040 TGCAGCGATT GGTGATAAAA ATCATGAATC AGTAAAAAGC GCTGATATTT TTCAATCTGA 2100 GATTCATAAT TCTGATAATA GAGATAGAAT TGTTTCTGAA AGTGTAGTTC AGGATTCTTC 2160 AGGAAGCTCT ATGAGTACTG AATCTATACG TACTGATAAC AAGGATTTTA AAACAAGTGA 2220 GGATATTGCA CCTTCTATTA ATGGTCGGAA TTCCCGGGTC GACGAGCTCA CTAGTCGGCG 2280 GCCGCTCT 2288 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 749 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Ala Asp Asn Asn Phe Thr Gin Glu Thr Ala Met Thr Met He Thr Pro 1 5 10 15 Ser Ser Asn Thr Thr His Tyr Arg Glu Ser Trp Tyr Ala Cys Arg Ser 20 25 30 Gly Pro Glu Phe Asn Lys He Phe Pro Glu Arg Asn Val Gin He His 35 40 45 He Ser Asn He Phe Lys Glu Tyr Lys Glu Asn Asn Val Asp He He 50 55 60 Phe Gly Thr Leu Asn Tyr Glu Tyr Asn Asn Phe Cys Lys Glu Lys Pro 65 70 75 80 Glu Leu Val Ser Ala Ala Lys Tyr Asn Leu Lys Ala Pro Asn Ala Lys 85 90 95 Ser Pro Arg He Tyr Lys Ser Lys Glu His Glu Glu Ser Ser Val Phe 100 105 110 Gly Cys Lys Thr Lys He Ser Lys Val Lys Lys Lys Trp Asn Cys Tyr 115 120 125 Ser Asn Asn Lys Val Thr Lys Pro Glu Gly Val Cys Gly Pro Pro Arg 130 135 140 Arg Gin Gin Leu Cys Leu Gly Tyr He Phe Leu He Arg Asp Gly Asn 145 150 155 160 Glu Glu Gly Leu Lys Asp His He Asn Lys Ala Ala Asn Tyr Glu Ala 165 170 175 Met His Leu Lys Glu Lys Tyr Glu Asn Ala Gly Gly Asp Lys He Cys 180 185 190 Asn Ala He Leu Gly Ser Tyr Ala Asp He Gly Asp He Val Arg Gly 195 200 205 Leu Asp Val Trp Arg Asp He Asn Thr Asn Lys Leu Ser Glu Lys Phe 210 215 220 Gin Lys He Phe Met Gly Gly Gly Asn Ser Arg Lys Lys Gin Asn Asp 225 230 235 240 Asn Asn Glu Arg Asn Lys Trp Trp Glu Lys Gin Arg Asn Leu He Trp 245 250 255 Ser Ser Met Val Lys His He Pro Lys Gly Lys Thr Cys Lys Arg His 260 265 270 Asn Asn Phe Glu Lys He Pro Gin Phe Leu Arg Trp Leu Lys Glu Trp 275 280 285 Gly Asp Glu Phe Cys Glu Glu Met Gly Thr Glu Val Lys Gin Leu Glu 290 295 300 Lys He Cys Glu Asn Lys Asn Cys Ser Glu Lys Lys Cys Lys Asn Ala 305 310 315 320 Cys Ser Ser Tyr Glu Lys Trp He Lys Glu Arg Lys Asn Glu Tyr Asn 325 330 335 Leu Gin Ser Lys Lys Phe Asp Ser Asp Lys Lys Leu Asn Lys Lys Asn 340 345 350 Asn Leu Tyr Asn Lys Phe Glu Asp Ser Lys Ala Tyr Leu Arg Ser Glu 355 360 365 Ser Lys Gin Cys Ser Asn He Glu Phe Asn Asp Glu Thr Phe Thr Phe 370 375 380 Pro Asn Lys Tyr Lys Glu Ala Cys Met Val Cys Glu Asn Pro Ser Ser 385 390 395 400 Ser Lys Ala Leu Lys Pro He Lys Thr Asn Val Phe Pro He Glu Glu 405 410 415 Ser Lys Lys Ser Glu Leu Ser Ser Leu Thr Asp Lys Ser Lys Asn Thr 420 425 430 Pro Asn Ser Ser Gly Gly Gly Asn Tyr Gly Asp Arg Gin He Ser Lys 435 440 445 Arg Asp Asp Val His His Asp Gly Pro Lys Glu Val Lys Ser Gly Glu 450 455 460 Lys Glu Val Pro Lys He Asp Ala Ala Val Lys Thr Glu Asn Glu Phe 465 470 475 480 Thr Ser Asn Arg Asn Asp He Glu Gly Lys Glu Lys Ser Lys Gly Asp 485 490 495 His Ser Ser Pro Val His Ser Lys Asp He Lys Asn Glu Glu Pro Gin 500 505 510 Arg Val Val Ser Glu Asn Leu Pro Lys He Glu Glu Lys Met Glu Ser 515 520 525 Ser Asp Ser He Pro He Thr His He Glu Ala Glu Lys Gly Gin Ser 530 535 540 Ser Asn Ser Ser Asp Asn Asp Pro Ala Val Val Ser Gly Arg Glu Ser 545 550 555 560 Lys Asp Val Asn Leu His Thr Ser Glu Arg He Lys Glu Asn Glu Glu 565 570 575 Gly Val He Lys Thr Asp Asp Ser Ser Lys Ser He Glu He Ser Lys 580 585 590 He Pro Ser Asp Gin Asn Asn His Ser Asp Leu Ser Gin Asn Ala Asn 595 600 605 Glu Asp Ser Asn Gin Gly Asn Lys Glu Thr He Asn Pro Pro Ser Thr 610 615 620 Glu Lys Asn Leu Lys Glu He His Tyr Lys Thr Ser Asp Ser Asp Asp 625 630 635 640 His Gly Ser Lys He Lys Ser Glu He Glu Pro Lys Glu Leu Thr Glu 645 650 655 Glu Ser Pro Leu Thr Asp Lys Lys Thr Glu Ser Ala Ala He Gly Asp 660 665 670 Lys Asn His Glu Ser Val Lys Ser Ala Asp He Phe Gin Ser Glu He 675 680 685 His Asn Ser Asp Asn Arg Asp Arg He Val Ser Glu Ser Val Val Gin 690 695 700 Asp Ser Ser Gly Ser Ser Met Ser Thr Glu Ser He Arg Thr Asp Asn 705 710 715 720 Lys Asp Phe Lys Thr Ser Glu Asp He Ala Pro Ser He Asn Gly Arg 725 730 735 Asn Ser Arg Val Asp Glu Leu Thr Ser Arg Arg Pro Leu 740 745 (2) INFORMATION FOR SEQ ID NO: 7 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2606 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) [iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 : AGCTCTATTA CGACTCACTA TAGGGAAAGC TGGTACGCCT GCAGGTACCG GTCCGGAATT 60 CCCGGGTCGA CGAGCTCACT AGTCGGCGGC CGCTCTAGAG GATCCAAGCT TAATAOTGTT 120 TATACGTCTA TTGGCTTATT TTTAAATAGC TTAAAAAGCG GACCATGTAAAAAGGATAAT 180 GATAATGCAGAGGATAATATAGATTTTGGTGATGAAGGTAAAACATTTAAAGAGGCAGAT 240 AATTGTAAAC CATGTTCTCAATTTACTGTT GATTGTAAAAATTGTAATGG TGGTGATACA 300 AAAGGGAAGT GCAATGGCAG CAATGGCAAAAAGAATGGAAATGATTATAT TACTGCAAGT 360 GATATTGAAAATGGAGGGAATTCTATTGGAAATATAGATATGGTTGTTAG TGATAAGGAT 420 GCAAATGGAT TTAATGGTTTAGACGCTTGT GGAAGTGCAAATATCTTTAAAGGTATTAGA 480 AAAGAACAAT GGAAATGTGC TAAAGTATGT GGTTTAGATG TATGTGGTCT TAAAAATGGT 540 AATGGTAGTA TAGATAAAGATCAAAAACAAATTATAATTA TTAGAGCATT GCTTAAACGT 600 TGGGTAGAATATTTTTTAGAAGATTATAATAAAATTAATG CCAAAATTTC ACATTGTACG 660 AAAAAGGATAATGAATCCACATGTACAAAT GATTGTCCAAATAAATGTACATGTGTAGAA 720 GAGTGGATAAATCAGAAAAG GACAGAATGGAAAAATATAAAAAAACATTA CAAAACACAA 780 AATGAAAATG GTGACAATAA CATGAAATCT TTGGTTACAGATATTTTGGG TGCCTTGCAA 840 CCCCAAAGTG ATGTTAACAAAGCTATAAAA CCTTGTAGTG GTTTAACTGC GTTCGAGAGT 900 TTTTGTGGTC TTAATGGCGC TGATAACTCA GAAAAAAAAG AAGGTGAAGA TTACGATCTT 960 GTTCTATGTA TGCTTAAAAA TCTTGAAAAA CAAATTCAGG AGTGCAAAAA GAAACATGGC 1020 GAAACTAGTG TCGAAAATGG TGGCAAATCA TGTACCCCCC TTGACAACAC CACCCTTGAG 1080 GAGGAACCCA TAGAAGAGGA AAACCAAGTG GAAGCGCCGA ACATTTGTCC AAAACAAACA 1140 GTGGAAGATA AAAAAAAAGA GGAAGAAGAA GAAACTTGTA CACCGGCATC ACCAGTACCA 1200 GAAAAACCGG TACCTCATGT GGCACGTTGG CGAACATTTA CACCACCTGA GGTATTCAAG 1260 ATATGGAGGG GAAGGAGAAA TAAAACTACG TGCGAAATAG TGGCAGAAAT GCTTAAAGAT 1320 AAGAATGGAA GGACTACAGT AGGTGAATGT TATAGAAAAG AAACTTATTC TGAATGGACG 1380 TGTGATGAAA GTAAGATTAA AATGGGACAG CATGGAGCAT GTATTCCTCC AAGAAGACAA 1440 AAATTATGTT TACATTATTT AGAAAAAATA ATGACAAATA CAAATGAATT GAAATACGCA 1500 TTTATTAAAT GTGCTGCAGC AGAAACTTTT TTGTTATGGC AAAACTACAA AAAAGATAAG 1560 AATGGTAATG CAGAAGATCT CGATGAAAAA TTAAAAGGTG GTATTATCCC CGAAGATTTT 1620 AAACGGCAAA TGTTCTATAC GTTTGCAGAT TATAGAGATA TATGTTTGGG TACGGATATA 1680 TCATCAAAAA AAGATACAAG TAAAGGTGTA GGTAAAGTAA AATGCAATAT TGATGATGTT 1740 TTTTATAAAA TTAGCAATAG TATTCGTTAC CGTAAAAGTT GGTGGGAAAC AAATGGTCCA 1800 GTTATATGGG AAGGAATGTT ATGCGCTTTA AGTTATGATA CGAGCCTAAA TAATGTTAAT 1860 CCGGAAACTC ACAAAAAACT TACCGAAGGC AATAACAACT TTGAGAAAGT CATATTTGGT 1920 AGTGATAGTA GCACTACTTT GTCCAAATTT TCTGAAAGAC CTCAATTTCT AAGATGGTTG 1980 ACTGAATGGG GAGAAAATTT CTGCAAAGAA CAAAAAAAGG AGTATAAGGT GTTGTTGGCA 2040 AAATGTAAGG ATTGTGATGT TGATGGTGAT GGTAAATGTA ATGGAAAATG TGTTGCGTGC 2100 AAAGATCAAT GTAAACAATA TCATAGTTGG ATTGGAATAT GGATAGATAA TTATAAAAAA 2160 CAAAAAGGAA GATATACTGA GGTTAAAAAA ATACCTCTGT ATAAAGAAGA TAAAGACGTG 2220 AAAAACTCAG ATGATGCTCG CGATTATTTA AAAACACAAT TACAAAATAT GAAATGTGTA 2280 AATGGAACTA CTGATGAAAA TTGTGAGTAT AAGTGTATGC ATAAAACCTC ATCCACAAAT 2340 AGTGATATGC CCGAATCGTT GGACGAAAAG CCGGAAAAGG TCAAAGACAA GTGTAATTGT 2400 GTACCTAATG AATGCAATGC ATTGAGTGTA AGTGGTAGCG GTTTTCCTGA TGGTCAAGCT 2460 TACGTACGCG TGCATGCGAC GTCATAGCTC TTCTATAGTG TCACCTAAAT TCAATTCACT 2520 GGCCGTCGTT TTACAACGTC GTGACTGGGA AAACCTGGCG TTACCCAACT TAATCGCCTT 2580 GCAGCACATC CCCCTTTCGC CAGCTG 2606 (2) INFORMATION FOR SEQ ID NO: 8 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 921 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Lys Leu Asn Ser Val Tyr Thr Ser He Gly Leu Phe Leu Asn Ser Leu 1 5 10 15 Lys Ser Gly Pro Cys Lys Lys Asp Asn Asp Asn Ala Glu Asp Asn He 20 25 30 Asp Phe Gly Asp Glu Gly Lys Thr Phe Lys Glu Ala Asp Asn Cys Lys 35 40 45 Pro Cys Ser Gin Phe Thr Val Asp Cys Lys Asn Cys Asn Gly Gly Asp 50 55 60 Thr Lys Gly Lys Cys Asn Gly Ser Asn Gly Lys Lys Asn Gly Asn Asp 65 70 75 80 Tyr He Thr Ala Ser Asp He Glu Asn Gly Gly Asn Ser He Gly Asn 85 90 95 He Asp Met Val Val Ser Asp Lys Asp Ala Asn Gly Phe Asn Gly Leu 100 105 110 Asp Ala Cys Gly Ser Ala Asn He Phe Lys Gly He Arg Lys Glu Gin 115 120 125 Trp Lys Cys Ala Lys Val Cys Gly Leu Asp Val Cys Gly Leu Lys Asn 130 135 140 Gly Asn Gly Ser He Asp Lys Asp Gin Lys Gin He He He He Arg 145 150 155 160 Ala Leu Leu Lys Arg Trp Val Glu Tyr Phe Leu Glu Asp Tyr Asn Lys 165 170 175 He Asn Ala Lys He Ser His Cys Thr Lys Lys Asp Asn Glu Ser Thr 180 185 190 Cys Thr Asn Asp Cys Pro Asn Lys Cys Thr Cys Val Glu Glu Trp He 195 200 205 Asn Gin Lys Arg Thr Glu Trp Lys Asn He Lys Lys His Tyr Lys Thr 210 215 220 Gin Asn Glu Asn Gly Asp Asn Asn Met Lys Ser Leu Val Thr Asp He 225 230 235 240 Leu Gly Ala Leu Gin Pro Gin Ser Asp Val Asn Lys Ala He Lys Pro 245 250 255 Cys Ser Gly Leu Thr Ala Phe Glu Ser Phe Cys Gly Leu Asn Gly Ala 260 265 270 Asp Asn Ser Glu Lys Lys Glu Gly Glu Asp Tyr Asp Leu Val Leu Cys 275 280 285 Met Leu Lys Asn Leu Glu Lys Gin He Gin Glu Cys Lys Lys Lys His 290 295 300 Gly Glu Thr Ser Val Glu Asn Gly Gly Lys Ser Cys Thr Pro Leu Asp 305 310 315 320 Asn Thr Thr Leu Glu Glu Glu Pro He Glu Glu Glu Asn Gin Val Glu 325 330 335 Ala Pro Asn He Cys Pro Lys Gin Thr Val Glu Asp Lys Lys Lys Glu 340 345 350 Glu Glu Glu Glu Thr Cys Thr Pro Ala Ser Pro Val Pro Glu Lys Pro 355 360 365 Val Pro His Val Ala Arg Trp Arg Thr Phe Thr Pro Pro Glu Val Phe 370 375 380 Lys He Trp Arg Gly Arg Arg Asn Lys Thr Thr Cys Glu He Val Ala 385 390 395 400 Glu Met Leu Lys Asp Lys Asn Gly Arg Thr Thr Val Gly Glu Cys Tyr 405 410 ' 415 Arg Lys Glu Thr Tyr Ser Glu Trp Thr Cys Asp Glu Ser Lys He Lys 420 425 430 Met Gly Gin His Gly Ala Cys He Pro Pro Arg Arg Gin Lys Leu Cys 435 • 440 445 Leu His Tyr Leu Glu Lys He Met Thr Asn Thr Asn Glu Leu Lys Tyr 450 455 460 Ala Phe He Lys Cys Ala Ala Ala Glu Thr Phe Leu Leu Trp Gin Asn 465 470 475 480 Tyr Lys Lys Asp Lys Asn Gly Asn Ala Glu Asp Leu Asp Glu Lys Leu 485 490 495 Lys Gly Gly He He Pro Glu Asp Phe Lys Arg Gin Met Phe Tyr Thr 500 505 510 Phe Ala Asp Tyr Arg Asp He Cys Leu Gly Thr Asp He Ser Ser Lys 515 520 525 Lys Asp Thr Ser Lys Gly Val Gly Lys Val Lys Cys Asn He Asp Asp 530 535 540 Val Phe Tyr Lys He Ser Asn Ser He Arg Tyr Arg Lys Ser Trp Trp 545 550 555 560 Glu Thr Asn Gly Pro Val He Trp Glu Gly Met Leu Cys Ala Leu Ser 565 570 575 Tyr Asp Thr Ser Leu Asn Asn Val Asn Pro Glu Thr His Lys Lys Leu 580 585 590 Thr Glu Gly Asn Asn Asn Phe Glu Lys Val He Phe Gly Ser Asp Ser 595 600 605 Ser Thr Thr Leu Ser Lys Phe Ser Glu Arg Pro Gin Phe Leu Arg Trp 610 615 620 Leu Thr Glu Trp Gly Glu Asn Phe Cys Lys Glu Gin Lys Lys Glu Tyr 625 630 635 640 Lys Val Leu Leu Ala Lys Cys Lys Asp Cys Asp Val Asp Gly Asp Gly 645 650 655 Lys Cys Asn Gly Lys Cys Val Ala Cys Lys Asp Gin Cys Lys Gin Tyr 660 665 670 His Ser Trp He Gly He Trp He Asp Asn Tyr Lys Lys Gin Lys Gly 675 680 685 Arg Tyr Thr Glu Val Lys Lys He Pro Leu Tyr Lys Glu Asp Lys Asp 690 695 700 Val Lys Asn Ser Asp Asp Ala Arg Asp Tyr Leu Lys Thr Gin Leu Gin 705 710 715 720 Asn Met Lys Cys Val Asn Gly Thr Thr Asp Glu Asn Cys Glu Tyr Lys 725 730 735 Cys Met His Lys Thr Ser Ser Thr Asn Ser Asp Met Pro Glu Ser Leu 740 745 750 Asp Glu Lys Pro Glu Lys Val Lys Asp Lys Cys Asn Cys Val Pro Asn 755 760 765 Glu Cys Asn Ala Leu Ser Val Ser Gly Ser Gly Phe Pro Asp Gly Gin 770 775 780 Ala Phe Gly Gly Gly Val Leu Glu Gly Thr Cys Lys Gly Leu Gly Glu 785 790 795 800 Pro Lys Lys Lys He Glu Pro Pro Gin Tyr Asp Pro Thr Asn Asp He 805 810 815 Leu Lys Ser Thr He Pro Val Thr He Val Leu Ala Leu Gly Ser He 820 825 830 Ala Phe Leu Phe Met Lys Val He Tyr He Tyr Val Trp Tyr He Tyr 835 840 845 Met Leu Cys Val Gly Ala Leu Asp Thr Tyr He Cys Gly Cys He Cys 850 855 860 He Cys He Phe He Cys Val Ser Val Tyr Val Cys Val Tyr Val Tyr 865 870 875 880 Val Phe Leu Tyr Met Cys Val Phe Tyr He Tyr Phe He Tyr He Tyr 885 890 895 Val Phe He Leu Lys Met Lys Lys Met Lys Lys Met Lys Lys Met Lys 900 905 910 Lys Met Lys Lys Arg Lys Lys Arg He 915 920 (2) INFORMATION FOR SEQ ID NO: 9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2101 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 : GGAACAGGGT GATAATAAAG TAGGAGCCTG TGCTCCGTAT AGACGATTAC ATTTATGTGA 60 TTATAATTTG GAATCTATAG ACACAACGTC GACGACGCATAAGTTGTTGT TAGAGGTGTG 120 TATGGCAGCAAAATACGAAG GAAACTCAATAAATACACAT TATACACAACATCAACGAAC 180 TAATGAGGAT TCTGCTTCCC AATTATGTAC TGTATTAGCA CGAAGTTTTG CAGATATAGG 240 TGATATCGTAAGAGGAAAAG ATCTATATCT CGGTTATGAT AATAAAGAAAAAGAACAAAG 300 AAAAAAATTA GAACAGAAAT TGAAAGATAT TTTCAAGAAAATACATAAGG ACGTGATGAA 360 GACGAATGGC GCACAAGAAC GCTACATAGATGATGCCAAA GGAGGAGATT TTTTTCAATT 420 AAGAGAAGAT TGGTGGACGT CGAATCGAGAAACAGTATGGAAAGCATTAATATGTCATGC 480 ACCAAAAGAA GCTAATTATT TTATAAAAAC AGCGTGTAAT GTAGGAAAAG GAACTAATGG 540 TCAATGCCAT TGCATTGGTG GAGATGTTCC CACATATTTC GATTATGTGC CGCAGTATCT 600 TCGCTGGTTC GAGGAATGGG CAGAAGACTT TTGCAGGAAAAAAAAAAAAAAACTAGAAAA 660 TTTGCAAAAA CAGTGTCGTG ATTACGAACAAAATTTATAT TGTAGTGGTAATGGCTACGA 720 TTGCACAAAAACTATATATAAAAAAGGTAAACTTGTTATAGGTGAACATT GTACAAACTG 780 TTCTGTTTGG TGTCGTATGT ATGAAACTTG GATAGATAAC CAGAAAAAAGAATTTCTAAA 840 ACAAAAAAGAAAATACGAAA CAGAAATATC AGGTGGTGGT AGTGGTAAGAGTCCTAAAAG 900 GACAAAACGG GCTGCACGTAGTAGTAGTAG TAGTGATGATAATGGGTATGAAAGTAAATT 960 TTATAAAAAA CTGAAAGAAG TTGGCTACCA AGATGTCGAT AAATTTTTAA AAATATTAAA 1020 CAAAGAAGGA ATATGTCAAA AACAACCTCA AGTAGGAAAT GAAAAAGCAG ATAATGTTGA 1080 TTTTACTAAT GAAAAATATG TAAAAACATT TTCTCGTACA GAAATTTGTG AACCGTGCCC 1140 ATGGTGTGGA TTGGAAAAAG GTGGTCCACC ATGGAAAGTT AAAGGTGACA AAACCTGCGG 1200 AAGTGCAAAA ACAAAGACAT ACGATCCTAA AAATATTACC GATATACCAG TACTCTACCC 1260 TGATAAATCA CAGCAAAATA TACTAAAAAA ATATAAAAAT TTTTGTGAAA AAGGTGCACC 1320 TGGTGGTGGT CAAATTAAAA AATGGCAATG TTATTATGAT GAACATAGGC CTAGTAGTAA 1380 AAATAATAAT AATTGTGTAG AAGGAACATG GGACAAGTTT ACACAAGGTA AACAAACCGT 1440 TAAGTCCTAT AATGTTTTTT TTTGGGATTG GGTTCATGAT ATGTTACACG ATTCTGTAGA 1500 GTGGAAGACA GAACTTAGTA AGTGTATAAA TAATAACACT AATGGCAACA CATGTAGAAA 1560 CAATAATAAA TGTAAAACAG ATTGTGGTTG TTTTCAAAAA TGGGTTGAAA AAAAACAACA 1620 AGAATGGATG GCAATAAAAG ACCATTTTGG AAAGCAAACA GATATTGTCC AACAAAAAGG 1680 TCTTATCGTA TTTAGTCCCT ATGGAGTTCT TGACCTTGTT TTGAAGGGCG GTAATCTGTT 1740 GCAAAATATT AAAGATGTTC ATGGAGATAC AGATGACATA AAACACATTA AGAAACTGTT 1800 GGATGAGGAA GACGCAGTAG CAGTTGTTCT TGGTGGCAAG GACAATACCA CAATTGATAA 1860 ATTACTACAA CACGAAAAAG AACAAGCAGA ACAATGCAAA CAAAAGCAGG AAGAATGCGA 1920 GAAAAAAGCA CAACAAGAAA GTCGTGGTCG CTCCGCCGAA ACCCGCGAAG ACGAAAGGAC 1980 ACAACAACCT GCTGATAGTG CCGGCGAAGT CGAAGAAGAA GAAGACGACG ACGACTACGA 2040 CGAAGACGAC GAAGATGACG ACGTAGTCCA GGACGTAGAT GTAAGTGAAA TAAGAGGTCC 2100 G 2101 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 700 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Glu Gin Gly Asp Asn Lys Val Gly Ala Cys Ala Pro Tyr Arg Arg Leu 1 5 10 15 His Leu Cys Asp Tyr Asn Leu Glu Ser He Asp Thr Thr Ser Thr Thr 20 25 30 His Lys Leu Leu Leu Glu Val Cys Met Ala Ala Lys Tyr Glu Gly Asn 35 40 45 Ser He Asn Thr His Tyr Thr Gin His Gin Arg Thr Asn Glu Asp Ser 50 55 60 Ala Ser Gin Leu Cys Thr Val Leu Ala Arg Ser Phe Ala Asp He Gly 65 70 75 80 Asp He Val Arg Gly Lys Asp Leu Tyr Leu Gly Tyr Asp Asn Lys Glu 85 90 95 Lys Glu Gin Arg Lys Lys Leu Glu Gin Lys Leu Lys Asp He Phe Lys 100 105 110 Lys He His Lys Asp Val Met Lys Thr Asn Gly Ala Gin Glu Arg Tyr 115 120 125 He Asp Asp Ala Lys Gly Gly Asp Phe Phe Gin Leu Arg Glu Asp Trp 130 135 140 Trp Thr Ser Asn Arg Glu Thr Val Trp Lys Ala Leu He Cys His Ala 145 150 155 160 Pro Lys Glu Ala Asn Tyr Phe He Lys Thr Ala Cys Asn Val Gly Lys 165 170 175 Gly Thr Asn Gly Gin Cys His Cys He Gly Gly Asp Val Pro Thr Tyr 180 185 190 Phe Asp Tyr Val Pro Gin Tyr Leu Arg Trp Phe Glu Glu Trp Ala Glu 195 200 205 Asp Phe Cys Arg Lys Lys Lys Lys Lys Leu Glu Asn Leu Gin Lys Gin 210 215 220 Cys Arg Asp Tyr Glu Gin Asn Leu Tyr Cys Ser Gly Asn Gly Tyr Asp 225 230 235 240 Cys Thr Lys Thr He Tyr Lys Lys Gly Lys Leu Val He Gly Glu His 245 250 255 Cys Thr Asn Cys Ser Val Trp Cys Arg Met Tyr Glu Thr Trp He Asp 260 265 270 Asn Gin Lys Lys Glu Phe Leu Lys Gin Lys Arg Lys Tyr Glu Thr Glu 275 280 285 He Ser Gly Gly Gly Ser Gly Lys Ser Pro Lys Arg Thr Lys Arg Ala 290 295 300 Ala Arg Ser Ser Ser Ser Ser Asp Asp Asn Gly Tyr Glu Ser Lys Phe 305 310 315 320 Tyr Lys Lys Leu Lys Glu Val Gly Tyr Gin Asp Val Asp Lys Phe Leu 325 330 335 Lys He Leu Asn Lys Glu Gly He Cys Gin Lys Gin Pro Gin Val Gly 340 345 350 Asn Glu Lys Ala Asp Asn Val Asp Phe Thr Asn Glu Lys Tyr Val Lys 355 360 365 Thr Phe Ser Arg Thr Glu He Cys Glu Pro Cys Pro Trp Cys Gly Leu 370 375 380 Glu Lys Gly Gly Pro Pro Trp Lys Val Lys Gly Asp Lys Thr Cys Gly 385 390 395 400 Ser Ala Lys Thr Lys Thr Tyr Asp Pro Lys Asn He Thr Asp He Pro 405 410 415 Val Leu Tyr Pro Asp Lys Ser Gin Gin Asn He Leu Lys Lys Tyr Lys 420 425 430 Asn Phe Cys Glu Lys Gly Ala Pro Gly Gly Gly Gin He Lys Lys Trp 435 440 ' 445 Gin Cys Tyr Tyr Asp Glu His Arg Pro Ser Ser Lys Asn Asn Asn Asn 450 455 460 Cys Val Glu Gly Thr Trp Asp Lys Phe Thr Gin Gly Lys Gin Thr Val 465 470 475 480 Lys Ser Tyr Asn Val Phe Phe Trp Asp Trp Val His Asp Met Leu His 485 490 495 Asp Ser Val Glu Trp Lys Thr Glu Leu Ser Lys Cys He Asn Asn Asn 500 505 510 Thr Asn Gly Asn Thr Cys Arg Asn Asn Asn Lys Cys Lys Thr Asp Cys 515 520 525 Gly Cys Phe Gin Lys Trp Val Glu Lys Lys Gin Gin Glu Trp Met Ala 530 535 540 He Lys Asp His Phe Gly Lys Gin Thr Asp He Val Gin Gin Lys Gly 545 550 555 560 Leu He Val Phe Ser Pro Tyr Gly Val Leu Asp Leu Val Leu Lys Gly 565 570 575 Gly Asn Leu Leu Gin Asn He Lys Asp Val His Gly Asp Thr Asp Asp 580 585 590 He Lys His He Lys Lys Leu Leu Asp Glu Glu Asp Ala Val Ala Val 595 600 605 Val Leu Gly Gly Lys Asp Asn Thr Thr He Asp Lys Leu Leu Gin His 610 615 620 Glu Lys Glu Gin Ala Glu Gin Cys Lys Gin Lys Gin Glu Glu Cys Glu 625 630 635 640 Lys Lys Ala Gin Gin Glu Ser Arg Gly Arg Ser Ala Glu Thr Arg Glu 645 650 655 Asp Glu Arg Thr Gin Gin Pro Ala Asp Ser Ala Gly Glu Val Glu Glu 660 665 670 Glu Glu Asp Asp Asp Asp Tyr Asp Glu Asp Asp Glu Asp Asp Asp Val 675 680 685 Val Gin Asp Val Asp Val Ser Glu He Arg Gly Pro 690 695 700 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8220 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: AAAAATGGGG CCCAAGGAGG CTGCAGGTGG GGATGATATT GAGGATGAAA GTGCCAAACA 60 TATGTTTGATAGGATAGGAAAAGATGTGTA CGATAAAGTAAAAGAGGAAG CTAAAGAACG 120 TGGTAAAGGC TTGCAAGGAC GTTTGTCAGAAGCAAAATTT GAGAAAAATGAAAGCGATCC 180 ACAAACACCAGAAGATCCAT GCGATCTTGATCATAAATAT CATACAAATG TAACTACTAA 240 TGTAATTAAT CCGTGCGCTGATAGATCTGA CGTGCGTTTT TCCGATGAATATGGAGGTCA 300 ATGTACACATAATAGAATAAAAGATAGTCAACAGGGTGATAATAAAGGTG CATGTGCTCC 360 ATATAGGCGATTGCATGTAT GCGATCAAAATTTAGAACAGATAGAGCCTATAAAAATAAC 420 AAATACTCATAATTTATTGG TAGATGTGTG TATGGCAGCAAAATTTGAAG GACAATCAAT 480 AACACAAGAT TATCCAAAATATCAAGCAACATATGGTGATTCTCCTTCTCAAATATGTAC 540 TATGCTGGCA CGAAGTTTTG CGGACATAGGGGACATTGTCAGAGGAAGAGATTTGTATTT 600 AGGTAATCCA CAAGAAATAAAACAAAGACAACAATTAGAAAATAATTTGAAAACAATTTT 660 CGGGAAAATATATGAAAAAT TGAATGGCGCAGAAGCACGCTACGGAAATGATCCGGAATT 720 TTTTAAATTA CGAGAAGATT GGTGGACTGC TAATCGAGAAACAGTATGGAAAGCCATCAC 780 ATGTAACGCT TGGGGTAATA CATATTTTCATGCAACGTGCAATAGAGGAGAACGAACTAA 840 AGGTTACTGC CGGTGTAACGACGACCAAGT TCCCACATAT TTTGATTATGTGCCGCAGTA 900 TCTTCGCTGG TTCGAGGAATGGGCAGAAGATTTTTGTAGGAAAAAAAATAAAAAAATAAA 960 AGATGTTAAA AGAAATTGTC GTGGAAAAGA TAAAGAGGAT AAGGATCGAT ATTGTAGCCG 1020 TAATGGCTAC GATTGCGAAA AAACTAAACG AGCGATTGGT AAGTTGCGTT ATGGTAAGCA 1080 ATGCATTAGC TGTTTGTATG CATGTAATCC TTACGTTGAT TGGATAAATA ACCAAAAAGA 1140 ACAATTTGAC AAACAGAAAA AAAAATATGA TGAAGAAATA AAAAAATATG AAAATGGAGC 1200 ATCAGGTGGT AGTAGGCAAA AACGGGATGC AGGTGGTACA ACTACTACTA ATTATGATGG 1260 ATATGAAAAA AAATTTTATG ACGAACTTAA TAAAAGTGAA TATAGAACCG TTGATAAATT 1320 TTTGGAAAAA TTAAGTAATG AAGAAATATG CACAAAAGTT AAAGACGAAG AAGGAGGAAC 1380 AATTGATTTT AAAAACGTTA ATAGTGATAG TACTAGTGGT GCTAGTGGCA CTAATGTTGA 1440 AAGTCAAGGA ACATTTTATC GTTCAAAATA TTGCCAACCC TGCCCTTATT GTGGAGTGAA 1500 AAAGGTAAAT AATGGTGGTA GTAGTAATGA ATGGGAAGAG AAAAATAATG GCAAGTGCAA 1560 GAGTGGAAAA CTTTATGAGC CTAAACCCGA CAAAGAAGGT ACTACTATTA CAATCCTTAA 1620 AAGTGGTAAA GGACATGATG ATATTGAAGA AAAATTAAAC AAATTTTGTG ATGAAAAAAA 1680 TGGTGATACA ATAAATAGTG GTGGTAGTGG TACGGGTGGT AGTGGTGGTG GTAACAGTGG 1740 TAGACAGGAA TTGTATGAAG AATGGAAATG TTATAAAGGT GAAGATGTAG TGAAAGTTGG 1800 ACACGATGAG GATGACGAGG AGGATTATGA AAATGTAAAA AATGCAGGCG GATTATGTAT 1860 ATTAAAAAAC CAAAAAAAGA ATAAAGAAGA AGGTGGAAAT ACGTCTGAAA AGGAGCCTGA 1920 TGAAATCCAA AAGACATTCA ATCCTTTTTT TTACTATTGG GTTGCACATA TGTTAAAAGA 1980 TTCCATACAT TGGAAAAAAA AACTTCAGAG ATGTTTACAA AATGGTAACA GAATAAAATG 2040 TGGAAACAAT AAATGTAATA ATGATTGTGA ATGTTTTAAA AGATGGATTA CACAAAAAAA 2100 AGACGAATGG GGGAAAATAG TACAACATTT TAAAACGCAA AATATTAAAG GTAGAGGAGG 2160 TAGTGACAAT ACGGCAGAAT TAATCCCATT TGATCACGAT TATGTTCTTC AATACAATTT 2220 GCAAGAAGAA TTTTTGAAAG GCGATTCCGA AGACGCTTCC GAAGAAAAAT CCGAAAATAG 2280 TCTGGATGCA GAGGAGGCAG AGGAACTAAA ACACCTTCGC GAAATCATTG AAAGTGAAGA 2340 CAATAATCAA GAAGCATCTG TTGGTGGTGG CGTCACTGAA CAAAAAAATA TAATGGATAA 2400 ATTGCTCAAC TACGAAAAAG ACGAAGCCGA TTTATGCCTA GAAATTCACG AAGATGAGGA 2460 AGAGGAAAAA GAAAAAGGAG ACGGAAACGA ATGTATCGAA GAGGGCGAAA ATTTTCGTTA 2520 TAATCCATGT AGTGGCGAAA GTGGTAACAA ACGATACCCC GTTCTTGCGA ACAAAGTAGC 2580 GTATCAAATG CATCACAAGG CAAAGACACA ATTGGCTAGT CGTGCTGGTA GAAGTGCGTT 2640 GAGAGGTGAT ATATCCTTAG CGCAATTTAA AAATGGTCGT AACGGAAGTA CATTGAAAGG 2700 ACAAATTTGC AAAATTAACG AAAACTATTC CAATGATAGT CGTGGTAATA GTGGTGGACC 2760 ATGTACAGGC AAAGATGGAG ATCACGGAGG TGTGCGCATG AGAATAGGAA CGGAATGGTC 2820 AAATATTGAA GGAAAAAAAC AAACGTCATA CAAAAACGTC TTTTTACCTC CCCGACGAGA 2880 ACACATGTGT ACATCCAATT TAGAAAATTT AGATGTTGGT AGTGTCACTA AAAATGATAA 2940 GGCTAGCCAC TCATTATTGG GAGATGTTCA GCTCGCAGCA AAAACTGATG CAGCTGAGAT 3000 AATAAAACGC TATAAAGATC AAAATAATAT ACAACTAACT GATCCAATAC AACAAAAAGA 3060 CCAGGAGGCT ATGTGTCGAG CTGTACGTTA TAGTTTTGCC GATTTAGGAG ACATTATTCG 3120 AGGAAGAGAT ATGTGGGATG AGGATAAGAG CTCAACAGAC ATGGAAACAC GTTTGATAAC 3180 CGTATTTAAA AACATTAAAG AAAAACATGA TGGAATCAAA GACAACCCTA AATATACCGG 3240 TGATGAAAGC AAAAAGCCCG CATATAAAAA ATTACGAGCA GATTGGTGGG AAGCAAATAG 3300 ACATCAAGTG TGGAGAGCCA TGAAATGCGC AACAAAAGGC ATCATATGTC CTGGTATGCC 3360 AGTTGACGAT TATATCCCCC AACGTTTACG CTGGATGACT GAATGGGCTG AATGGTATTG 3420 TAAAGCGCAA TCACAGGAGT ATGACAAGTT AAAAAAAATC TGTGCAGATT GTATGAGTAA 3480 GGGTGATGGA AAATGTACGC AAGGTGATGT CGATTGTGGA AAGTGCAAAG CAGCATGTGA 3540 TAAATATAAA GAGGAAATAG AAAAATGGAA TGAACAATGG AGAAAAATAT CAGATAAATA 3600 CAATCTATTA TACCTACAAG CAAAAACTAC TTCTACTAAT CCTGGCCGTA CTGTTCTTGG 3660 TGATGACGAT CCCGACTATC AACAAATGGT AGATTTTTTG ACCCCAATAC ACAAAGCAAG 3720 TATTGCCGCA CGTGTTCTTG TTAAACGTGC TGCTGGTAGT CCCACTGAGA TCGCCGCCGC 3780 CGCCCCGATC ACCCCCTACA GTACTGCTGC CGGATATATA CACCAGGAAA TAGGATATGG 3840 GGGGTGCCAG GAACAAACAC AATTTTGTGA AAAAAAACAT GGTGCAACAT CAACTAGTAC 3900 CACGAAAGAA AACAAAGAAT ACACCTTTAA ACAACCTCCG CCGGAGTATG CTACAGCGTG 3960 TGATTGCATA AATAGGTCGC AAACAGAGGA GCCGAAGAAA AAGGAAGAAA ATGTAGAGAG 4020 TGCCTGCAAA ATAGTGGAGA AAATACTTGA GGGTAAGAAT GGAAGGACTA CAGTAGGTGA 4080 ATGTAATCCA AAAGAGAGTT ATCCTGATTG GGATTGCAAA AACAATATTG ACATTAGTCA 140 TGATGGTGCT TGTATGCCTC CAAGGAGACA AAAACTATGT TTATATTATA TAGCACATGA 4200 GAGTCAAACA GAAAATATAA AAACAGACGA TAATTTGAAA GATGCTTTTA TTAAAACTGC 4260 AGCAGCAGAA ACTTTTCTTT CATGGCAATA TTATAAGAGT AAGAATGATA GTGAAGCTAA 4320 AATATTAGAT AGAGGCCTTA TTCCATCCCA ATTTTTAAGA TCCATGATGT ACACGTTTGG 4380 AGATTATAGA GATATATGTT TGAACACAGA TATATCTAAA AAACAAAATG ATGTAGCTAA 4440 GGCAAAAGAT AAAATAGGTA AATTTTTCTC AAAAGATGGC AGCAAATCTC CTAGTGGCTT 4500 ATCACGCCAA GAATGGTGGA AAACAAATGG TCCAGAGATT TGGAAAGGAA TGTTATGTGC 4560 CTTAACAAAA TACGTCACAG ATACCGATAA CAAAAGAAAA ATCAAAAACG ACTACTCATA 4620 CGATAAAGTC AACCAATCCC AAAATGGCAA CCCTTCCCTT GAAGAGTTTG CTGCTAAACC 4680 TCAATTTCTA CGTTGGATGA TCGAATGGGG AGAAGAGTTT TGTGCTGAAC GTCAGAAGAA 4740 GGAAAATATC ATAAAAGATG CATGTAATGA AATAAATTCT ACACAACAGT GTAATGATGC 4800 GAAACATCGT TGTAATCAAG CATGTAGAGC ATATCAAGAA TATGTTGAAA ATAAAAAAAA 4860 AGAATTTTCG GGACAAACAA ATAACTTTGT TCTAAAGGCA AATGTTCAGC CCCAAGATCC 4920 AGAATATAAA GGATATGAAT ATAAAGACGG CGTACAACCG ATACAGGGGA ATGAGTATTT 4980 ACTGCAAAAA TGTGATAATA ATAAATGTTC TTGCATGGAT GGAAATGTAC TTTCCGTCTC 5040 TCCAAAAGAA AAACCTTTTG GAAAATATGC CCATAAATAT CCTGAGAAAT GTGATTGTTA 5100 TCAAGGAAAA CATGTACCTA GCATACCACC TCCCCCCCCA CCTGTACAAC CACAACCGGA 5160 AGCACCAACA GTAACAGTAG ACGTTTGCAG CATAGTAAAA ACACTATTTA AAGACACAAA 5220 CAATTTTTCC GACGCTTGTG GTCTAAAATA CGGCAAAACC GCACCATCCA GTTGGAAATG 5280 TATACCAAGT GACACAAAAA GTGGTGCTGG TGCCACCACC GGCAAAAGTG GTAGTGATAG 5340 TGGTAGTATT TGTATCCCAC CCAGGAGGCG ACGATTATAT GTGGGGAAAC TACAGGAGTG 5400 GGCTACCGCG CTCCCACAAG GTGAGGGCGC CGCGCCGTCC CACTCACGCG CCGACGACTT 5460 GCGCAATGCG TTCATCCAAT CTGCTGCAAT AGAGACTTTT TTCTTATGGG ATAGATATAA 5520 -50- AGAAGAGAAA AAACCACAGG GTGATGGGTC ACAACAAGCA CTATCACAAC TAACCAGTAC 5580 ATACAGTGAT GACGAGGAGG ACCCCCCCGA CAAACTGTTA CAAAATGGTA AGATACCCCC 5640 CGATTTTTTG AGATTAATGT TCTATACATT AGGAGATTAT AGGGATATTT TAGTACACGG 5700 TGGTAACACA AGTGACAGTG GTAACACAAA TGGTAGTAAC AACAACAATA TTGTGCTTGA 5760 AGCGAGTGGT AACAAGGAGG ACATGCAAAA AATACAAGAG AAAATAGAAC AAATTCTCCC 5820 AAAAAATGGT GGCACACCTC TTGTCCCAAA ATCTAGTGCC CAAACACCTG ATAAATGGTG 5880 GAATGAACAC GCCGAATCTA TCTGGAAAGG TATGATATGT GCATTGACAT ATACAGAAAA 5940 GAACCCTGAC ACCAGTGCAA GAGGCGACGA AAACAAAATA GAAAAGGATG ATGAAGTGTA 6000 CGAGAAATTT TTTGGCAGCA CAGCCGACAA ACATGGCACA GCCTCAACCC CAACCGGCAC 6060 ATACAAAACC CAATACGACT ACGAAAAAGT CAAACTTGAG GATACAAGTG GTGCCAAAAC 6120 CCCCTCAGCC TCTAGTGATA CACCCCTTCT CTCCGATTTC GTGTTACGCC CCCCCTACTT 6180 CCGTTACCTT GAAGAATGGG GTCAAAATTT TTGTAAAAAA AGAAAGCATA AATTGGCACA 6240 AATAAAACAT GAGTGTAAAG TAGAAGAAAA TGGTGGTGGT AGTCGTCGTG GTGGTATAAC 6300 AAGACAATAT AGTGGGGATG GCGAAGCGTG TAATGAGATG CTTCCAAAAA ACGATGGAAC 6360 TGTTCCGGAT TTAGAAAAGC CGAGTTGTGC CAAACCTTGT AGTTCTTATA GAAAATGGAT 6420 AGAAAGCAAG GGAAAAGAGT TTGAGAAACA AGAAAAGGCA TATGAACAAC AAAAAGACAA 6480 ATGTGTAAAT GGAAGTAATA AGCATGATAA TGGATTTTGT GAAACACTAA CAACGTCCTC 6540 TAAAGCTAAA GACTTTTTAA AAACGTTAGG ACCATGTAAA CCTAATAATG TAGAGGGTAA 6600 AACAATTTTT GATGATGATA AAACCTTTAA ACATACAAAA GATTGTGATC CATGTCTTAA 6660 ATTTAGTGTT AATTGTAAAA AAGATGAATG TGATAATTCT AAAGGAACCG ATTGCCGAAA 6720 TAAAAATAGT ATTGATGCAA CAGATATTGA AAATGGAGTG GATTCTACTG TACTAGAAAT 6780 GCGTGTCAGT GCTGATAGTA AAAGTGGATT TAATGGTGAT GGTTTAGAGA ATGCTTGTAG 6840 AGGTGCTGGT ATCTTTGAAG GTATTAGAAA AGATGAATGG AAATGTCGTA ATGTATGTGG 6900 TTATGTTGTA TGTAAACCGG AAAACGTTAA TGGGGAAGCA AAGGGAAAAC ACATTATACA 6960 AATTAGAGCA CTGGTTAAAC GTTGGGTAGA ATATTTTTTT GAAGATTATA ATAAAATAAA 7020 ACATAAAATT TCACATCGCA TAAAAAATGG TGAAATATCT CCATGTATAA AAAATTGTGT 7080 AGAAAAATGG GTAGATCAGA AAAGAAAAGA ATGGAAGGAA ATTACTGAAC GTTTCAAAGA 7140 TCAATATAAA AATGACAATT CAGATGATGA CAATGTGAGA AGTTTTTTGG AGACCTTGAT 7200 ACCTCAAATT ACTGATGCAA ACGCTAAAAA TAAGGTTATA AAATTAAGTA AGTTCGGTAA 7260 TTCTTGTGGA TGTAGTGCCA GTGCGAACGA ACAAAACAAA AATGGTGAAT ACAAGGACGC 7320 TATAGATTGT ATGCTTAAAA AGCTTAAAGA TAAAATTGGC GAGTGCGAAA AGAAACACCA 7380 TCAAACTAGT GATACCGAGT GTTCCGACAC ACCACAACCG CAAACCCTTG AAGACGAAAC 7440 TTTGGATGAT GATATAGAAA CAGAGGAGGC GAAGAAGAAC ATGATGCCGA AAATTTGTGA 7500 AAATGTGTTA AAAACAGCAC AACAAGAGGA TGAAGGCGGT TGTGTCCCAG CAGAAAATAG 7560 TGAAGAACCG GCAGCAACAG ATAGTGGTAA GGAAACCCCC GAACAAACCC CCGTTCTCAA 7620 ACCCGAAGAA GAAGCAGTAC CGGAACCACC ACCTCCACCC CCACAGGAAA AAGCCCCGGC 7680 ACCAATACCC CAACCACAAC CACCAACCCC CCCCACACAA CTCTTGGATA ATCCCCACGT 7740 TCTAACCGCC CTGGTGACCT CCACCCTCGC CTGGAGCGTT GGCATCGGTT TTGCTACATT 7800 CACTTATTTT TATCTAAAGG TAAATGGAAG TATATATATG GGGATGTGGA TGTATGTGGA 7860 TGTATGTGAA TGTATGTGGA TGTATGTGGA TGTATGTGGA TGTGTTTTAT GGATATGTAT 7920 TTGTGATTAT GTTTGGATAT ATATATATAT ATATATATGT TTATGTATAT GTGTTTTTGG 7980 ATATATATAT GTGTATGTAT ATGATTTTCT GTATATGTAT TTGTGGGTTA AGGATATATA 8040 TATATGGATG TACTTGTATG TGTTTTATAT ATATATTTTA TATATATGTA TTTATATTAA 8100 AAAAGAAATA TAAAAACAAA TTTATTAAAA TGAAAAAAAG AAAAATGAAA TATAAAAAAA 8160 AATTTATTAA AATAAAAAAA AAAAAAAAAA AAAAGGAGAA AAATTTTTTA AAAAATAATA 8220 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2710 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Plasmodium falciparum (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Asn Val Met Val Glu Leu Ala Lys Met Gly Pro Lys Glu Ala Ala Gly 1 5 10 15 Gly Asp Asp He Glu Asp Glu Ser Ala Lys His Met Phe Asp Arg He 20 25 30 Gly Lys Asp Val Tyr Asp Lys Val Lys Glu Glu Ala Lys Glu Arg Gly 35 40 45 Lys Gly Leu Gin Gly Arg Leu Ser Glu Ala Lys Phe Glu Lys Asn Glu 50 55 60 Ser Asp Pro Gin Thr Pro Glu Asp Pro Cys Asp Leu Asp His Lys Tyr 65 70 75 80 His Thr Asn Val Thr Thr Asn Val He Asn Pro Cys Ala Asp Arg Ser 85 90 95 Asp Val Arg Phe Ser Asp Glu Tyr Gly Gly Gin Cys Thr His Asn Arg 100 105 110 He Lys Asp Ser Gin Gin Gly Asp Asn Lys Gly Ala Cys Ala Pro Tyr 115 120 125 Arg Arg Leu His Val Cys Asp Gin Asn Leu Glu Gin He Glu Pro He 130 135 140 Lys He Thr Asn Thr His Asn Leu Leu Val Asp Val Cys Met Ala Ala 145 150 155 160 Lys Phe Glu Gly Gin Ser He Thr Gin Asp Tyr Pro Lys Tyr Gin Ala 165 170 175 Thr Tyr Gly Asp Ser Pro Ser Gin He Cys Thr Met Leu Ala Arg Ser 180 185 190 Phe Ala Asp He Gly Asp He Val Arg Gly Arg Asp Leu Tyr Leu Gly 195 200 205 Asn Pro Gin Glu He Lys Gin Arg Gin Gin Leu Glu Asn Asn Leu Lys 210 215 220 Thr He Phe Gly Lys He Tyr Glu Lys Leu Asn Gly Ala Glu Ala Arg 225 230 235 240 Tyr Gly Asn Asp Pro Glu Phe Phe Lys Leu Arg Glu Asp Trp Trp Thr 245 250 255 Ala Asn Arg Glu Thr Val Trp Lys Ala He Thr Cys Asn Ala Trp Gly 260 265 270 Asn Thr Tyr Phe His Ala Thr Cys Asn Arg Gly Glu Arg Thr Lys Gly 275 280 285 Tyr Cys Arg Cys Asn Asp Asp Gin Val Pro Thr Tyr Phe Asp Tyr Val 290 295 300 Pro Gin Tyr Leu Arg Trp Phe Glu Glu Trp Ala Glu Asp Phe Cys Arg 305 310 315 320 Lys Lys Asn Lys Lys He Lys Asp Val Lys Arg Asn Cys Arg Gly Lys 325 330 335 Asp Lys Glu Asp Lys Asp Arg Tyr Cys Ser Arg Asn Gly Tyr Asp Cys 340 345 350 Glu Lys Thr Lys Arg Ala He Gly Lys Leu Arg Tyr Gly Lys Gin Cys 355 360 365 He Ser Cys Leu Tyr Ala Cys Asn Pro Tyr Val Asp Trp He Asn Asn 370 375 380 Gin Lys Glu Gin Phe Asp Lys Gin Lys Lys Lys Tyr Asp Glu Glu He 385 390 395 400 Lys Lys Tyr Glu Asn Gly Ala Ser Gly Gly Ser Arg Gin Lys Arg Asp 405 410 415 Ala Gly Gly Thr Thr Thr Thr Asn Tyr Asp Gly Tyr Glu Lys Lys Phe 420 425 430 Tyr Asp Glu Leu Asn Lys Ser Glu Tyr Arg Thr Val Asp Lys Phe Leu 435 440 445 Glu Lys Leu Ser Asn Glu Glu He Cys Thr Lys Val Lys Asp Glu Glu 450 455 460 Gly Gly Thr He Asp Phe Lys Asn Val Asn Ser Asp Ser Thr Ser Gly 465 470 475 480 Ala Ser Gly Thr Asn Val Glu Ser Gin Gly Thr Phe Tyr Arg Ser Lys 485 490 495 Tyr Cys Gin Pro Cys Pro Tyr Cys Gly Val Lys Lys Val Asn Asn Gly 500 505 510 Gly Ser Ser Asn Glu Trp Glu Glu Lys Asn Asn Gly Lys Cys Lys Ser 515 520 525 Gly Lys Leu Tyr Glu Pro Lys Pro Asp Lys Glu Gly Thr Thr He Thr 530 535 540 He Leu Lys Ser Gly Lys Gly His Asp Asp He Glu Glu Lys Leu Asn 545 550 555 560 Lys Phe Cys Asp Glu Lys Asn Gly Asp Thr He Asn Ser Gly Gly Ser 565 570 575 Gly Thr Gly Gly Ser Gly Gly Gly Asn Ser Gly Arg Gin Glu Leu Tyr 580 585 590 Glu Glu Trp Lys Cys Tyr Lys Gly Glu Asp Val Val Lys Val Gly His 595 600 605 Asp Glu Asp Asp Glu Glu Asp Tyr Glu Asn Val Lys Asn Ala Gly Gly 610 615 620 Leu Cys He Leu Lys Asn Gin Lys Lys Asn Lys Glu Glu Gly Gly Asn 625 630 635 640 Thr Ser Glu Lys Glu Pro Asp Glu He Gin Lys Thr Phe Asn Pro Phe 645 650 655 Phe Tyr Tyr Trp Val Ala His Met Leu Lys Asp Ser He His Trp Lys 660 665 670 Lys Lys Leu Gin Arg Cys Leu Gin Asn Gly Asn Arg He Lys Cys Gly 675 680 685 Asn Asn Lys Cys Asn Asn Asp Cys Glu Cys Phe Lys Arg Trp He Thr 690 695 700 Gin Lys Lys Asp Glu Trp Gly Lys He Val Gin His Phe Lys Thr Gin 705 710 715 720 Asn He Lys Gly Arg Gly Gly Ser Asp Asn Thr Ala Glu Leu He Pro 725 730 735 Phe Asp His Asp Tyr Val Leu Gin Tyr Asn Leu Gin Glu Glu Phe Leu 740 745 750 Lys Gly Asp Ser Glu Asp Ala Ser Glu Glu Lys Ser Glu Asn Ser Leu 755 760 765 Asp Ala Glu Glu Ala Glu Glu Leu Lys His Leu Arg Glu He He Glu 770 775 780 Ser Glu Asp Asn Asn Gin Glu Ala Ser Val Gly Gly Gly Val Thr Glu 785 790 795 800 Gin Lys Asn He Met Asp Lys Leu Leu Asn Tyr Glu Lys Asp Glu Ala 805 810 815 Asp Leu Cys Leu Glu He His Glu Asp Glu Glu Glu Glu Lys Glu Lys 820 825 830 Gly Asp Gly Asn Glu Cys He Glu Glu Gly Glu Asn Phe Arg Tyr Asn 835 840 845 Pro Cys Ser Gly Glu Ser Gly Asn Lys Arg Tyr Pro Val Leu Ala Asn 850 855 860 Lys Val Ala Tyr Gin Met His His Lys Ala Lys Thr Gin Leu Ala Ser 865 870 875 880 Arg Ala Gly Arg Ser Ala Leu Arg Gly Asp He Ser Leu Ala Gin Phe 885 890 895 Lys Asn Gly Arg Asn Gly Ser Thr Leu Lys Gly Gin He Cys Lys He 900 905 910 Asn Glu Asn Tyr Ser Asn Asp Ser Arg Gly Asn Ser Gly Gly Pro Cys 915 920 925 Thr Gly Lys Asp Gly Asp His Gly Gly Val Arg Met Arg He Gly Thr 930 935 940 Glu Trp Ser Asn He Glu Gly Lys Lys Gin Thr Ser Tyr Lys Asn Val 945 950 955 960 Phe Leu Pro Pro Arg Arg Glu His Met Cys Thr Ser Asn Leu Glu Asn 965 970 975 Leu Asp Val Gly Ser Val Thr Lys Asn Asp Lys Ala Ser His Ser Leu 980 985 990 Leu Gly Asp Val Gin Leu Ala Ala Lys Thr Asp Ala Ala Glu He He 995 1000 1005 Lys Arg Tyr Lys Asp Gin Asn Asn He Gin Leu Thr Asp Pro He Gin 1010 1015 1020 Gln Lys Asp Gin Glu Ala Met Cys Arg Ala Val Arg Tyr Ser Phe Ala 1025 1030 1035 1040 Asp Leu Gly Asp He He Arg Gly Arg Asp Met Trp Asp Glu Asp Lys 1045 1050 1055 Ser Ser Thr Asp Met Glu Thr Arg Leu He Thr Val Phe Lys Asn He 1060 1065 1070 Lys Glu Lys His Asp Gly He Lys Asp Asn Pro Lys Tyr Thr Gly Asp 1075 1080 1085 Glu Ser Lys Lys Pro Ala Tyr Lys Lys Leu Arg Ala Asp Trp Trp Glu 1090 1095 1100 Ala Asn Arg His Gin Val Trp Arg Ala Met Lys Cys Ala Thr Lys Gly 1105 1110 1115 1120 He He Cys Pro Gly Met Pro Val Asp Asp Tyr He Pro Gin Arg Leu 1125 1130 1135 Arg Trp Met Thr Glu Trp Ala Glu Trp Tyr Cys Lys Ala Gin Ser Gin 1140 1145 1150 Glu Tyr Asp Lys Leu Lys Lys He Cys Ala Asp Cys Met Ser Lys Gly 1155 1160 1165 Asp Gly Lys Cys Thr Gin Gly Asp Val Asp Cys Gly Lys Cys Lys Ala 1170 1175 1180 Ala Cys Asp Lys Tyr Lys Glu Glu He Glu Lys Trp Asn Glu Gin Trp 1185 1190 1195 1200 Arg Lys He Ser Asp Lys Tyr Asn Leu Leu Tyr Leu Gin Ala Lys Thr 1205 1210 1215 Thr Ser Thr Asn Pro Gly Arg Thr Val Leu Gly Asp Asp Asp Pro Asp 1220 1225 1230 Tyr Gin Gin Met Val Asp Phe Leu Thr Pro He His Lys Ala Ser He 1235 1240 1245 Ala Ala Arg Val Leu Val Lys Arg Ala Ala Gly Ser Pro Thr Glu He 1250 1255 1260 Ala Ala Ala Ala Pro He Thr Pro Tyr Ser Thr Ala Ala Gly Tyr He 1265 1270 1275 1280 His Gin Glu He Gly Tyr Gly Gly Cys Gin Glu Gin Thr Gin Phe Cys 1285 1290 1295 Glu Lys Lys His Gly Ala Thr Ser Thr Ser Thr Thr Lys Glu Asn Lys 1300 1305 1310 Glu Tyr Thr Phe Lys Gin Pro Pro Pro Glu Tyr Ala Thr Ala Cys Asp 1315 1320 1325 Cys He Asn Arg Ser Gin Thr Glu Glu Pro Lys Lys Lys Glu Glu Asn 1330 1335 1340 Val Glu Ser Ala Cys Lys He Val Glu Lys He Leu Glu Gly Lys Asn 1345 1350 1355 1360 Gly Arg Thr Thr Val Gly Glu Cys Asn Pro Lys Glu Ser Tyr Pro Asp 1365 1370 1375 Trp Asp Cys Lys Asn Asn He Asp He Ser His Asp Gly Ala Cys Met 1380 1385 1390 Pro Pro Arg Arg Gin Lys Leu Cys Leu Tyr Tyr He Ala His Glu Ser 1395 1400 1405 Gin Thr Glu Asn He Lys Thr Asp Asp Asn Leu Lys Asp Ala Phe He 1410 1415 • 1420 Lys Thr Ala Ala Ala Glu Thr Phe Leu Ser Trp Gin Tyr Tyr Lys Ser 1425 1430 1435 1440 Lys Asn Asp Ser Glu Ala Lys He Leu Asp Arg Gly Leu He Pro Ser 1445 1450 1455 Gin Phe Leu Arg Ser Met Met Tyr Thr Phe Gly Asp Tyr Arg Asp He 1460 1465 1470 Cys Leu Asn Thr Asp He Ser Lys Lys Gin Asn Asp Val Ala Lys Ala 1475 1480 1485 Lys Asp Lys He Gly Lys Phe Phe Ser Lys Asp Gly Ser Lys Ser Pro 1490 1495 1500 Ser Gly Leu Ser Arg Gin Glu Trp Trp Lys Thr Asn Gly Pro Glu He 1505 1510 1515 1520 Trp Lys Gly Met Leu Cys Ala Leu Thr Lys Tyr Val Thr Asp Thr Asp 1525 1530 1535 Asn Lys Arg Lys He Lys Asn Asp Tyr Ser Tyr Asp Lys Val Asn Gin 1540 1545 1550 Ser Gin Asn Gly Asn Pro Ser Leu Glu Glu Phe Ala Ala Lys Pro Gin 1555 1560 1565 Phe Leu Arg Trp Met He Glu Trp Gly Glu Glu Phe Cys Ala Glu Arg 1570 1575 1580 Gin Lys Lys Glu Asn He He Lys Asp Ala Cys Asn Glu He Asn Ser 1585 1590 1595 1600 Thr Gin Gin Cys Asn Asp Ala Lys His Arg Cys Asn Gin Ala Cys Arg 1605 1610 1615 Ala Tyr Gin Glu Tyr Val Glu Asn Lys Lys Lys Glu Phe Ser Gly Gin 1620 1625 1630 Thr Asn Asn Phe Val Leu Lys Ala Asn Val Gin Pro Gin Asp Pro Glu 1635 1640 1645 Tyr Lys Gly Tyr Glu Tyr Lys Asp Gly Val Gin Pro He Gin Gly Asn 1650 1655 1660 Glu Tyr Leu Leu Gin Lys Cys Asp Asn Asn Lys Cys Ser Cys Met Asp 1665 1670 1675 1680 Gly Asn Val Leu Ser Val Ser Pro Lys Glu Lys Pro Phe Gly Lys Tyr 1685 1690 1695 Ala His Lys Tyr Pro Glu Lys Cys Asp Cys Tyr Gin Gly Lys His Val 1700 1705 1710 Pro Ser He Pro Pro Pro Pro Pro Pro Val Gin Pro Gin Pro Glu Ala 1715 1720 1725 Pro Thr Val Thr Val Asp Val Cys Ser He Val Lys Thr Leu Phe Lys 1730 1735 1740 Asp Thr Asn Asn Phe Ser Asp Ala Cys Gly Leu Lys Tyr Gly Lys Thr 1745 1750 1755 1760 Ala Pro Ser Ser Trp Lys Cys He Pro Ser Asp Thr Lys Ser Gly Ala 1765 1770 1775 Gly Ala Thr Thr Gly Lys Ser Gly Ser Asp Ser Gly Ser He Cys He 1780 1785 1790 Pro Pro Arg Arg Arg Arg Leu Tyr Val Gly Lys Leu Gin Glu Trp Ala 1795 1800 1805 Thr Ala Leu Pro Gin Gly Glu Gly Ala Ala Pro Ser His Ser Arg Ala 1810 1815 1820 Asp Asp Leu Arg Asn Ala Phe He Gin Ser Ala Ala He Glu Thr Phe 1825 1830 1835 1840 Phe Leu Trp Asp Arg Tyr Lys Glu Glu Lys Lys Pro Gin Gly Asp Gly 1845 1850 1855 Ser Gin Gin Ala Leu Ser Gin Leu Thr Ser Thr Tyr Ser Asp Asp Glu 1860 1865 1870 Glu Asp Pro Pro Asp Lys Leu Leu Gin Asn Gly Lys He Pro Pro Asp 1875 1880 1885 Phe Leu Arg Leu Met Phe Tyr Thr Leu Gly Asp Tyr Arg Asp He Leu 1890 1895 1900 Val His Gly Gly Asn Thr Ser Asp Ser Gly Asn Thr Asn Gly Ser Asn 1905 1910 1915 1920 Asn Asn Asn He Val Leu Glu Ala Ser Gly Asn Lys Glu Asp Met Gin 1925 1930 1935 Lys He Gin Glu Lys He Glu Gin He Leu Pro Lys Asn Gly Gly Thr 1940 1945 1950 Pro Leu Val Pro Lys Ser Ser Ala Gin Thr Pro Asp Lys Trp Trp Asn 1955 1960 1965 Glu His Ala Glu Ser He Trp Lys Gly Met He Cys Ala Leu Thr Tyr 1970 1975 1980 Thr Glu Lys Asn Pro Asp Thr Ser Ala Arg Gly Asp Glu Asn Lys He 1985 1990 1995 2000 Glu Lys Asp Asp Glu Val Tyr Glu Lys Phe Phe Gly Ser Thr Ala Asp 2005 2010 2015 Lys His Gly Thr Ala Ser Thr Pro Thr Gly Thr Tyr Lys Thr Gin Tyr 2020 2025 2030 Asp Tyr Glu Lys Val Lys Leu Glu Asp Thr Ser Gly Ala Lys Thr Pro 2035 2040 2045 Ser Ala Ser Ser Asp Thr Pro Leu Leu Ser Asp Phe Val Leu Arg Pro 2050 2055 2060 Pro Tyr Phe Arg Tyr Leu Glu Glu Trp Gly Gin Asn Phe Cys Lys Lys 2065 2070 2075 2080 Arg Lys His Lys Leu Ala Gin He Lys His Glu Cys Lys Val Glu Glu 2085 2090 2095 Asn Gly Gly Gly Ser Arg Arg Gly Gly He Thr Arg Gin Tyr Ser Gly 2100 2105 2110 Asp Gly Glu Ala Cys Asn Glu Met Leu Pro Lys Asn Asp Gly Thr Val 2115 2120 2125 Pro Asp Leu Glu Lys Pro Ser Cys Ala Lys Pro Cys Ser Ser Tyr Arg 2130 2135 2140 Lys Trp He Glu Ser Lys Gly Lys Glu Phe Glu Lys Gin Glu Lys Ala 2145 2150 2155 2160 Tyr Glu Gin Gin Lys Asp Lys Cys Val Asn Gly Ser Asn Lys His Asp 2165 2170 2175 Asn Gly Phe Cys Glu Thr Leu Thr Thr Ser Ser Lys Ala Lys Asp Phe 2180 2185 2190 Leu Lys Thr Leu Gly Pro Cys Lys Pro Asn Asn Val Glu Gly Lys Thr 2195 2200 2205 He Phe Asp Asp Asp Lys Thr Phe Lys His Thr Lys Asp Cys Asp Pro 2210 2215 2220 Cys Leu Lys Phe Ser Val Asn Cys Lys Lys Asp Glu Cys Asp Asn Ser 2225 2230 2235 2240 Lys Gly Thr Asp Cys Arg Asn Lys Asn Ser He Asp Ala Thr Asp He 2245 2250 2255 Glu Asn Gly Val Asp Ser Thr Val Leu Glu Met Arg Val Ser Ala Asp 226,0 2265 2270 Ser Lys Ser Gly Phe Asn Gly Asp Gly Leu Glu Asn Ala Cys Arg Gly 2275 2280 2285 Ala Gly He Phe Glu Gly He Arg Lys Asp Glu Trp Lys Cys Arg Asn 2290 2295 2300 Val Cys Gly Tyr Val Val Cys Lys Pro Glu Asn Val Asn Gly Glu Ala 2305 2310 2315 2320 Lys Gly Lys His He He Gin He Arg Ala Leu Val Lys Arg Trp Val 2325 2330 2335 Glu Tyr Phe Phe Glu Asp Tyr Asn Lys He Lys His Lys He Ser His 2340 2345 2350 Arg He Lys Asn Gly Glu He Ser Pro Cys He Lys Asn Cys Val Glu 2355 2360 2365 Lys Trp Val Asp Gin Lys Arg Lys Glu Trp Lys Glu He Thr Glu Arg 2370 2375 2380 Phe Lys Asp Gin Tyr Lys Asn Asp Asn Ser Asp Asp Asp Asn Val Arg 2385 2390 2395 2400 Ser Phe Leu Glu Thr Leu He Pro Gin He Thr Asp Ala Asn Ala Lys 2405 2410 2415 Asn Lys Val He Lys Leu Ser Lys Phe Gly Asn Ser Cys Gly Cys Ser 2420 2425 2430 Ala Ser Ala Asn Glu Gin Asn Lys Asn Gly Glu Tyr Lys Asp Ala He 2435 2440 ' 2445 Asp Cys Met Leu Lys Lys Leu Lys Asp Lys He Gly Glu Cys Glu Lys 2450 2455 2460 Lys His His Gin Thr Ser Asp Thr Glu Cys Ser Asp Thr Pro Gin Pro 2465 2470 2475 2480 Gin Thr Leu Glu Asp Glu Thr Leu Asp Asp Asp He Glu Thr Glu Glu 2485 2490 2495 Ala Lys Lys Asn Met Met Pro Lys He Cys Glu Asn Val Leu Lys Thr 2500 2505 2510 Ala Gin Gin Glu Asp Glu Gly Gly Cys Val Pro Ala Glu Asn Ser Glu 2515 2520 2525 Glu Pro Ala Ala Thr Asp Ser Gly Lys Glu Thr Pro Glu Gin Thr Pro 2530 2535 2540 Val Leu Lys Pro Glu Glu Glu Ala Val Pro Glu Pro Pro Pro Pro Pro 2545 2550 2555 2560 Pro Gin Glu Lys Ala Pro Ala Pro He Pro Gin Pro Gin Pro Pro Thr 2565 2570 2575 Pro Pro Thr Gin Leu Leu Asp Asn Pro His Val Leu Thr Ala Leu Val 2580 2585 2590 Thr Ser Thr Leu Ala Trp Ser Val Gly He Gly Phe Ala Thr Phe Thr 2595 2600 2605 Tyr Phe Tyr Leu Lys Val Asn Gly Ser He Tyr Met Gly Met Trp Met 2610 2615 2620 Tyr Val Asp Val Cys Glu Cys Met Trp Met Tyr Val Asp Val Cys Gly 2625 2630 2635 2640 Cys Val Leu Trp He Cys He Cys Asp Tyr Val Trp He Tyr He Tyr 2645 2650 2655 He Tyr He Cys Leu Cys He Cys Val Phe Gly Tyr He Tyr Val Tyr 2660 2665 2670 Val Tyr Asp Phe Leu Tyr Met Tyr Leu Trp Val Lys Asp He Tyr He 2675 2680 2685 Trp Met Tyr Leu Tyr Val Phe Tyr He Tyr He Leu Tyr He Cys He 2690 2695 2700 Tyr He Lys Lys Glu He 2705 2710 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19124 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13 ACATTTTTTC GTAATATATA TATATATATA TATATATAAT TCTCTTTTTC TAATATATAT 60 ATCCTTCTAT TTTCGATTTT TTCATTTTTT TCCAGTATTAATTTATTTAT TTATTTGTGA 120 TATTTTATAA TATATTATTT AAATGTGTAT TTATATATGT GTTTTATTTT TGTTATTAAT 180 TTGAATAATC CGAGCGAAAAAAAATATATAATCTCATATAAAAATTATTTATAATACAAT 240 ATTATATAGT TTCCTATTAAAATAAATTAA TATAATATAC AATAATATTT CTTGTTATTT 300 TTATAAATAT AACTAATTTC TTATTTTTAT TTAACTTTAT TCCTTTTTAA TTTCTTAATT 360 CTTTTATGCAAACAAAAAAC ATAAAGTAAT TCTACATATC AACAAAAAAAAAAAAAAAAA 420 AAAAAAAAAAATTTATTATAATATAATAAAAAATATAAAGACATACGTTC ACTTATTATT 480 ATAAATGATT TATTACGATT AAAACATATT GAGATTATAA TAATATAATT TAACATAGAA 540 AGAGTTAAGAATACATTTTT ττττττττττ TGATATGTAATTCAACATAT ATATATATAT 600 ATATCTTTTT AATTTAATTAAATAAAATTC CTTATTATTC ATATTGTTTC TTTTATCACA 660 TGTGAAATAT TAAAAATAAT TTTCGATTTTATCGATATAT TTATGTCGTT TATATACTTA 720 TATAGGTCTT TATAACTATT GATTAATAGAAGGTAATAGC CTAATAATAT AAATACTCGT 780 ATTTATAAAT TCATTTATAT ATTTCAAATA TATTTCGATG GTTTATTTTC AAATACAATT 840 AATTAGATTT CTTAAATATT TCTTCATTTATTCATTTTTATAGCATATACATGCACATTA 900 TAAATTATTAATAAAAAATT TTTATTTTAA TATATAATAA CAATTTTCAT ACATTACATT 960 TTTCACACAA CATTTAAGTT GTCATAATGT AACACATTAA ATAATATATT ACTTATATAT 1020 ATATAATTAT TAATTATATA TTAAATAAAA ATGTATTATC GCCTGTATTA TCATAGTATA 1080 TATAATGTTG TATAACGCTT CAAAATATAT ATAATAATAT AATTAAAAAT ATATATATAG 1140 TAATTAATTA TTTTGTTATG TTATGTAATA ATGCAATTAA TATAAGATAA AATTCTATAG 1200 CTATTATTTA AAATATATAT ATATATATAT ATATATATAT ATATTAGTAT ATGTTATCAA 1260 AATATTATAA TATGTAAATT ATTAATAAAA TATATTTGTA TAACATACAA GACTAAAGAA 1320 AACTATACAA TCTGGTATCT AATAGTATAT ATATATAATA TCTTTTTTAT TTAATTGTTC 1380 TCTCTTTTTT TTTTTTTTAA ATAATAATAA ATATTAATAT ATTTTTTTTC ATAATTATAT 1440 GATTTAGTAT TTTAATAATA AATAAATCTT TTAAAAAACT TCAAAACATT TTTGCATAAA 1500 ATAATATTAA TATTAGTAAC CACCTAGATA AATTAGAGAG AAACGTAGAA CATACCAAAA 1560 AAAATTAGAA CAAAAAGAAT ATTACAAAAA ATAATAAAAT TAAATTATTT CTTTACTATT 1620 AATTTAAAGT TTTTTTTCAT ATCATATATT ATGATACACA ATGTTTGTTG TTAAATGTTT 1680 TATATACATG CAATGATATG TTTCTGTTGG AATATGTATT ATATACTTAT ATGTTCTAAT 1740 AAATGTATTG TACACCTTTA GCAACTATTA CTACACACAT TTTTATATAA TTTATAACAG 1800 GAAAATATGT TATATTATTA CAATATCTTA ATGTGTTTTT GCAAAAATAT AAAAAACAAG 1860 AAAATTACAA TTGTAATTAA TCGTATGACA TAAAATTATA TTATATTAGA AATTAAAATT 1920 CAAAATTATA AAAAATATGG AAATGTTTTG TTATATTATT TTTTTAAAAA TTTAATTATT 1980 TTATTTTATT ATTTATTTTT ττττττττττ GTGTTCTAAA TAAAAAGGCA AATATGATTC 2040 AAGTAAAAAA TATATATATT TACATAATGG CAAAATAATT GTTTATTATA TTATATGACT 2100 ATAATAATAT TTTAGATTAA ACATATGTAA TTCATTTAAC AGAATAAAAT AAAATATTAT 2160 ATATATATAT TAATTATTAA GTTATAGATT TAATAAAAAT ATATTATACA TATGAGATTA 2220 AAAATGAAAG TTCACTACAG TAATATATTA TTATATGTCG TCAATTTAAG TATATTCTTA 2280 ATATCACGTA TGCACTAAAT AATGACAATA ATAATATATA TGTAACATTT TATAATTGAT 2340 GTAAATAAAA AAATATACAT ATATACAAAA ACATATATGA TATTTACATT CTTTTTTATA 2400 GATAAATATC CAGAAGAACT ATTACATCAC TTCACTTCAT ATACCAAACA CGAAAAAAAT 2460 ACAACCACTA GGTTATTATG CGAATGTGAC TTATATACGT CCATTTATGA TAATGACCCG 2520 GAAATGATAT TAGTGATGGA AAATTTCAAT AAACAGACAG AAGAAAGGTT TCATGAATAC 2580 AATGAACGCA TGCAAGAAAA ACGAAAAATA TGTAAAGAAC AATGCGAAAA GGATATACAA 2640 AAAATTATTT TAAAAGATAA AATCGAAAAG GAATTAACAG AAAAGTTAGA GGCATTGGAA 2700 ACGAATATAA AGACTGAGGA TATACCTACT TGTGTATGCG AAAAATCAGT AGCAGATAAA 2760 GTGGAAAAAA CGTGTTTGAA ATGTGGAGGT ATATTGGGTG TTGGTGTGAC TCCATCTTTA 2820 GGTTTATTAG GAGAAATAGG TGGACTTGTT ATAAATAATT GGACAAATAC TCCTTTTTAT 2880 AAAGCTTTTC TTACTTTTGC TCAAAAGGAA GGTATAGCTG CCGGTAAAAT TGCTAGTGAT 2940 ACTGCTCGTA TTGATACAGT TATTTAAGGA ATAATATCAA ATTTTGATGT GCACACTATA 3000 AATGGTTCTA CGTTGGGGAA AGTTATTACC GTAGAAGCTC TTAAGGATGA CACTACTCTT 3060 ACTACGGCAC TATATAATGA ATATGTAAGC ATGTGTGTAA ATACGAACCC TGTCGAAGAC 3120 AAATTAATTT GTGCTTTTGG GATGAGAGAC GGTCTAGTTG CAGGGCAATA TGCTTCATCG 3180 CGAGACGTTA TAGGATCAAG TGTAAAAGGA ATTATTAGAA AAGCTGCAAA CGCTGCTTCA 3240 CAAGCTGCTG AGACAGCTGC TAACGAAACT ACTTCCGGAA TGATCGAAGC CGAGTTAAGT 3300 AAAATAACAT CTGCAGGTGC TAATTTACAC AGTGCAATTA CTTACTCAGT AACTGCGATA 3360 TTGGTTATAG TTTTGGTTAT GGTAATTATT TATTTAATAT TACGTTATCG TAGAAAAAAA 3420 AAAATGAAGA AAAAATTGCA ATATATAAAA TTATTAAAGG AATAGATATA CGATGTCGAG 3480 CTATTAGCGG TAATTTAAAG TATTGTGAAT TTTTCATTTA ATATGCTATG ATCATTTGAT 3540 AATTAATTTT TTTTTATAAT ATTATATTTT TTTATACCTT GGATTCTTAC ATTGTTTTAT 3600 TATTATATGA TTATTTAATT ATTATACTTA TATATATATA TATTTTTACA TTAAGATATT 3660 ATATATGTAT CTATCTATCT ATCTATCTAT ATATATATAT ATATATATAT ATTATAATAA 3720 TTATTATTAT TAGATGCATA TTAGTGATGA TTATAATAAT AACCTATTGA AGAGAATAGA 3780 ACATAATAAT ATATTAAATT AATAGAACTT CATTTTTATT GTTATATGTA TATAAAAATA 3840 AGAAATTTGA AAAAGTAATT TACACATGAT AATGTATTTT ATTTTATTTG TGTTGTTTTA 3900 TATTTATTTA TAAAAATTGT TTAATATAAG TTGTTATTAT AATTTTTTAA TATGGCACCA 3960 TTAGCTTTCC ATTATACAAA TATATATTTC CTCATTAGAA TCTGAATATT TATTGTATTA 4020 TAAAAAAAGT ATAATATAAT AAAATATCTA AGATTTTTTC TAATTTGTTT AATTTATAAT 4080 AAATTTTAAT TTTATACGAT AGAATAAATT ATAATCAACA TATATATATG TATTCATCTT 4140 AAGAACCTAT TACAATATAG TAACAACTGG TTCCTTTTTA TTATAAATAA CATAAGAATG 4200 TGTAAAAGGA TAGTTGTTAA AGGCTTTTTT AATATTGATT ATAAATGTTT GTAAGATATA 4260 TATAATAGAT ATCTTAACAT ACAACTTTGC ATAATTGTAA TTAAAAAAAT ATATATAATA 4320 AGAAATATTA TAAATAATAT TATAAAAAAT TAAGCATAAA TGTCACAATA AATTTTTTTT 4380 TATTAATTTA ATTTTATTTT ATTGTTCTAA AATATATTGA TTATGAGAAT ATTATTTGTG 4440 TCTAATATAA TTAAGATATT TCTAATATTA ATTTATATAT ATATATTTAA AAGTATTTTA 4500 AGAATAATTT TTTACTTATT TATTATAATA TGAAATATGC ATGGAGTATA TATAAATATT 4560 GATGACAAAA AAAAAACTTT TAAAATGGAA AATATGCATA TAATAAAATA CTATATAGTA 4620 TAATTGGTGA AATAGTTGTA ACTTATACAA ACATGTTGCA TTCATAATTT AGAGATTATG 4680 TAATATTGTT TATGTATCGT AATATATATT AATATAATTG TTTTTTTAGT ATGTATGGTA 4740 TTCTAATAAT ATATTCATAT GTAGTCATAG TGTCAATGAA TATAAAATAT GGTATATTTA 4800 TATTATTGTA TATATTAAAT AAGTAACACA GAACATTATA TATAGTAATA AATAGAAGAA 4860 ATAATATATT TTTATGTTAT ATATTATTAG TTATTATAAA GGGGAAAATT CATAATATTT 4920 ATGAAAATTT TTGTATATGA TATAGTTATA AGTTAAAAAA AAAAAAAAAC AAGAACAAAA 4980 ATGGAAAGCA TAAAAAATGT TACTGTAATA GGATAAAATA TATTATATAA AATGTTTATT 5040 TTATCTTAAA AAGGTTCCTA TTATAACATT AAAAAAAATT TGTCCCATTT TATAAATAAT 5100 TAACTACATT TACATAATGA AATTTCGATT TTGTGTTTTT TTGATGAATA TTATGGACTA 5160 ATTATTTATA TGTGAATGCG TTCTATATAA TAATAATAAT TTTATTTAAA AAAATGAAAA 5220 ATAAGAAATA AATATCCTGA TTTTGTAGTT CCAATAGCTT AATATAATTA TGGACTCATA 5280 TATATATTAT ATATATCTTT ACAACAAGTA ATAAGTAAAT ATTATTTTAA TCTTAATAAG 5340 GAAAATAAAA ATAATAAAAT AAGAATACTG AATAATAAGT CAT TTATAC ATTTTTTAAA 5400 AATGTAACAT AATTACAAAT ACGTAACATG TATTATAGAA ATAATAAGAA TTTAATATTA 5460 AGGATAAATA TAAATATTTA AAATTATATT TTTTTATGTC AATTTATGTT ATATTATATT 5520 ATATTAACAT GATTAGTTTT TTGAAAAATA TTTAAATATC ATATAATAAT AATAAATTAG 5580 TTAAAATAAT AGTATTTCAT ACAAAATACT AACTTATAAG TATATCATAT AATATTATAT 5640 ATATATATAT TTATGTGTTT TTGATTGGGT GTATATAAGG CTATAAGTAT ATATGGGTTG 5700 TTCATTATAT ATTTATATGT GAATAGATAC ATATAAGTTA ATATATTTAT TTGTGTATAT 5760 GTCTGTGTTA AGATAGATAT GCATTACAGT TAAGGGTTAT AGTTTTTTTT ττττττττττ 582 o GTACATATAT ATAAAAAATA GATAACTAAC AATATGCATA TTACAAGAAT AATATTTGTA 5880 TAAAATATAT ATATATATAT ATATATAAAG ACATTAAAAC TATACTAATA GGTAATTAGT 5940 TTTATTATAT CATCCTTTTA TTATTATAAT TTTTTTTGTT TTACTTCTTG TCGTTCTTTT 6000 TTGTTATTAT AATATAACAA ATATAAAACA ATATCAGTAT TTGGAATATA AATAAATTTA 6060 TTCTACATAT ATGCATATAT ATATATATAT ATATATATAT ATATATATAT ATATATATAT 6120 ATATGTATGA TTTTATACTA TTTTTATACA TGCATTTTTA TATATTTTAG TATATACTTT 6180 AAAGATATTA TTAATATTTA TATAGTAGCA TATATGTATT TATATTATAA CAAATATTTT 6240 CATTTATATA AATATATAGA ACATGAACAT TTTATTAATA ACTCATATTT GAATATATAT 6300 ATTTATAATG TGTATTTTTA CTTATTTTTT TATATTATAC AATAAAATTT TGAAATTCAT 6360 AAAATGCATG AAATACATAA AAAAATACAA CAAAACAAAT GATAAAAACA TTTTTATTAA 6420 TATAATATAA TATAATATAA TAATATATTT TTCCTGTTAT TTATTTATCA TTTTTTTTTT 6480 GATGCTATAT ATATTATTAT ATAATAAATT ATAATATATA ACAACAAAAA TTAATAATAA 6540 TAATATACTA CTTTTAATAT AATACAACAA TACAAAGAAT ATGTATCTAT ATCAATTATA 6600 TATATATGAA TATATAAATA TGATAGATAA TATAGATAGA GAGAAACGAA GAACATATTT 6660 GTCTCTTTTG TTATCTCTAA TATATATATA TATATAATAA ATTAAAATAA AGTCAAAAAA 6720 AATATACATA TATTAATGTT AATAATTAAA TATATAAACA CGTTGCATAT ATACTTTTTT 6780 ATATGTTTGT ATTTTCGTAT TTTTTTTTTC TCATTTATAA TTTTACTTAA TAAATAAAAC 6840 ATAAAAAAAA TAATATATAT ATAATTAAAT AGATAAATAA AGGAATACAT AAAATATAAT 6900 ATTTCTGATT ATATTTTTTT TTTGTTAGAA TATTTAAATT TATTATAAAT TTATTAATAT 6960 ATATATATAT TTTTTTTAAA AATATATAAA ACTAATAATT ATTATTATAT ACATATTAAA 7020 TATTATTTTT TTAACATATA CATATATTGT AATATTATAA TAGTACAACT ATTAATATAT 7080 ATATATATAT ATATACAATA TTTATATATA TTGTAATACA TAAATTATAC CTTACATATA 7140 TATATACATT CACAAAAGTG TTATTATTCT TATTCTACCA TATTATAATA CTACTGTAAT 7200 ATACATATAT ACATACCCCC ACGTACGTAC GAAACACCAC CAAACCATGT ATCACGTATG 7260 TATGTATGCC ACGATATAAA CCACGTACCA CGTATGACAT AATGTAATGG TGGAGTTAGC 7320 AAAAATGGGG CCCAAGGAGG CTGCAGGTGG GGATGATATT GAGGATGAAA GTGCCAAACA 7380 TATGTTTGAT AGGATAGGAA AAGATGTGTA CGATAAAGTA AAAGAGGAAG CTAAAGAACG 7440 TGGTAAAGGC TTGCAAGGAC GTTTGTCAGA AGCAAAATTT GAGAAAAATG AAAGCGATCC 7500 ACAAACACCA GAAGATCCAT GCGATCTTGA TCATAAATAT CATACAAATG TAACTACTAA 7560 TGTAATTAAT CCGTGCGCTG ATAGATCTGA CGTGCGTTTT TCCGATGAAT ATGGAGGTCA 7620 ATGTACACAT AATAGAATAA AAGATAGTCA ACAGGGTGAT AATAAAGGTG CATGTGCTCC 7680 ATATAGGCGA TTGCATGTAT GCGATCAAAA TTTAGAACAG ATAGAGCCTA TAAAAATAAC 7740 AAATACTCAT AATTTATTGG TAGATGTGTG TATGGCAGCA AAATTTGAAG GACAATCAAT 7800 AACACAAGAT TATCCAAAAT ATCAAGCAAC ATATGGTGAT TCTCCTTCTC AAATATGTAC 7860 TATGCTGGCA CGAAGTTTTG CGGACATAGG GGACATTGTC AGAGGAAGAG ATTTGTATTT 7920 AGGTAATCCA CAAGAAATAA AACAAAGACA ACAATTAGAA AATAATTTGA AAACAATTTT 7980 CGGGAAAATA TATGAAAAAT TGAATGGCGC AGAAGCACGC TACGGAAATG ATCCGGAATT 8040 TTTTAAATTA CGAGAAGATT GGTGGACTGC TAATCGAGAA ACAGTATGGA AAGCCATCAC 8100 ATGTAACGCT TGGGGTAATA CATATTTTCA TGCAACGTGC AATAGAGGAG AACGAACTAA 8160 AGGTTACTGC CGGTGTAACG ACGACCAAGT TCCCACATAT TTTGATTATG TGCCGCAGTA 8220 TCTTCGCTGG TTCGAGGAAT GGGCAGAAGA TTTTTGTAGG AAAAAAAATA AAAAAATAAA 8280 AGATGTTAAA AGAAATTGTC GTGGAAAAGA TAAAGAGGAT AAGGATCGAT ATTGTAGCCG 8340 TAATGGCTAC GATTGCGAAA AAACTAAACG AGCGATTGGT AAGTTGCGTT ATGGTAAGCA 8400 ATGCATTAGC TGTTTGTATG CATGTAATCC TTACGTTGAT TGGATAAATA ACCAAAAAGA 8460 ACAATTTGAC AAACAGAAAA AAAAATATGA TGAAGAAATA AAAAAATATG AAAATGGAGC 8520 ATCAGGTGGT AGTAGGCAAA AACGGGATGC AGGTGGTACA ACTACTACTA ATTATGATGG 8580 ATATGAAAAA AAATTTTATG ACGAACTTAA TAAAAGTGAA TATAGAACCG TTGATAAATT 8640 TTTGGAAAAA TTAAGTAATG AAGAAATATG CACAAAAGTT AAAGACGAAG AAGGAGGAAC 8700 AATTGATTTT AAAAACGTTA ATAGTGATAG TACTAGTGGT GCTAGTGGCA CTAATGTTGA 8760 AAGTCAAGGA ACATTTTATC GTTCAAAATA TTGCCAACCC TGCCCTTATT GTGGAGTGAA 8820 AAAGGTAAAT AATGGTGGTA GTAGTAATGA ATGGGAAGAG AAAAATAATG GCAAGTGCAA 8880 GAGTGGAAAA CTTTATGAGC CTAAACCCGA CAAAGAAGGT ACTACTATTA CAATCCTTAA 8940 AAGTGGTAAA GGACATGATG ATATTGAAGA AAAATTAAAC AAATTTTGTG ATGAAAAAAA 9000 TGGTGATACA ATAAATAGTG GTGGTAGTGG TACGGGTGGT AGTGGTGGTG GTAACAGTGG 9060 TAGACAGGAA TTGTATGAAG AATGGAAATG TTATAAAGGT GAAGATGTAG TGAAAGTTGG 9120 ACACGATGAG GATGACGAGG AGGATTATGA AAATGTAAAA AATGCAGGCG GATTATGTAT 9180 ATTAAAAAAC CAAAAAAAGA ATAAAGAAGA AGGTGGAAAT ACGTCTGAAA AGGAGCCTGA 9240 TGAAATCCAA AAGACATTCA ATCCTTTTTT TTACTATTGG GTTGCACATA TGTTAAAAGA 9300 TTCCATACAT TGGAAAAAAA AACTTCAGAG ATGTTTACAA AATGGTAACA GAATAAAATG 9360 TGGAAACAAT AAATGTAATA ATGATTGTGA ATGTTTTAAA AGATGGATTA CACAAAAAAA 9420 AGACGAATGG GGGAAAATAG TACAACATTT TAAAACGCAA AATATTAAAG GTAGAGGAGG 9480 TAGTGACAAT ACGGCAGAAT TAATCCCATT TGATCACGAT TATGTTCTTC AATACAATTT 9540 GCAAGAAGAA TTTTTGAAAG GCGATTCCGA AGACGCTTCC GAAGAAAAAT CCGAAAATAG 9600 TCTGGATGCA GAGGAGGCAG AGGAACTAAA ACACCTTCGC GAAATCATTG AAAGTGAAGA 9660 CAATAATCAA GAAGCATCTG TTGGTGGTGG CGTCACTGAA CAAAAAAATA TAATGGATAA 9720 ATTGCTCAAC TACGAAAAAG ACGAAGCCGA TTTATGCCTA GAAATTCACG AAGATGAGGA 9780 AGAGGAAAAA GAAAAAGGAG ACGGAAACGA ATGTATCGAA GAGGGCGAAA ATTTTCGTTA 9840 TAATCCATGT AGTGGCGAAA GTGGTAACAA ACGATACCCC GTTCTTGCGA ACAAAGTAGC 9900 GTATCAAATG CATCACAAGG CAAAGACACA ATTGGCTAGT CGTGCTGGTA GAAGTGCGTT 9960 GAGAGGTGAT ATATCCTTAG CGCAATTTAA AAATGGTCGT AACGGAAGTA CATTGAAAGG 10020 ACAAATTTGC AAAATTAACG AAAACTATTC CAATGATAGT CGTGGTAATA GTGGTGGACC 10080 ATGTACAGGC AAAGATGGAGATCACGGAGG TGTGCGCATG AGAATAGGAA CGGAATGGTC 10140 AAATATTGAA GGAAAAAAAC AAACGTCATA CAAAAACGTC TTTTTACCTC CCCGACGAGA 10200 ACACATGTGT ACATCCAATT TAGAAAATTT AGATGTTGGT AGTGTCACTA AAAATGATAA 10260 GGCTAGCCAC TCATTATTGG GAGATGTTCA GCTCGCAGCAAAAACTGATG CAGCTGAGAT 10320 AATAAAACGC TATAAAGATC AAAATAATAT ACAACTAACT GATCCAATAC AACAAAAAGA 10380 CCAGGAGGCT ATGTGTCGAG CTGTACGTTA TAGTTTTGCC GATTTAGGAG ACATTATTCG 10440 AGGAAGAGAT ATGTGGGATG AGGATAAGAG CTCAACAGAC ATGGAAACAC GTTTGATAAC 10500 CGTATTTAAA AACATTAAAG AAAAACATGA TGGAATCAAA GACAACCCTA AATATACCGG 10560 TGATGAAAGC AAAAAGCCCG CATATAAAAA ATTACGAGCA GATTGGTGGG AAGCAAATAG 10620 ACATCAAGTG TGGAGAGCCA TGAAATGCGC AACAAAAGGC ATCATATGTC CTGGTATGCC 10680 AGTTGACGAT TATATCCCCC AACGTTTACG CTGGATGACT GAATGGGCTG AATGGTATTG 10740 TAAAGCGCAA TCACAGGAGT ATGACAAGTT AAAAAAAATC TGTGCAGATT GTATGAGTAA 10800 GGGTGATGGA AAATGTACGC AAGGTGATGT CGATTGTGGA AAGTGCAAAG CAGCATGTGA 10860 TAAATATAAA GAGGAAATAG AAAAATGGAA TGAACAATGG AGAAAAATAT CAGATAAATA 10920 CAATCTATTA TACCTACAAG CAAAAACTAC TTCTACTAAT CCTGGCCGTA CTGTTCTTGG 10980 TGATGACGAT CCCGACTATC AACAAATGGT AGATTTTTTG ACCCCAATAC ACAAAGCAAG 11040 TATTGCCGCA CGTGTTCTTG TTAAACGTGC TGCTGGTAGT CCCACTGAGA TCGCCGCCGC 11100 CGCCCCGATC ACCCCCTACA GTACTGCTGC CGGATATATA CACCAGGAAA TAGGATATGG 11160 GGGGTGCCAG GAACAAACAC AATTTTGTGA AAAAAAACAT GGTGCAACAT CAACTAGTAC 11220 CACGAAAGAA AACAAAGAAT ACACCTTTAA ACAACCTCCG CCGGAGTATG CTACAGCGTG 11280 TGATTGCATA AATAGGTCGC AAACAGAGGA GCCGAAGAAAAAGGAAGAAA ATGTAGAGAG 11340 TGCCTGCAAA ATAGTGGAGA AAATACTTGA GGGTAAGAAT GGAAGGACTA CAGTAGGTGA 11400 ATGTAATCCA AAAGAGAGTT ATCCTGATTG GGATTGCAAA AACAATATTG ACATTAGTCA 11460 TGATGGTGCT TGTATGCCTC CAAGGAGACA AAAACTATGT TTATATTATA TAGCACATGA 11520 GAGTCAAACA GAAAATATAA AAACAGACGA TAATTTGAAA GATGCTTTTA TTAAAACTGC 11580 AGCAGCAGAA ACTTTTCTTT CATGGCAATA TTATAAGAGT AAGAATGATA GTGAAGCTAA 11640 AATATTAGAT AGAGGCCTTA TTCCATCCCA ATTTTTAAGA TCCATGATGT ACACGTTTGG 11700 AGATTATAGA GATATATGTT TGAACACAGA TATATCTAAA AAACAAAATG ATGTAGCTAA 11760 GGCAAAAGAT AAAATAGGTA AATTTTTCTC AAAAGATGGC AGCAAATCTC CTAGTGGCTT 118 0 ATCACGCCAA GAATGGTGGAAAACAAATGG TCCAGAGATT TGGAAAGGAA TGTTATGTGC 11880 CTTAACAAAA TACGTCACAG ATACCGATAA CAAAAGAAAA ATCAAAAACG ACTACTCATA 11940 CGATAAAGTC AACCAATCCC AAAATGGCAA CCCTTCCCTT GAAGAGTTTG CTGCTAAACC 12000 TCAATTTCTA CGTTGGATGA TCGAATGGGG AGAAGAGTTT TGTGCTGAAC GTCAGAAGAA 12060 GGAAAATATC ATAAAAGATG CATGTAATGA AATAAATTCT ACACAACAGT GTAATGATGC 12120 GAAACATCGT TGTAATCAAG CATGTAGAGC ATATCAAGAA TATGTTGAAA ATAAAAAAAA 12180 AGAATTTTCG GGACAAACAA ATAACTTTGT TCTAAAGGCAAATGTTCAGC CCCAAGATCC 12240 AGAATATAAA GGATATGAAT ATAAAGACGG CGTACAACCG ATACAGGGGA ATGAGTATTT 12300 ACTGCAAAAA TGTGATAATAATAAATGTTC TTGCATGGAT GGAAATGTAC TTTCCGTCTC 12360 TCCAAAAGAA AAACCTTTTG GAAAATATGC CCATAAATAT CCTGAGAAAT GTGATTGTTA 12420 TCAAGGAAAA CATGTACCTA GCATACCACC TCCCCCCCCA CCTGTACAAC CACAACCGGA 12480 AGCACCAACA GTAACAGTAG ACGTTTGCAG CATAGTAAAAACACTATTTA AAGACACAAA 12540 CAATTTTTCC GACGCTTGTG GTCTAAAATA CGGCAAAACC GCACCATCCA GTTGGAAATG 12600 TATACCAAGT GACACAAAAA GTGGTGCTGG TGCCACCACC GGCAAAAGTG GTAGTGATAG 12660 TGGTAGTATT TGTATCCCAC CCAGGAGGCG ACGATTATAT GTGGGGAAAC TACAGGAGTG 12720 GGCTACCGCG CTCCCACAAG GTGAGGGCGC CGCGCCGTCC CACTCACGCG CCGACGACTT 12780 GCGCAATGCG TTCATCCAAT CTGCTGCAAT AGAGACTTTT TTCTTATGGG ATAGATATAA 12840 AGAAGAGAAA AAACCACAGG GTGATGGGTC ACAACAAGCA CTATCACAAC TAACCAGTAC 12900 ATACAGTGAT GACGAGGAGG ACCCCCCCGA CAAACTGTTA CAAAATGGTA AGATACCCCC 12960 CGATTTTTTG AGATTAATGT TCTATACATT AGGAGATTAT AGGGATATTT TAGTACACGG 13020 TGGTAACACA AGTGACAGTG GTAACACAAA TGGTAGTAAC AACAACAATA TTGTGCTTGA 13080 AGCGAGTGGT AACAAGGAGG ACATGCAAAA AATACAAGAG AAAATAGAAC AAATTCTCCC 13140 AAAAAATGGT GGCACACCTC TTGTCCCAAA ATCTAGTGCC CAAACACCTG ATAAATGGTG 13200 GAATGAACAC GCCGAATCTA TCTGGAAAGG TATGATATGT GCATTGACAT ATACAGAAAA 13260 GAACCCTGAC ACCAGTGCAA GAGGCGACGAAAACAAAATA GAAAAGGATG ATGAAGTGTA 13320 CGAGAAATTT TTTGGCAGCA CAGCCGACAA ACATGGCACA GCCTCAACCC CAACCGGCAC 13380 ATACAAAACC CAATACGACT ACGAAAAAGT CAAACTTGAG GATACAAGTG GTGCCAAAAC 13440 CCCCTCAGCC TCTAGTGATA CACCCCTTCT CTCCGATTTC GTGTTACGCC CCCCCTACTT 13500 CCGTTACCTT GAAGAATGGG GTCAAAATTT TTGTAAAAAA AGAAAGCATA AATTGGCACA 13560 AATAAAACAT GAGTGTAAAG TAGAAGAAAA TGGTGGTGGT AGTCGTCGTG GTGGTATAAC 13620 AAGACAATAT AGTGGGGATG GCGAAGCGTG TAATGAGATG CTTCCAAAAA ACGATGGAAC 13680 TGTTCCGGAT TTAGAAAAGC CGAGTTGTGC CAAACCTTGT AGTTCTTATA GAAAATGGAT 13740 AGAAAGCAAG GGAAAAGAGT TTGAGAAACA AGAAAAGGCA TATGAACAAC AAAAAGACAA 13800 ATGTGTAAAT GGAAGTAATAAGCATGATAA TGGATTTTGT GAAACACTAA CAACGTCCTC 13860 TAAAGCTAAA GACTTTTTAA AAACGTTAGG ACCATGTAAA CCTAATAATG TAGAGGGTAA 13920 AACAATTTTT GATGATGATA AAACCTTTAA ACATACAAAA GATTGTGATC CATGTCTTAA 13980 ATTTAGTGTT AATTGTAAAA AAGATGAATG TGATAATTCT AAAGGAACCG ATTGCCGAAA 14040 TAAAAATAGT ATTGATGCAA CAGATATTGA AAATGGAGTG GATTCTACTG TACTAGAAAT 14100 GCGTGTCAGT GCTGATAGTAAAAGTGGATT TAATGGTGAT GGTTTAGAGAATGCTTGTAG 14160 AGGTGCTGGT ATCTTTGAAG GTATTAGAAA AGATGAATGG AAATGTCGTA ATGTATGTGG 14220 TTATGTTGTA TGTAAACCGG AAAACGTTAA TGGGGAAGCA AAGGGAAAAC ACATTATACA 14280 AATTAGAGCA CTGGTTAAAC GTTGGGTAGA ATATTTTTTT GAAGATTATA ATAAAATAAA 14340 ACATAAAATT TCACATCGCA TAAAAAATGG TGAAATATCT CCATGTATAA AAAATTGTGT 14400 AGAAAAATGG GTAGATCAGA AAAGAAAAGA ATGGAAGGAA ATTACTGAAC GTTTCAAAGA 14460 TCAATATAAA AATGACAATT CAGATGATGA CAATGTGAGAAGTTTTTTGG AGACCTTGAT 14520 ACCTCAAATT ACTGATGCAA ACGCTAAAAA TAAGGTTATA AAATTAAGTA AGTTCGGTAA 14580 TTCTTGTGGA TGTAGTGCCA GTGCGAACGA ACAAAACAAAAATGGTGAAT ACAAGGACGC 14640 TATAGATTGT ATGCTTAAAA AGCTTAAAGA TAAAATTGGC GAGTGCGAAA AGAAACACCA 14700 TCAAACTAGT GATACCGAGT GTTCCGACAC ACCACAACCG CAAACCCTTG AAGACGAAAC 14760 TTTGGATGAT GATATAGAAA CAGAGGAGGC GAAGAAGAAC ATGATGCCGA AAATTTGTGA 14820 AAATGTGTTA AAAACAGCAC AACAAGAGGA TGAAGGCGGT TGTGTCCCAG CAGAAAATAG 14880 TGAAGAACCG GCAGCAACAG ATAGTGGTAA GGAAACCCCC GAACAAACCC CCGTTCTCAA 14940 ACCCGAAGAA GAAGCAGTAC CGGAACCACC ACCTCCACCC CCACAGGAAA AAGCCCCGGC 15000 ACCAATACCC CAACCACAAC CACCAACCCC CCCCACACAA CTCTTGGATA ATCCCCACGT 15060 TCTAACCGCC CTGGTGACCT CCACCCTCGC CTGGAGCGTT GGCATCGGTT TTGCTACATT 15120 CACTTATTTT TATCTAAAGG TAAATGGAAG TATATATATG GGGATGTGGA TGTATGTGGA 15180 TGTATGTGAA TGTATGTGGA TGTATGTGGA TGTATGTGGA TGTGTTTTAT GGATATGTAT 15240 TTGTGATTAT GTTTGGATAT ATATATATAT ATATATATGT TTATGTATAT GTGTTTTTGG 15300 ATATATATAT GTGTATGTAT ATGATTTTCT GTATATGTAT TTGTGGGTTA AGGATATATA 15360 TATATGGATG TACTTGTATG TGTTTTATAT ATATATTTTA TATATATGTA TTTATATTAA 15420 AAAAGAAATA TAAAAACAAA TTTATTAAAA TGAAAAAAAG AAAAATGAAA TATAAAAAAA 15480 AATTTATTAA AATAAAAAAA AAAAAAAAAA AAAAGGAGAA AAATTTTTTA AAAAATAATA 15540 AAAATTATAA TAAAATATAA ATTTTGATAG AATAAAAAAT GAAAAAGATT ATCAAAAAAA 15600 AATTAAAAAA AAATTTTATA TAAAAAAAAA ATGATTATAA AAAAAATAAA AACAAAAGAA 15660 GAAAAAAAAA AACATTAAAA AAAAAAAAAT ATATATCATA AAAACAAAAA AAAAAGAAAA 15720 AAATATATTA AAATAAAAAT ATATATCATA AAATAAAAAAAAATTAAAAA AATGTTAAAA 15780 AAAAAATATA TACATAAAAT AAAAAAAATT TATTTAAATA AAAAAAAATA ATAAATAAAA 15840 AAATTTAATT AAATAAAAAA AAATAATAAA TAAAAAAATT TAATTAAATA AAAAAAAATT 15900 AAAAAAATTT AATGAAATAA AAAAAAATAA AAAAATTTAA TTAAATAAAA AAAATAAAAT 15960 AAAATTAATT ACATGCACAT ATACATACAT ATATATATAT ATATACCCAT AACTACATAC 16020 AACATTTACA CATACATATA TATATATATA TATACCCATA ACTACATACA CATTTACACA 16080 TACATATATA TATTATATAT ATATATATAT ATACCCATAA CTACATACAT ATATACATTA 16140 ACAAACACAT ATATAATACC TAAATACATA TATACATACA CATATATGTT CATTTTTTTT 16200 TTTAGAAAAA AACCAAATCA TCTGTTGGAA ATTTATTCCA AATACTGCAA ATACCCAAAA 16260 GTGATTATGA TATACCGACA AAACTTTCAC CCAATAGATA TATACCTTAT ACTAGTGGTA 16320 AATACAGAGG CAAACGGTAC ATTTACCTTG AAGGAGATAG TGGAACAGAT AGTGGTTACA 16380 CCGATCATTA TAGTGATATAACTTCCTCAG AAAGTGAATA TGAAGAGATG GATATAAATG 16440 ATATATATGT ACCAGGTAGT CCTAAATATA AAACATTAAT TGAAGTGGTA CTTGAACCTA 16500 GTGGTAACAA CACAACAGCT AGTGGTAACA ACACAACAGC TAGTGGTAAC AACACAACAG 16560 CTAGTGGTAA AAACACACCT AGTGATACAC AAAATGATAT ACAAAATGAT GGTATACCTA 16620 GTAGTAAAAT TACAGATAAT GAATGGAATC AATTGAAAGA TGAATTTATA TCACAATATC 16680 TACAAAGTGA ACCAAATACA GAACCAAATA TGTTAGGTTA TAATGTGGAT AATAATACCC 16740 ATCCTACCAC GTCACATCAT AATGTGGAAG AAAAACCTTT TATTATGTCC ATTCATGATA 16800 GAAATTTATT TAGTGGAGAA GAATACAATT ATGATATGTT TAATAGTGGG AATAATCCAA 16860 TAAACATTAG TGATTCAACAAATAGTATGG ATAGTCTAAC AAGTAACAAC CATAGTCCAT 16920 ATAATGATAA AAATGATTTA TATAGTGGTA TCGACCTAAT CAACGACGCA CTAAGTGGTA 16980 ATCATATTGA TATATATGAT GAAATGCTCA AACGAAAAGAAAATGAATTA TTTGGAACAA 17040 AACATCATAC AAAACATACA AATACATATA ATGTCGCCAA ACCTGCACGT GACGACCCTA 17100 TAACCAATCA AATAAATTTG TTCCATAAAT GGTTAGATAG GCATAGAGAT ATGTGCGAAA 17160 AGTGGAAAAA TAATCACGAA CGGTTACCCA AATTGAAAGA ATTGTGGGAA AATGAGACAC 17220 ATAGTGGTGA CATAAATAGT GGTATACCTA GTGGTAACCA TGTGTTGAAT ACTGATGTTT 17280 CTATTCAAAT AGATATGGAT AATCCTAAAA CAAAGAATGA AATTACGAAT ATGGATACAA 17340 ACCCAGACAA ATCTACTATG GATACTATAC TGGATGATCT GGAAAAATAT AATGAACCCT 17400 ACTACTATGA TTTTTATGAA GATGATATCA TCTATCATGA TGTAGATGTT GAAAAATCAT 17460 CTATGGATGA TATATATGTG GATCATAATA ATGTGACTAA TAATAATATG GATGTACCTA 17520 CTAAAATGCA CATCGAAATG AATATTGTTA ATAATAAAAA GGAGATTTTC GAAGAGGAAT 17580 ATCCTATATC AGATATATGG AATATCTAAA ATTAATATAC TTTTTTTGTG TGTGTCATAT 17640 ATATTTTGTA TTATTTGTAT ATGTTTTTAT TTTATTTATT TATTTATTTA TTTATTGTTT 17700 TTGGTATATT TGTAAAAAAT ATGTTTTTGT TTATAATCAT ATTATTATAT TTTTAATAAT 17760 TTGCAACATG ATTTTTTTTT TTCTTTCTTA TTGTGTAATT TTTTTCATAA TATTTATATA 17820 TATATATGTA TTTTATTTTT TAGTATAATA ATTGTATCTA TATTTGATTA ATAATTATGT 17880 ATATTATGGT TATTTTGTTT CTTTTTCTGT ACATTTTTTC GTAATATATA TATATATATA 17940 TATATATAAT TCTCTTTTTC TAATATATAT ATCCTTCTAT TTTCGATTTT TTCATTTTTT 18000 TCCAGTATTA ATTTATTTAT TTATTTGTGA TATTTTATAA TATATTATTT AAATGTGTAT 18060 TTATATATGT GTTTTATATA TGTGTTTTAT TTTTGTTACT CTAATTCTGA ATAATCCGAG 18120 CGAAAAAAAA ATATATAATC TCATATAAAA ATTATTTATA ATACAATATT ATATAGTTTC 18180 CTATTAAAAT AAATTAATAT AATATACAAT AATATTTCTT GTTATTTTTA TAAATATAAC 18240 TAATTTCTTA TTTTTATTTA ACTTTATTCC TTTTTAATTT CTTAATTCTT TTATCAAACA 18300 AAAAACATAA AGTAATTCTA CATATCAACA AAAAAAAAAA AAAAAAAAAA AAAAAAAATT 18360 TATTATAATA TAATAAAAAA TATAAAGACA TACGTTCACT TATTATTATA AATGATTTAT 18420 TACGATTAAA ACATATTGAG ATTATAATAA TATAATTTAA CATAGAAAGA GTTAAGAATA 18480 CATTTTTTTT TTTATTTCGA TATGTAATTC AACATATATA TATATATATA TCTTTTTAAT 18540 TTAATTAAAT AAAATTCCTT ATTATTCATA TTGTTTCTTT TATCACATGT GAAATATTAA 18600 AAATAATTTT CGATTTTATC GATATATTTA TGTCGTTTAT ATACTTATAT AGGTCTTTAT 18660 AACTATTGAT TAATAGAAGG TAATAGCCTA ATAATATAAA TACTCGTATT TATAAATTCA 18720 TTTATATATT TCAAATATAT TTGCATGGTT TATTTTCAAA TACAATTAAT TAGATTTCTT 18780 AAATATTTCT TCATTTATTC ATTTTTATAG CATATACATG CACATTATAA ATTATTAATA 18840 AAAAATTTTT ATTTTAATAT ATAATAACAA TTTTCATACA TTACATTTTT CACACAACAT 18900 TTAAGTTGTC ATAATGTAAC ACATTAAATA ATATATTACT TATATATATA TAATTATTAA 18960 TTATATATTA AATAAAAATG TATTATCGCC TGTATTATCA TAGTATATAT AATGTTGTAT 19020 AACGCTTCAA AATATATATA ATAATATAAT TAAAAATATA TATATAGTAA TTAATTATTT 19080 TGTTATGTTA TGTAATAATG CAATTAATAT AAGATAAAAT TCAT 19124 (2) INFORMATION FOR SEQ ID NO:14 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3060 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14 Met Val Glu Leu Ala Lys Met Gly Pro Lys Glu Ala Ala Gly Gly Asp 1 5 10 15 Asp He Glu Asp Glu Ser Ala Lys His Met Phe Asp Arg He Gly Lys 20 25 ' 30 Asp Val Tyr Asp Lys Val Lys Glu Glu Ala Lys Glu Arg Gly Lys Gly 35 40 45 Leu Gin Gly Arg Leu Ser Glu Ala Lys Phe Glu Lys Asn Glu Ser Asp 50 55 60 Pro Gin Thr Pro Glu Asp Pro Cys Asp Leu Asp His Lys Tyr His Thr 65 70 75 80 Asn Val Thr Thr Asn Val He Asn Pro Cys Ala Asp Arg Ser Asp Val 85 90 95 Arg Phe Ser Asp Glu Tyr Gly Gly Gin Cys Thr His Asn Arg He Lys 100 105 110 Asp Ser Gin Gin Gly Asp Asn Lys Gly Ala Cys Ala Pro Tyr Arg Arg 115 120 125 Leu His Val Cys Asp Gin Asn Leu Glu Gin He Glu Pro He Lys He 130 135 ' 140 Thr Asn Thr His Asn Leu Leu Val Asp Val Cys Met Ala Ala Lys Phe 145 150 155 160 Glu Gly Gin Ser He Thr Gin Asp Tyr Pro Lys Tyr Gin Ala Thr Tyr 165 170 175 Gly Asp Ser Pro Ser Gin He Cys Thr Met Leu Ala Arg Ser Phe Ala 180 185 190 Asp He Gly Asp He Val Arg Gly Arg Asp Leu Tyr Leu Gly Asn Pro 195 200 205 Gin Glu He Lys Gin Arg Gin Gin Leu Glu Asn Asn Leu Lys Thr He 210 215 220 Phe Gly Lys He Tyr Glu Lys Leu Asn Gly Ala Glu Ala Arg Tyr Gly 225 230 235 240 Asn Asp Pro Glu Phe Phe Lys Leu Arg Glu Asp Trp Trp Thr Ala Asn 245 250 255 Arg Glu Thr Val Trp Lys Ala He Thr Cys Asn Ala Trp Gly Asn Thr 260 265 270 Tyr Phe His Ala Thr Cys Asn Arg Gly Glu Arg Thr Lys Gly Tyr Cys 275 280 285 Arg Cys Asn Asp Asp Gin Val Pro Thr Tyr Phe Asp Tyr Val Pro Gin 290 295 300 Tyr Leu Arg Trp Phe Glu Glu Trp Ala Glu Asp Phe Cys Arg Lys Lys 305 310 315 320 Asn Lys Lys He Lys Asp Val Lys Arg Asn Cys Arg Gly Lys Asp Lys 325 330 335 Glu Asp Lys Asp Arg Tyr Cys Ser Arg Asn Gly Tyr Asp Cys Glu Lys 340 345 350 Thr Lys Arg Ala He Gly Lys Leu Arg Tyr Gly Lys Gin Cys He Ser 355 360 365 Cys Leu Tyr Ala Cys Asn Pro Tyr Val Asp Trp He Asn Asn Gin Lys 370 375 380 Glu Gin Phe Asp Lys Gin Lys Lys Lys Tyr Asp Glu Glu He Lys Lys 385 390 395 400 Tyr Glu Asn Gly Ala Ser Gly Gly Ser Arg Gin Lys Arg Asp Ala Gly 405 410 415 Gly Thr Thr Thr Thr Asn Tyr Asp Gly Tyr Glu Lys Lys Phe Tyr Asp 420 425 430 Glu Leu Asn Lys Ser Glu Tyr Arg Thr Val Asp Lys Phe Leu Glu Lys 435 440 445 Leu Ser Asn Glu Glu He Cys Thr Lys Val Lys Asp Glu Glu Gly Gly 450 455 460 Thr He Asp Phe Lys Asn Val Asn Ser Asp Ser Thr Ser Gly Ala Ser 465 470 475 480 Gly Thr Asn Val Glu Ser Gin Gly Thr Phe Tyr Arg Ser Lys Tyr Cys 485 490 495 Gin Pro Cys Pro Tyr Cys Gly Val Lys Lys Val Asn Asn Gly Gly Ser 500 505 510 Ser Asn Glu Trp Glu Glu Lys Asn Asn Gly Lys Cys Lys Ser Gly Lys 515 520 525 Leu Tyr Glu Pro Lys Pro Asp Lys Glu Gly Thr Thr He Thr He Leu 530 535 540 Lys Ser Gly Lys Gly His Asp Asp He Glu Glu Lys Leu Asn Lys Phe 545 550 555 560 Cys Asp Glu Lys Asn Gly Asp Thr He Asn Ser Gly Gly Ser Gly Thr 565 570 575 Gly Gly Ser Gly Gly Gly Asn Ser Gly Arg Gin Glu Leu Tyr Glu Glu 580 585 590 Trp Lys Cys Tyr Lys Gly Glu Asp Val Val Lys Val Gly His Asp Glu 595 600 605 Asp Asp Glu Glu Asp Tyr Glu Asn Val Lys Asn Ala Gly Gly Leu Cys 610 615 620 He Leu Lys Asn Gin Lys Lys Asn Lys Glu Glu Gly Gly Asn Thr Ser 625 630 635 640 Glu Lys Glu Pro Asp Glu He Gin Lys Thr Phe Asn Pro Phe Phe Tyr 645 650 655 Tyr Trp Val Ala His Met Leu Lys Asp Ser He His Trp Lys Lys Lys 660 665 670 Leu Gin Arg Cys Leu Gin Asn Gly Asn Arg He Lys Cys Gly Asn Asn 675 680 685 Lys Cys Asn Asn Asp Cys Glu Cys Phe Lys Arg Trp He Thr Gin Lys 690 695 700 Lys Asp Glu Trp Gly Lys He Val Gin His Phe Lys Thr Gin Asn He 705 710 715 720 Lys Gly Arg Gly Gly Ser Asp Asn Thr Ala Glu Leu He Pro Phe Asp 725 730 735 His Asp Tyr Val Leu Gin Tyr Asn Leu Gin Glu Glu Phe Leu Lys Gly 740 745 750 Asp Ser Glu Asp Ala Ser Glu Glu Lys Ser Glu Asn Ser Leu Asp Ala 755 760 765 Glu Glu Ala Glu Glu Leu Lys His Leu Arg Glu He He Glu Ser Glu 770 775 780 Asp Asn Asn Gin Glu Ala Ser Val Gly Gly Gly Val Thr Glu Gin Lys 785 •>* 790 795 800 . Asn He Met Asp !5y * s Leu Leu Asn Tyr Glu Lys Asp Glu Ala Asp Leu " '"> * •' 805 810 815 Cys Leu Glu He His Glu Asp Glu Glu Glu Glu Lys Glu Lys Gly Asp 820 825 830 Gly Asn Glu Cys He Glu Glu Gly Glu Asn Phe Arg Tyr Asn Pro Cys 835 840 845 Ser Gly Glu Ser Gly Asn Lys Arg Tyr Pro Val Leu Ala Asn Lys Val 850 855 860 Ala Tyr Gin Met His His Lys Ala Lys Thr Gin Leu Ala Ser Arg Ala 865 870 875 880 Gly Arg Ser Ala Leu Arg Gly Asp He Ser Leu Ala Gin Phe Lys Asn 885 890 895 Gly Arg Asn Gly Ser Thr Leu Lys Gly Gin He Cys Lys He Asn Glu 900 905 910 Asn Tyr Ser Asn Asp Ser Arg Gly Asn Ser Gly Gly Pro Cys Thr Gly 915 920 925 Lys Asp Gly Asp His Gly Gly Val Arg Met Arg He Gly Thr Glu Trp 930 935 940 Ser Asn He Glu Gly Lys Lys Gin Thr Ser Tyr Lys Asn Val Phe Leu 945 950 955 960 Pro Pro Arg Arg Glu His Met Cys Thr Ser Asn Leu Glu Asn Leu Asp 965 970 975 Val Gly Ser Val Thr Lys Asn Asp Lys Ala Ser His Ser Leu Leu Gly 980 985 990 Asp Val Gin Leu Ala Ala Lys Thr Asp Ala Ala Glu He He Lys Arg 995 1000 1005 Tyr Lys Asp Gin Asn Asn He Gin Leu Thr Asp Pro He Gin Gin Lys 1010 1015 1020 Asp Gin Glu Ala Met Cys Arg Ala Val Arg Tyr Ser Phe Ala Asp Leu 1025 1030 1035 1040 Gly Asp He He Arg Gly Arg Asp Met Trp Asp Glu Asp Lys Ser Ser 1045 1050 1055 Thr Asp Met Glu Thr Arg Leu He Thr Val Phe Lys Asn He Lys Glu 1060 1065 ' 1070 Lys His Asp Gly He Lys Asp Asn Pro Lys Tyr Thr Gly Asp Glu Ser 1075 1080 1085 Lys Lys Pro Ala Tyr Lys Lys Leu Arg Ala Asp Trp Trp Glu Ala Asn 1090 1095 1100 Arg His Gin Val Trp Arg Ala Met Lys Cys Ala Thr Lys Gly He He 1105 1110 1115 1120 Cys Pro Gly Met Pro Val Asp Asp Tyr He Pro Gin Arg Leu Arg Trp 1125 1130 1135 Met Thr Glu Trp Ala Glu Trp Tyr Cys Lys Ala Gin Ser Gin Glu Tyr 1140 1145 1150 Asp Lys Leu Lys Lys He Cys Ala Asp Cys Met Ser Lys Gly Asp Gly 1155 1160 1165 Lys Cys Thr Gin Gly Asp Val Asp Cys Gly Lys Cys Lys Ala Ala Cys 1170 1175 1180 Asp Lys Tyr Lys Glu Glu He Glu Lys Trp Asn Glu Gin Trp Arg Lys 1185 1190 1195 1200 He Ser Asp Lys Tyr Asn Leu Leu Tyr Leu Gin Ala Lys Thr Thr Ser 1205 1210 1215 Thr Asn Pro Gly Arg Thr Val Leu Gly Asp Asp Asp Pro Asp Tyr Gin 1220 1225 1230 Gin Met Val Asp Phe Leu Thr Pro He His Lys Ala Ser He Ala Ala 1235 1240 1245 Arg Val Leu Val Lys Arg Ala Ala Gly Ser Pro Thr Glu He Ala Ala 1250 1255 1260 Ala Ala Pro He Thr Pro Tyr Ser Thr Ala Ala Gly Tyr He His Gin 1265 1270 1275 1280 Glu He Gly Tyr Gly Gly Cys Gin Glu Gin Thr Gin Phe Cys Glu Lys 1285 1290 1295 Lys His Gly Ala Thr Ser Thr Ser Thr Thr Lys Glu Asn Lys Glu Tyr 1300 1305 1310 Thr Phe Lys Gin Pro Pro Pro Glu Tyr Ala Thr Ala Cys Asp Cys He 1315 1320 1325 Asn Arg Ser Gin Thr Glu Glu Pro Lys Lys Lys Glu Glu Asn Val Glu 1330 1335 1340 Ser Ala Cys Lys He Val Glu Lys He Leu Glu Gly Lys Asn Gly Arg 1345 1350 1355 1360 Thr Thr Val Gly Glu Cys Asn Pro Lys Glu Ser Tyr Pro Asp Trp Asp 1365 1370 1375 Cys Lys Asn Asn He Asp He Ser His Asp Gly Ala Cys Met Pro Pro 1380 1385 1390 Arg Arg Gin Lys Leu Cys Leu Tyr Tyr He Ala His Glu Ser Gin Thr 1395 1400 1405 Glu Asn He Lys Thr Asp Asp Asn Leu Lys Asp Ala Phe He Lys Thr 1410 1415 1420 Ala Ala Ala Glu Thr Phe Leu Ser Trp Gin Tyr Tyr Lys Ser Lys Asn 1425 1430 1435 1440 Asp Ser Glu Ala Lys He Leu Asp Arg Gly Leu He Pro Ser Gin Phe 1445 1450 1455 Leu Arg Ser Met Met Tyr Thr Phe Gly Asp Tyr Arg Asp He Cys Leu 1460 1465 1470 Asn Thr Asp He Ser Lys Lys Gin Asn Asp Val Ala Lys Ala Lys Asp 1475 1480 1485 Lys He Gly Lys Phe Phe Ser Lys Asp Gly Ser Lys Ser Pro Ser Gly 1490 1495 1500 Leu Ser Arg Gin Glu Trp Trp Lys Thr Asn Gly Pro Glu He Trp Lys 1505 1510 1515 1520 Gly Met Leu Cys Ala Leu Thr Lys Tyr Val Thr Asp Thr Asp Asn Lys 1525 1530 1535 Arg Lys He Lys Asn Asp Tyr Ser Tyr Asp Lys Val Asn Gin Ser Gin 1540 1545 1550 Asn Gly Asn Pro Ser Leu Glu Glu Phe Ala Ala Lys Pro Gin Phe Leu 1555 1560 1565 Arg Trp Met He Glu Trp Gly Glu Glu Phe Cys Ala Glu Arg Gin Lys 1570 1575 1580 Lys Glu Asn He He Lys Asp Ala Cys Asn Glu He Asn Ser Thr Gin 1585 1590 1595 1600 Gin Cys Asn Asp Ala Lys His Arg Cys Asn Gin Ala Cys Arg Ala Tyr 1605 1610 1615 Gin Glu Tyr Val Glu Asn Lys Lys Lys Glu Phe Ser Gly Gin Thr Asn 1620 1625 1630 Asn Phe Val Leu Lys Ala Asn Val Gin Pro Gin Asp Pro Glu Tyr Lys 1635 1640 1645 Gly Tyr Glu Tyr Lys Asp Gly Val Gin Pro He Gin Gly Asn Glu Tyr 1650 1655 1660 Leu Leu Gin Lys Cys Asp Asn Asn Lys Cys Ser Cys Met Asp Gly Asn 1665 1670 1675 1680 Val Leu Ser Val Ser Pro Lys Glu Lys Pro Phe Gly Lys Tyr Ala His 1685 1690 1695 Lys Tyr Pro Glu Lys Cys Asp Cys Tyr Gin Gly Lys His Val Pro Ser 1700 1705 1710 He Pro Pro Pro Pro Pro Pro Val Gin Pro Gin Pro Glu Ala Pro Thr 1715 1720 1725 Val Thr Val Asp Val Cys Ser He Val Lys Thr Leu Phe Lys Asp Thr 1730 1735 1740 Asn Asn Phe Ser Asp Ala Cys Gly Leu Lys Tyr Gly Lys Thr Ala Pro 1745 1750 1755 1760 Ser Ser Trp Lys Cys He Pro Ser Asp Thr Lys Ser Gly Ala Gly Ala 1765 1770 1775 Thr Thr Gly Lys Ser Gly Ser Asp Ser Gly Ser He Cys He Pro Pro 1780 1785 1790 Arg Arg Arg Arg Leu Tyr Val Gly Lys Leu Gin Glu Trp Ala Thr Ala 1795 1800 1805 Leu Pro Gin Gly Glu Gly Ala Ala Pro Ser His Ser Arg Ala Asp Asp 1810 1815 1820 Leu Arg Asn Ala Phe He Gin Ser Ala Ala He Glu Thr Phe Phe Leu 1825 1830 1835 1840 Trp Asp Arg Tyr Lys Glu Glu Lys Lys Pro Gin Gly Asp Gly Ser Gin 1845 1850 1855 Gin Ala Leu Ser Gin Leu Thr Ser Thr Tyr Ser Asp Asp Glu Glu Asp 1860 1865 1870 Pro Pro Asp Lys Leu Leu Gin Asn Gly Lys He Pro Pro Asp Phe Leu 1875 1880 1885 Arg Leu Met Phe Tyr Thr Leu Gly Asp Tyr Arg Asp He Leu Val His 1890 1895 1900 Gly Gly Asn Thr Ser Asp Ser Gly Asn Thr Asn Gly Ser Asn Asn Asn 1905 1910 1915 1920 Asn He Val Leu Glu Ala Ser Gly Asn Lys Glu Asp Met Gin Lys He 1925 1930 1935 Gin Glu Lys He Glu Gin He Leu Pro Lys Asn Gly Gly Thr Pro Leu 1940 1945 1950 Val Pro Lys Ser Ser Ala Gin Thr Pro Asp Lys Trp Trp Asn Glu His 1955 1960 1965 Ala Glu Ser He Trp Lys Gly Met He Cys Ala Leu Thr Tyr Thr Glu 1970 1975 1980 Lys Asn Pro Asp Thr Ser Ala Arg Gly Asp Glu Asn Lys He Glu Lys 1985 1990 1995 2000 Asp Asp Glu Val Tyr Glu Lys Phe Phe Gly Ser Thr Ala Asp Lys His 2005 2010 2015 Gly Thr Ala Ser Thr Pro Thr Gly Thr Tyr Lys Thr Gin Tyr Asp Tyr 2020 2025 2030 Glu Lys Val Lys Leu Glu Asp Thr Ser Gly Ala Lys Thr Pro Ser Ala 2035 2040 2045 Ser Ser Asp Thr Pro Leu Leu Ser Asp Phe Val Leu Arg Pro Pro Tyr 2050 2055 2060 Phe Arg Tyr Leu Glu Glu Trp Gly Gin Asn Phe Cys Lys Lys Arg Lys 2065 2070 2075 2080 His Lys Leu Ala Gin He Lys His Glu Cys Lys Val Glu Glu Asn Gly 2085 2090 2095 Gly Gly Ser Arg Arg Gly Gly He Thr Arg Gin Tyr Ser Gly Asp Gly 2100 2105 ' 2110 Glu Ala Cys Asn Glu Met Leu Pro Lys Asn Asp Gly Thr Val Pro Asp 2115 2120 2125 Leu Glu Lys Pro Ser Cys Ala Lys Pro Cys Ser Ser Tyr Arg Lys Trp 2130 2135 2140 He Glu Ser Lys Gly Lys Glu Phe Glu Lys Gin Glu Lys Ala Tyr Glu 2145 2150 2155 2160 Gin Gin Lys Asp Lys Cys Val Asn Gly Ser Asn Lys His Asp Asn Gly 2165 2170 2175 Phe Cys Glu Thr Leu Thr Thr Ser Ser Lys Ala Lys Asp Phe Leu Lys 2180 2185 2190 Thr Leu Gly Pro Cys Lys Pro Asn Asn Val Glu Gly Lys Thr He Phe 2195 2200 2205 Asp Asp Asp Lys Thr Phe Lys His Thr Lys Asp Cys Asp Pro Cys Leu 2210 2215 2220 Lys Phe Ser Val Asn Cys Lys Lys Asp Glu Cys Asp Asn Ser Lys Gly 2225 2230 2235 2240 Thr Asp Cys Arg Asn Lys Asn Ser He Asp Ala Thr Asp He Glu Asn 2245 2250 2255 Gly Val Asp Ser Thr Val Leu Glu Met Arg Val Ser Ala Asp Ser Lys 2260 2265 2270 Ser Gly Phe Asn Gly Asp Gly Leu Glu Asn Ala Cys Arg Gly Ala Gly 2275 2280 2285 He Phe Glu Gly He Arg Lys Asp Glu Trp Lys Cys Arg Asn Val Cys 2290 2295 2300 Gly Tyr Val Val Cys Lys Pro Glu Asn Val Asn Gly Glu Ala Lys Gly 2305 2310 2315 2320 Lys His He He Gin He Arg Ala Leu Val Lys Arg Trp Val Glu Tyr 2325 2330 2335 Phe Phe Glu Asp Tyr Asn Lys He Lys His Lys He Ser His Arg He 2340 2345 2350 Lys Asn Gly Glu He Ser Pro Cys He Lys Asn Cys Val Glu Lys Trp 2355 2360 2365 Val Asp Gin Lys Arg Lys Glu Trp Lys Glu He Thr Glu Arg Phe Lys 2370 2375 2380 Asp Gin Tyr Lys Asn Asp Asn Ser Asp Asp Asp Asn Val Arg Ser Phe 2385 2390 2395 2400 Leu Glu Thr Leu He Pro Gin He Thr Asp Ala Asn Ala Lys Asn Lys 2405 2410 2415 Val He Lys Leu Ser Lys Phe Gly Asn Ser Cys Gly Cys Ser Ala Ser 2420 2425 2430 Ala Asn Glu Gin Asn Lys Asn Gly Glu Tyr Lys Asp Ala He Asp Cys 2435 2440 2445 Met Leu Lys Lys Leu Lys Asp Lys He Gly Glu Cys Glu Lys Lys His 2450 2455 2460 His Gin Thr Ser Asp Thr Glu Cys Ser Asp Thr Pro Gin Pro Gin Thr 2465 2470 2475 2480 Leu Glu Asp Glu Thr Leu Asp Asp Asp He Glu Thr Glu Glu Ala Lys 2485 2490 2495 Lys Asn Met Met Pro Lys He Cys Glu Asn Val Leu Lys Thr Ala Gin 2500 2505 2510 Gin Glu Asp Glu Gly Gly Cys Val Pro Ala Glu Asn Ser Glu Glu Pro 2515 2520 2525 Ala Ala Thr Asp Ser Gly Lys Glu Thr Pro Glu Gin Thr Pro Val Leu 2530 2535 2540 Lys Pro Glu Glu Glu Ala Val Pro Glu Pro Pro Pro Pro Pro Pro Gin 2545 2550 2555 2560 Glu Lys Ala Pro Ala Pro He Pro Gin Pro Gin Pro Pro Thr Pro Pro 2565 2570 2575 Thr Gin Leu Leu Asp Asn Pro His Val Leu Thr Ala Leu Val Thr Ser 2580 2585 2590 Thr Leu Ala Trp Ser Val Gly He Gly Phe Ala Thr Phe Thr Tyr Phe 2595 2600 2605 Tyr Leu Lys Lys Lys Thr Lys Ser Ser Val Gly Asn Leu Phe Gin He 2610 2615 2620 Leu Gin He Pro Lys Ser Asp Tyr Asp He Pro Thr Lys Leu Ser Pro 2625 2630 2635 2640 Asn Arg Tyr He Pro Tyr Thr Ser Gly Lys Tyr Arg Gly Lys Arg Tyr 2645 2650 2655 He Tyr Leu Glu Gly Asp Ser Gly Thr Asp Ser Gly Tyr Thr Asp His 2660 2665 2670 Tyr Ser Asp He Thr Ser Ser Glu Ser Glu Tyr Glu Glu Met Asp He 2675 2680 2685 Asn Asp He Tyr Val Pro Gly Ser Pro Lys Tyr Lys Thr Leu He Glu 2690 2695 2700 Val Val Leu Glu Pro Ser Gly Asn Asn Thr Thr Ala Ser Gly Asn Asn 2705 2710 2715 2720 Thr Thr Ala Ser Gly Asn Asn Thr Thr Ala Ser Gly Lys Asn Thr Pro 2725 2730 2735 Ser Asp Thr Gin Asn Asp He Gin Asn Asp Gly He Pro Ser Ser Lys 2740 2745 2750 He Thr Asp Asn Glu Trp Asn Gin Leu Lys Asp Glu Phe He Ser Gin 2755 2760 2765 Tyr Leu Gin Ser Glu Pro Asn Thr Glu Pro Asn Met Leu Gly Tyr Asn 2770 2775 2780 Val Asp Asn Asn Thr His Pro Thr Thr Ser His His Asn Val Glu Glu 2785 2790 2795 2800 Lys Pro Phe He Met Ser He His Asp Arg Asn Leu Phe Ser Gly Glu 2805 2810 2815 Glu Tyr Asn Tyr Asp Met Phe Asn Ser Gly Asn Asn Pro He Asn He 2820 2825 2830 Ser Asp Ser Thr Asn Ser Met Asp Ser Leu Thr Ser Asn Asn His Ser 2835 2840 2845 Pro Tyr Asn Asp Lys Asn Asp Leu Tyr Ser Gly He Asp Leu He Asn 2850 2855 2860 Asp Ala Leu Ser Gly Asn His He Asp He Tyr Asp Glu Met Leu Lys 2865 2870 2875 2880 Arg Lys Glu Asn Glu Leu Phe Gly Thr Lys His His Thr Lys His Thr 2885 2890 2895 Asn Thr Tyr Asn Val Ala Lys Pro Ala Arg Asp Asp Pro He Thr Asn 2900 2905 2910 Gin He Asn Leu Phe His Lys Trp Leu Asp Arg His Arg Asp Met Cys 2915 2920 2925 Glu Lys Trp Lys Asn Asn His Glu Arg Leu Pro Lys Leu Lys Glu Leu 2930 2935 2940 Trp Glu Asn Glu Thr His Ser Gly Asp He Asn Ser Gly He Pro Ser 2945 2950 2955 2960 Gly Asn His Val Leu Asn Thr Asp Val Ser He Gin He Asp Met Asp 2965 2970 2975 Asn Pro Lys Thr Lys Asn Glu He Thr Asn Met Asp Thr Asn Pro Asp 2980 2985 2990 Lys Ser Thr Met Asp Thr He Leu Asp Asp Leu Glu Lys Tyr Asn Glu 2995 3000 3005 Pro Tyr Tyr Tyr Asp Phe Tyr Glu Asp Asp He He Tyr His Asp Val 3010 3015 3020 Asp Val Glu Lys Ser Ser Met Asp Asp He Tyr Val Asp His Asn Asn 3025 3030 3035 3040 Val Thr Asn Asn Asn Met Asp Val Pro Thr Lys Met His He Glu Met 3045 3050 3055 Asn He Val Asn 3060 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7295 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: TCCAAGCTGT TTTTTTTTCT TTTTCTAGTT TTTCCATTGT ATATTCGTCA AATACGTACA 60 CATATATATA TATATGTATA ACATGTGAGT ATTATTTTAT ACATCACATC GATTACATTT 120 TAGCGTTTTT TTTCCCCAGA TCACATATAG TACGACTAAG AAACAAAATA ACATCATAAC 180 AAACATAGTG ATTATCAATA CATGATATTA CCACATAATA TAAAGTATTA AATAATATTA 240 TTGCATGTTA GTGATAACTA CTATATCATA TACACCACTA CTAACTATCA CTACATAGTA 300 ACAGTAGTAG TCACAATCAT AGCATCATGG TAATATAGAT TTTCATTTCA TATCTTCCTT 360 ATTGTTTGTT ATACATACAC TATTAATATG TATTTATGTT ATAATGGTAG ACTATGTTAA 420 CAATGTATGA ATGACCATCA TAAATTAATA ACAGACGCAT CAAAACAGTG TATATGTGTG 480 CATTTATGAC ATAATGTAGT CGGGAAGCAT ACAAAAATGG AGCCAGGAGG TAGCGGTGGT 540 CGTGGTAGTG GCGGTAGTAG TAGTGGTAAA GGGAAGAAGG ATACATCTGA GTATATTTAT 600 GTGAGCGATG CTAAGGATCT TTTGGATAGA GTTGGAGAAA AAGTGTACGA AGAAAAAGTG 660 AAAAATGGTG ATGCTAAAAA ATATATTGAG GCGTTGAAAG GAAATTTGAA CACAGCAAAT 720 GGTCGTAGTT CGGAAACAGC TAGCAGTATT GAAACGTGCA CCCTTGTAAA AGAATATTAT 780 GAGCGTGTTA ATGGTGATGG TAAAAGGCAT CCGTGCAGAA AAGACGCAAA AAATGAAGAT 840 GTAAACCGTT TTTCGGATAC ACTTGGTGGC CAATGTACAT ACAATAGGAT AAAAGATAGT 900 CAACAGGGTG ATAATAAAGT AGGAGCCTGT GCTCCGTATA GACGATTACA TTTATGTGAT 960 TATAATTTGG AATCTATAGA CACAACGTCG ACGACGCATA AGTTGTTGTT AGAGGTGTGT 1020 ATGGCAGCAA AATACGAAGG AAACTCAATA AATACACATT ATACACAACA TCAACGAACT 1080 AATGAGGATT CTGCTTCCCA ATTATGTACT GTATTAGCAC GAAGTTTTGC AGATATAGGT 1140 GATATCGTAA GAGGAAAAGA TCTATATCTC GGTTATGATA ATAAAGAAAA AGAACAAAGA 1200 AAAAAATTAG AACAGAAATT GAAAGATATT TTCAAGAAAA TACATAAGGA CGTGATGAAG 1260 ACGAATGGCG CACAAGAACG CTACATAGAT GATGCCAAAG GAGGAGATTT TTTTCAATTA 1320 AGAGAAGATT GGTGGACGTC GAATCGAGAA ACAGTATGGA AAGCATTAAT ATGTCATGCA 1380 CCAAAAGAAG CTAATTATTT TATAAAAACA GCGTGTAATG TAGGAAAAGG AACTAATGGT 1440 CAATGCCATT GCATTGGTGG AGATGTTCCC ACATATTTCG ATTATGTGCC GCAGTATCTT 1500 CGCTGGTTCG AGGAATGGGC AGAAGACTTT TGCAGGAAAA AAAAAAAAAA ACTAGAAAAT 1560 TTGCAAAAAC AGTGTCGTGA TTACGAACAA AATTTATATT GTAGTGGTAA TGGCTACGAT 1620 TGCACAAAAA CTATATATAA AAAAGGTAAA CTTGTTATAG GTGAACATTG TACAAACTGT 1680 TCTGTTTGGT GTCGTATGTA TGAAACTTGG ATAGATAACC AGAAAAAAGA ATTTCTAAAA 1740 CAAAAAAGAA AATACGAAAC AGAAATATCA GGTGGTGGTA GTGGTAAGAG TCCTAAAAGG 1800 ACAAAACGGG CTGCACGTAG TAGTAGTAGT AGTGATGATA ATGGGTATGA AAGTAAATTT 1860 TATAAAAAAC TGAAAGAAGT TGGCTACCAA GATGTCGATA AATTTTTAAA AATATTAAAC 1920 AAAGAAGGAA TATGTCAAAA ACAACCTCAA GTAGGAAATG AAAAAGCAGA TAATGTTGAT 1980 TTTACTAATG AAAAATATGT AAAAACATTT TCTCGTACAG AAATTTGTGA ACCGTGCCCA 2040 TGGTGTGGAT TGGAAAAAGG TGGTCCACCA TGGAAAGTTA AAGGTGACAA AACCTGCGGA 2100 AGTGCAAAAA CAAAGACATA CGATCCTAAA AATATTACCG ATATACCAGT ACTCTACCCT 2160 GATAAATCAC AGCAAAATAT ACTAAAAAAA TATAAAAATT TTTGTGAAAA AGGTGCACCT 2220 GGTGGTGGTC AAATTAAAAA ATGGCAATGT TATTATGATG AACATAGGCC TAGTAGTAAA 2280 AATAATAATA ATTGTGTAGA AGGAACATGG GACAAGTTTA CACAAGGTAA ACAAACCGTT 2340 AAGTCCTATA ATGTTTTTTT TTGGGATTGG GTTCATGATA TGTTACACGA TTCTGTAGAG 2400 TGGAAGACAG AACTTAGTAA GTGTATAAAT AATAACACTA ATGGCAACAC ATGTAGAAAC 2460 AATAATAAAT GTAAAACAGA TTGTGGTTGT TTTCAAAAAT GGGTTGAAAA AAAACAACAA 2520 GAATGGATGG CAATAAAAGA CCATTTTGGA AAGCAAACAG ATATTGTCCA ACAAAAAGGT 2580 CTTATCGTAT TTAGTCCCTA TGGAGTTCTT GACCTTGTTT TGAAGGGCGG TAATCTGTTG 2640 CAAAATATTA AAGATGTTCA TGGAGATACA GATGACATAA AACACATTAA GAAACTGTTG 2700 GATGAGGAAG ACGCAGTAGC AGTTGTTCTT GGTGGCAAGG ACAATACCAC AATTGATAAA 2760 TTACTACAAC ACGAAAAAGA ACAAGCAGAA CAATGCAAAC AAAAGCAGGA AGAATGCGAG 2820 AAAAAAGCAC AACAAGAAAG TCGTGGTCGC TCCGCCGAAA CCCGCGAAGA CGAAAGGACA 2880 CAACAACCTG CTGATAGTGC CGGCGAAGTC GAAGAAGAAG AAGACGACGA CGACTACGAC 2940 GAAGACGACG AAGATGACGA CGTAGTCCAG GAGGAGGAAG AGGGAAAGGA GGAAGGAACG 3000 GTCACAGAGG TAACAGAGGT AACAGAGGTC GTGGAAGAGA CGGTAACAGA ACAGGAAGGG 3060 GTGAAGCCAT GTGACATAGT GGGCAAACTA TTTGAGGACG ACAAAAGTCT CAAAGAGGCA 3120 TGTGGTCTAA AATACGGTCC AGGTGGAAAA GAAAAATTCC CCAATTGGAA GTGTGTCACA 3180 CCAAGTGGTG TCAGTACTGC CACTAGTGGA AAAGACGGCG CTATATGTGT GCCACCCAGG 3240 AGACGACGAT TATACGTAGG TGGTTTATCA CAATGGGCAA GTCGTGGTGG TGACGAGACC 3300 ACGGAGGTGT CGAGTGAAGC CACTTCGGCG CCGTCACAGT CAGAAAGTGA AAAACTACGT 3360 ACTGCGTTTA TTGAGTCCGC TGCAATAGAG ACGTTTTTTT TGTGGCATAA GTATAAAGAA 3420 GAGAAAAAAC CACCAGCAAC ACAAGATGGA GCGGGACTTG GAGTATCACT CCCAGAACCG 3480 TCACCACCGG GAGAGGACCC CCAAACACAA TTACAACAAA CTGGTGTTAT ACCCCCCGAT 3540 TTTTTGCGTC AAATGTTTTA TACATTAGCA GACTACAAAG ACATATTATA CAGTGGTAGT 3600 AACGACACAA GTGACACAAC TGGTAAACAG ACACCTAGTA GTAGTAATGA CAACCTCAAA 3660 AATATTGTTC TGGAAGCAAG TGGTAGTACT GAGCAGGAGA AGGAGAAAAT GAAACAAATA 3720 CAAGCGAAAA TAAAAAAAAT TTTAAACGGT GCCACATCTG GTGTCCCACC TGTCACCAAA 3780 AATAGTGTCA AAACCCCCCA ACAAACCTGG TGGGAAAACA TCGCGAAGGA TATCTGGAAT 3840 GCTATGGTAT GTGCACTAAC ATATAAAGAA AATGACGCCA GAGGCACAAG TGCCAAAATA 3900 GAACAGAATA AGGATTTGAA AAAGGCACTT TGGGACGAAG CCAACAAAAA CACCCCCATA 3960 GAGAAATACC AATACACAAA TGTCAAACTC GAAGATGAAA GTGGTGCCAA AAGCAACGAC 4020 ACCATCCAAC CCCCCACGTT AAAAAATTTT GTGGAAATAC CTACATTTTT TCGTTGGTTA 4080 CATGAGTGGG GAAACAGTTT TTGTTTTGAG AGAGCAAAAC GATTGGCACA AATAAAACAT 4140 GAGTGTATGG ATGAGGATGG TGAAAAACAA TATAGTGGGG ATGGGGAATA TTGTGAAGAA 4200 ATTTTTAGTA AGCAATATAA TGTTCTCCAG GATTTAAGTT CCAGTTGCGC TAAACCTTGT 4260 AGATTGTATA AAACGTGGAT AGAAAAAAAA AAAACAGAAT ATGAGAAACA ACAAAAGGCA 4320 TATGAACAAC AAAAAAGTAA TTACGAAAAT GAACAAAAAG ACAAATGCCA AACACAAAGT 4380 AATAATAATG CTAATGAATT TTCTAGAACA CTAGGAGCGT CCCCTACAGC TGCAGAATTT 4440 TTACAAAAGT TAGGATCATG TAAAAATGAT AATGGATATG AGAATGGAGA GGATAATAAA 4500 ATAGATTTTA AAAATCCAGA TAAAACATTT AAGGAAGCAC ACAGTTGTGA TCCATGTCCT 4560 ATAACTGGAG TTAAATGTCA AAATGGTCAT TGTGTGGGTT CTGCTAATGG AAAGGAGTGC 4620 AAAAACAATA AGATTACTGC AGAAGATATT AAAAATAAGA CAGATCCTAA TGGAAACATA 4680 GAAATGGTTG TCAGTGATGA CAGTACAAAT ACATTTGAAC ATTTAGGCGA TTGTAAAAGC 4740 TCAGGTATCT TTAAAGGTAT CAGAAAAGAT GAATGGAAAT GCGCTAATGT ATGTGGTGTA 4800 GATATATGTA CTCTGGAAAA AAAAATTAAG AATGGGCAAG AAGGTGATAA AAAATATATC 4860 ACAATGAAAG AATTGCTTAA ACGATGGCTA GAATATTTTT TAGAAGATTA TAATAGAATT 4920 AGAAAAAAAA TAAAGCTATG TACGAAAAAG GAAGATGGAT GCAAATGTAT AAAAGGTTGT 4980 ATAGAAAAAT GGGTACAAGA AAAAACGAAA GAATGGCAAA AAATAAACGA TACTTATCTT 5040 GAACAATATA AAAATGATGA TGGTAATACT TTAACTAATT TTTTGGAGCA ATTCCAATAT 5100 CGAACTGAAT TTAAAAACGC TATAAAACCT TGTGATGGTT TAGACCAGTT CAAGACTTCG 5160 TGTGGTCTTA ATAGTACTGA TAATTCACAA AATGGTAATA ATAACGATCT TGTTCTATGT 5220 TTGCTTAATA AACTTCAAAA AAAAATTAGT GAGTGTAAAG AACAACATAG TGGCCAAACC 5280 CAAACACCGT GTGATAACTC TTCCCTTAGT GGTAAAGAAT CCACCCTCGT TGAAGACGTT 5340 GATGATTATG AGGAACAAAA CCCAGAAAAC AAAGTGGAAC AACCTAAATT TTGTCCAGAT 5400 ATGAAAGAAC CAAAAAAAGA AAACGATGAA GAAGTAGGCA CTTGTGGCGG AGACGAAGAA 5460 AAAAAAAAAG TGGAAGACAG TGTAATCGAA CAAAAAGAGG AAGAAGCAGC TAGTGCCCCA 5520 GAGGAATCTC CTCCATTAAC CCCGGAAGCA CCAAAAAAAG AGGAAAATGT GGTACCAAAA 5580 CCACCACCAC CACCAAAAAA ACGCCGAATC AAAACCCGTA ATGTGTTGGA CCACCCCGCT 5640 GTCATACCCG CCCTCATGTC TTCTACCATC ATGTGGAGTA TTGGCATCGG TTTTGCTGCG 5700 TTCACTTATT TTTATCTAAA GAAAAAAACC AAATCATCTG TTGGAAATTT ATTCCAAATA 5760 CTGCAAATAC CCAAAAGTGA TTATGATATA CCTACATTGA AATCAAGCAA TCGTTATATA 5820 CCCTATGCAA GTGATAGACA TAAAGGCAAA ACATATATTT ATATGGAAGG AGATAGCAGT 5880 GGAGATGAAA AATATGCATT TATGTCTGAT ACTACTGATA TAACTTCATC CGAAAGTGAG 5940 TATGAAGAAT TGGATATTAA TGATATATAT GTACCAGGTA GTCCTAAATA TAAAACATTG 6000 ATAGAAGTAG TACTTGAACC ATCAAAAAGA GATACACAAA ATGATATACA CAATGATATA 6060 CCTAGTGATA TACCAAATAG TGACACACCA CCACCCATTA CTGATGATGA ATGGAATCAA 6120 TTGAAAAAAG ATTTTATATC TAATATGTTA CAAAATACAC AAAATACGGA ACCAAATATT 6180 TTACATGATA ATGTGGATAA TAATACCCAT CCTACCATGT CACGTCATAA TATGGACCAA 6240 AAACCTTTTA TTATGTCCAT ACATGATAGA AATTTATTTA GTGGAGAAGA ATACAATTAT 6300 GATATGTTTA ATAGTGGGAA TAATCCAATA AACATTAGTG ATTCAACAAA TAGTATGGAT 6360 AGTCTAACAA GTAACAACCA TAGTCCATAT AATGATAAAA ATGATTTATA TAGTGGTATC 6420 GACCTAATCA ACGACGCACT AAGTGGTAAT CATATTGATA TATATGATGA AATGCTCAAA 6480 CGAAAAGAAA ATGAATTATT CGGGACGCAA CATCATCCAA AAAATATAAC GTCTAACCGT 6540 GTCGTTACCC AAACAAGTAG TGACGACCCT ATAACCAATC AAATAAATTT GTTCCATAAA 6600 TGGTTAGATA GGCATAGAGA TATGTGCGAA AAGTGGAAAA ATAATCACGA ACGGTTACCC 6660 AAATTGAAAG AATTGTGGGA AAATGAGACA CATAGTGGTG ACATAAATAG TGGTATACCT 6720 AGTGGTAACC ATGTGTTGAA TACTGATGTT TCTATTCAAA TAGATATGGA TAATCCGAAA 6780 ACAATGAATG AATTTACTAA TATGGATACA AACCCCGACA AATCTACTAT GGATACTATA 6840 TTGGATGATC TAGAAAAATA TAACGAACCC TACTACTATG ATTTTTATAA ACATGATATC 6900 TATTATGATG TAAATGATGA TAAAGCATCT GAGGATCATA TAAATATGGA TCATAATAAG 6960 ATGGATAATA ATAATTCGGA TGTCCCCACT AACGTACAAA TTGAAATGAA TGTCATTAAT 7020 AATCAGGAGT TACTACAAAA TGAATATCCT ATATCGCATA TGTAGGGAAT ATGAAAATAA 7080 TAGATGTATA TATGTTTTTT TCTTTTTTTG TGTGTGTGCA GTTTATATTT TTTATTTGTA 7140 GATGTTATAT ATTTTTTTTA TTTGTGGGTT ATATTATAAT TTTTATTTAT GGGTTATATA 7200 TATATTTTTT TTTTTGTGCA TTTGTCTATT TTTTATTTGT GCTTTATATA TATATATATT 7260 TTATTCAGCT TGGACTTAAC CAGGCTGAAC TTGCT 7295 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2182 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE : N- terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Met Glu Pro Gly Gly Ser Gly Gly Arg Gly Ser Gly Gly Ser Ser Ser 1 5 10 15 Gly Lys Gly Lys Lys Asp Thr Ser Glu Tyr He Tyr Val Ser Asp Ala 20 25 30 Lys Asp Leu Leu Asp Arg Val Gly Glu Lys Val Tyr Glu Glu Lys Val 35 40 45 Lys Asn Gly Asp Ala Lys Lys Tyr He Glu Ala Leu Lys Gly Asn Leu 50 55 60 Asn Thr Ala Asn Gly Arg Ser Ser Glu Thr Ala Ser Ser He Glu Thr 65 70 75 80 Cys Thr Leu Val Lys Glu Tyr Tyr Glu Arg Val Asn Gly Asp Gly Lys 85 90 95 Arg His Pro Cys Arg Lys Asp Ala Lys Asn Glu Asp Val Asn Arg Phe 100 105 110 Ser Asp Thr Leu Gly Gly Gin Cys Thr Tyr Asn Arg He Lys Asp Ser 115 120 125 Gin Gin Gly Asp Asn Lys Val Gly Ala Cys Ala Pro Tyr Arg Arg Leu 130 135 ' 140 His Leu Cys Asp Tyr Asn Leu Glu Ser He Asp Thr Thr Ser Thr Thr 145 150 155 160 His Lys Leu Leu Leu Glu Val Cys Met Ala Ala Lys Tyr Glu Gly Asn 165 170 175 Ser He Asn Thr His Tyr Thr Gin His Gin Arg Thr Asn Glu Asp Ser 180 185 190 Ala Ser Gin Leu Cys Thr Val Leu Ala Arg Ser Phe Ala Asp He Gly 195 200 205 Asp He Val Arg Gly Lys Asp Leu Tyr Leu Gly Tyr Asp Asn Lys Glu 210 215 220 Lys Glu Gin Arg Lys Lys Leu Glu Gin Lys Leu Lys Asp He Phe Lys 225 230 235 240 Lys He His Lys Asp Val Met Lys Thr Asn Gly Ala Gin Glu Arg Tyr 245 250 255 He Asp Asp Ala Lys Gly Gly Asp Phe Phe Gin Leu Arg Glu Asp Trp 260 265 270 Trp Thr Ser Asn Arg Glu Thr Val Trp Lys Ala Leu He Cys His Ala 275 280 285 Pro Lys Glu Ala Asn Tyr Phe He Lys Thr Ala Cys Asn Val Gly Lys 290 295 300 Gly Thr Asn Gly Gin Cys His Cys He Gly Gly Asp Val Pro Thr Tyr 305 310 315 320 Phe Asp Tyr Val Pro Gin Tyr Leu Arg Trp Phe Glu Glu Trp Ala Glu 325 330 335 Asp Phe Cys Arg Lys Lys Lys Lys Lys Leu Glu Asn Leu Gin Lys Gin 340 345 350 Cys Arg Asp Tyr Glu Gin Asn Leu Tyr Cys Ser Gly Asn Gly Tyr Asp 355 360 365 Cys Thr Lys Thr He Tyr Lys Lys Gly Lys Leu Val He Gly Glu His 370 375 380 Cys Thr Asn Cys Ser Val Trp Cys Arg Met Tyr Glu Thr Trp He Asp 385 390 395 400 Asn Gin Lys Lys Glu Phe Leu Lys Gin Lys Arg Lys Tyr Glu Thr Glu 405 410 415 He Ser Gly Gly Gly Ser Gly Lys Ser Pro Lys Arg Thr Lys Arg Ala 420 425 430 Ala Arg Ser Ser Ser Ser Ser Asp Asp Asn Gly Tyr Glu Ser Lys Phe 435 440 445 Tyr Lys Lys Leu Lys Glu Val Gly Tyr Gin Asp Val Asp Lys Phe Leu 450 455 460 Lys He Leu Asn Lys Glu Gly He Cys Gin Lys Gin Pro Gin Val Gly 465 470 475 480 Asn Glu Lys Ala Asp Asn Val Asp Phe Thr Asn Glu Lys Tyr Val Lys 485 490 495 Thr Phe Ser Arg Thr Glu He Cys Glu Pro Cys Pro Trp Cys Gly Leu 500 505 510 Glu Lys Gly Gly Pro Pro Trp Lys Val Lys Gly Asp Lys Thr Cys Gly 515 520 525 Ser Ala Lys Thr Lys Thr Tyr Asp Pro Lys Asn He Thr Asp He Pro 530 535 540 Val Leu Tyr Pro Asp Lys Ser Gin Gin Asn He Leu Lys Lys Tyr Lys 545 550 555 560 Asn Phe Cys Glu Lys Gly Ala Pro Gly Gly Gly Gin He Lys Lys Trp 565 570 575 Gin Cys Tyr Tyr Asp Glu His Arg Pro Ser Ser Lys Asn Asn Asn Asn 580 585 590 Cys Val Glu Gly Thr Trp Asp Lys Phe Thr Gin Gly Lys Gin Thr Val 595 600 605 Lys Ser Tyr Asn Val Phe Phe Trp Asp Trp Val His Asp Met Leu His 610 615 620 Asp Ser Val Glu Trp Lys Thr Glu Leu Ser Lys Cys He Asn Asn Asn 625 630 635 640 Thr Asn Gly Asn Thr Cys Arg Asn Asn Asn Lys Cys Lys Thr Asp Cys 645 650 655 Gly Cys Phe Gin Lys Trp Val Glu Lys Lys Gin Gin Glu Trp Met Ala 660 665 670 He Lys Asp His Phe Gly Lys Gin Thr Asp He Val Gin Gin Lys Gly 675 680 685 Leu He Val Phe Ser Pro Tyr Gly Val Leu Asp Leu Val Leu Lys Gly 690 695 700 Gly Asn Leu Leu Gin Asn He Lys Asp Val His Gly Asp Thr Asp Asp 705 710 715 720 He Lys His He Lys Lys Leu Leu Asp Glu Glu Asp Ala Val Ala Val 725 730 735 Val Leu Gly Gly Lys Asp Asn Thr Thr He Asp Lys Leu Leu Gin His 740 745 750 Glu Lys Glu Gin Ala Glu Gin Cys Lys Gin Lys Gin Glu Glu Cys Glu 755 760 765 Lys Lys Ala Gin Gin Glu Ser Arg Gly Arg Ser Ala Glu Thr Arg Glu 770 775 780 Asp Glu Arg Thr Gin Gin Pro Ala Asp Ser Ala Gly Glu Val Glu Glu 785 790 795 800 Glu Glu Asp Asp Asp Asp Tyr Asp Glu Asp Asp Glu Asp Asp Asp Val 805 810 815 Val Gin Glu Glu Glu Glu Gly Lys Glu Glu Gly Thr Val Thr Glu Val 820 825 830 Thr Glu Val Thr Glu Val Val Glu Glu Thr Val Thr Glu Gin Glu Gly 835 840 845 Val Lys Pro Cys Asp He Val Gly Lys Leu Phe Glu Asp Asp Lys Ser 850 855 860 Leu Lys Glu Ala Cys Gly Leu Lys Tyr Gly Pro Gly Gly Lys Glu Lys 865 870 875 880 Phe Pro Asn Trp Lys Cys Val Thr Pro Ser Gly Val Ser Thr Ala Thr 885 890 895 Ser Gly Lys Asp Gly Ala He Cys Val Pro Pro Arg Arg Arg Arg Leu 900 905 ' 910 Tyr Val Gly Gly Leu Ser Gin Trp Ala Ser Arg Gly Gly Asp Glu Thr 915 920 925 Thr Glu Val Ser Ser Glu Ala Thr Ser Ala Pro Ser Gin Ser Glu Ser 930 935 940 Glu Lys Leu Arg Thr Ala Phe He Glu Ser Ala Ala He Glu Thr Phe 945 950 955 960 Phe Leu Trp His Lys Tyr Lys Glu Glu Lys Lys Pro Pro Ala Thr Gin 965 970 975 Asp Gly Ala Gly Leu Gly Val Ser Leu Pro Glu Pro Ser Pro Pro Gly 980 985 990 Glu Asp Pro Gin Thr Gin Leu Gin Gin Thr Gly Val He Pro Pro Asp 995 1000 1005 Phe Leu Arg Gin Met Phe Tyr Thr Leu Ala Asp Tyr Lys Asp He Leu 1010 1015 1020 Tyr Ser Gly Ser Asn Asp Thr Ser Asp Thr Thr Gly Lys Gin Thr Pro 1025 1030 1035 1040 Ser Ser Ser Asn Asp Asn Leu Lys Asn He Val Leu Glu Ala Ser Gly 1045 1050 1055 Ser Thr Glu Gin Glu Lys Glu Lys Met Lys Gin He Gin Ala Lys He 1060 1065 1070 Lys Lys He Leu Asn Gly Ala Thr Ser Gly Val Pro Pro Val Thr Lys 1075 1080 1085 Asn Ser Val Lys Thr Pro Gin Gin Thr Trp Trp Glu Asn He Ala Lys 1090 1095 1100 Asp He Trp Asn Ala Met Val Cys Ala Leu Thr Tyr Lys Glu Asn Asp 1105 1110 1115 1120 Ala Arg Gly Thr Ser Ala Lys He Glu Gin Asn Lys Asp Leu Lys Lys 1125 1130 1135 Ala Leu Trp Asp Glu Ala Asn Lys Asn Thr Pro He Glu Lys Tyr Gin 1140 1145 1150 Tyr Thr Asn Val Lys Leu Glu Asp Glu Ser Gly Ala Lys Ser Asn Asp 1155 1160 1165 Thr He Gin Pro Pro Thr Leu Lys Asn Phe Val Glu He Pro Thr Phe 1170 1175 1180 Phe Arg Trp Leu His Glu Trp Gly Asn Ser Phe Cys Phe Glu Arg Ala 1185 1190 1195 1200 Lys Arg Leu Ala Gin He Lys His Glu Cys Met Asp Glu Asp Gly Glu 1205 1210 1215 Lys Gin Tyr Ser Gly Asp Gly Glu Tyr Cys Glu Glu He Phe Ser Lys 1220 1225 1230 Gin Tyr Asn Val Leu Gin Asp Leu Ser Ser Ser Cys Ala Lys Pro Cys 1235 1240 1245 Arg Leu Tyr Lys Thr Trp He Glu Lys Lys Lys Thr Glu Tyr Glu Lys 1250 1255 1260 Gin Gin Lys Ala Tyr Glu Gin Gin Lys Ser Asn Tyr Glu Asn Glu Gin 1265 1270 1275 1280 Lys Asp Lys Cys Gin Thr Gin Ser Asn Asn Asn Ala Asn Glu Phe Ser 1285 1290 1295 Arg Thr Leu Gly Ala Ser Pro Thr Ala Ala Glu Phe Leu Gin Lys Leu 1300 1305 1310 Gly Ser Cys Lys Asn Asp Asn Gly Tyr Glu Asn Gly Glu Asp Asn Lys 1315 1320 1325 He Asp Phe Lys Asn Pro Asp Lys Thr Phe Lys Glu Ala His Ser Cys 1330 1335 1340 Asp Pro Cys Pro He Thr Gly Val Lys Cys Gin Asn Gly His Cys Val 1345 1350 1355 1360 Gly Ser Ala Asn Gly Lys Glu Cys Lys Asn Asn Lys He Thr Ala Glu 1365 1370 1375 Asp He Lys Asn Lys Thr Asp Pro Asn Gly Asn He Glu Met Val Val 1380 1385 1390 Ser Asp Asp Ser Thr Asn Thr Phe Glu His Leu Gly Asp Cys Lys Ser 1395 1400 1405 Ser Gly He Phe Lys Gly He Arg Lys Asp Glu Trp Lys Cys Ala Asn 1410 1415 1420 Val Cys Gly Val Asp He Cys Thr Leu Glu Lys Lys He Lys Asn Gly 1425 1430 1435 1440 Gin Glu Gly Asp Lys Lys Tyr He Thr Met Lys Glu Leu Leu Lys Arg 1445 1450 1455 Trp Leu Glu Tyr Phe Leu Glu Asp Tyr Asn Arg He Arg Lys Lys He 1460 1465 1470 Lys Leu Cys Thr Lys Lys Glu Asp Gly Cys Lys Cys He Lys Gly Cys 1475 1480 1485 He Glu Lys Trp Val Gin Glu Lys Thr Lys Glu Trp Gin Lys He Asn 1490 1495 1500 Asp Thr Tyr Leu Glu Gin Tyr Lys Asn Asp Asp Gly Asn Thr Leu Thr 1505 1510 1515 1520 Asn Phe Leu Glu Gin Phe Gin Tyr Arg Thr Glu Phe Lys Asn Ala He 1525 1530 1535 Lys Pro Cys Asp Gly Leu Asp Gin Phe Lys Thr Ser Cys Gly Leu Asn 1540 1545 1550 Ser Thr Asp Asn Ser Gin Asn Gly Asn Asn Asn Asp Leu Val Leu Cys 1555 1560 1565 Leu Leu Asn Lys Leu Gin Lys Lys He Ser Glu Cys Lys Glu Gin His 1570 1575 1580 Ser Gly Gin Thr Gin Thr Pro Cys Asp Asn Ser Ser Leu Ser Gly Lys 1585 1590 1595 1600 Glu Ser Thr Leu Val Glu Asp Val Asp Asp Tyr Glu Glu Gin Asn Pro 1605 1610 1615 Glu Asn Lys Val Glu Gin Pro Lys Phe Cys Pro Asp Met Lys Glu Pro 1620 1625 1630 Lys Lys Glu Asn Asp Glu Glu Val Gly Thr Cys Gly Gly Asp Glu Glu 1635 1640 1645 Lys Lys Lys Val Glu Asp Ser Val He Glu Gin Lys Glu Glu Glu Ala 1650 1655 1660 Ala Ser Ala Pro Glu Glu Ser Pro Pro Leu Thr Pro Glu Ala Pro Lys 1665 1670 1675 1680 Lys Glu Glu Asn Val Val Pro Lys Pro Pro Pro Pro Pro Lys Lys Arg 1685 1690 1695 Arg He Lys Thr Arg Asn Val Leu Asp His Pro Ala Val He Pro Ala 1700 1705 1710 Leu Met Ser Ser Thr He Met Trp Ser He Gly He Gly Phe Ala Ala 1715 1720 1725 Phe Thr Tyr Phe Tyr Leu Lys Lys Lys Thr Lys Ser Ser Val Gly Asn 1730 1735 1740 Leu Phe Gin He Leu Gin He Pro Lys Ser Asp Tyr Asp He Pro Thr 1745 1750 1755 1760 Leu Lys Ser Ser Asn Arg Tyr He Pro Tyr Ala Ser Asp Arg His Lys 1765 1770 1775 Gly Lys Thr Tyr He Tyr Met Glu Gly Asp Ser Ser Gly Asp Glu Lys 1780 1785 1790 Tyr Ala Phe Met Ser Asp Thr Thr Asp He Thr Ser Ser Glu Ser Glu 1795 1800 1805 Tyr Glu Glu Leu Asp He Asn Asp He Tyr Val Pro Gly Ser Pro Lys 1810 1815 1820 Tyr Lys Thr Leu He Glu Val Val Leu Glu Pro Ser Lys Arg Asp Thr 1825 1830 1835 1840 Gin Asn Asp He His Asn Asp He Pro Ser Asp He Pro Asn Ser Asp 1845 1850 1855 Thr Pro Pro Pro He Thr Asp Asp Glu Trp Asn Gin Leu Lys Lys Asp 1860 1865 1870 Phe He Ser Asn Met Leu Gin Asn Thr Gin Asn Thr Glu Pro Asn He 1875 1880 1885 Leu His Asp Asn Val Asp Asn Asn Thr His Pro Thr Met Ser Arg His 1890 1895 1900 Asn Met Asp Gin Lys Pro Phe He Met Ser He His Asp Arg Asn Leu 1905 1910 1915 1920 Phe Ser Gly Glu Glu Tyr Asn Tyr Asp Met Phe Asn Ser Gly Asn Asn 1925 1930 1935 Pro He Asn He Ser Asp Ser Thr Asn Ser Met Asp Ser Leu Thr Ser 1940 1945 " 1950 Asn Asn His Ser Pro Tyr Asn Asp Lys Asn Asp Leu Tyr Ser Gly He 1955 1960 1965 Asp Leu He Asn Asp Ala Leu Ser Gly Asn His He Asp He Tyr Asp 1970 • 1975 1980 Glu Met Leu Lys Arg Lys Glu Asn Glu Leu Phe Gly Thr Gin His His 1985 1990 1995 2000 Pro Lys Asn He Thr Ser Asn Arg Val Val Thr Gin Thr Ser Ser Asp 2005 2010 2015 Asp Pro He Thr Asn Gin He Asn Leu Phe His Lys Trp Leu Asp Arg 2020 2025 2030 His Arg Asp Met Cys Glu Lys Trp Lys Asn Asn His Glu Arg Leu Pro 2035 2040 2045 Lys Leu Lys Glu Leu Trp Glu Asn Glu Thr His Ser Gly Asp He Asn 2050 2055 2060 •74- Ser Gly He Pro Ser Gly Asn His Val Leu Asn Thr Asp Val Ser He 2065 2070 2075 2080 Gin He Asp Met Asp Asn Pro Lys Thr Met Asn Glu Phe Thr Asn Met 2085 2090 2095 Asp Thr Asn Pro Asp Lys Ser Thr Met Asp Thr He Leu Asp Asp Leu 2100 2105 2110 Glu Lys Tyr Asn Glu Pro Tyr Tyr Tyr Asp Phe Tyr Lys His Asp He 2115 2120 2125 Tyr Tyr Asp Val Asn Asp Asp Lys Ala Ser Glu Asp His He Asn Met 2130 2135 2140 Asp His Asn Lys Met Asp Asn Asn Asn Ser Asp Val Pro Thr Asn Val 2145 2150 2155 2160 Gin He Glu Met Asn Val He Asn Asn Gin Glu Leu Leu Gin Asn Glu 2165 2170 2175 Tyr Pro He Ser His Met 2180 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ATCGATCAGC TGGGAAGAAA TACTTCATCT 30 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: ATCGATGGGC CCCGAAGTTT GTTCATTATT 30 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: TCTCGTCAGC TGACGATCTC TAGTGCTATT 30 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: ACGAGTGGGC CCTGTCACAA CTTCCTGAGT 30 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: AGACCTCAAT TTCTAAG 17 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: AATCGCGAGC ATCATCTG 18 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CCRAGRAGRC AARAAYTATG 20 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: CCA CKKARR AATTG GG 18 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 291 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Val Cys He Pro Asp Arg Arg Tyr Gin Leu Cys Met Lys 20 25 30 Glu Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Asp Phe Cys Lys Asp He Arg Trp Ser Leu Gly Asp Phe Gly Asp 85 90 95 He He Met Gly Thr Asp Met Glu Gly He Gly Tyr Ser Lys Xaa Xaa 100 105 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Asp Glu Lys Ala Gin Gin 115 120 125 Arg Arg Lys Gin Trp Trp Asn Glu Ser Lys Ala Gin He Trp Thr Ala 130 135 140 Met Met Tyr Ser Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu Pro Gin He Tyr Arg Trp 165 170 175 He Arg Glu Trp Gly Arg Asp Tyr Val Ser Glu Leu Pro Thr Glu Val 180 185 190 Gin Lys Leu Lys Glu Lys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Cys Xaa Val Pro Pro Cys Gin Asn Ala Cys Lys Ser Tyr Asp 210 215 220 Gin Trp He Thr Arg Lys Lys Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 275 280 285 Cys Xaa Cys 290 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 271 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Val Cys He Pro Asp Arg Arg He Gin Leu Cys 20 25 30 He Val Asn Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Phe Cys Asn Asp Leu Lys Asn 65 70 75 80 Ser Phe Leu Asp Tyr Gly His Leu Ala Met Gly Asn Asp Met Asp Phe 85 90 95 Gly Gly Tyr Ser Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 ' 110 Xaa Xaa Xaa Xaa Xaa Xaa Ser Glu His Lys He Lys Asn Phe Arg Lys 115 120 125 Glu Trp Trp Asn Glu Phe Arg Glu Lys Leu Trp Glu Ala Met Leu Ser 130 135 140 Glu His Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Glu 145 150 155 160 Leu Gin He Thr Gin Trp He Lys Glu Trp His Gly Glu Phe Leu Leu 165 170 175 Glu Arg Asp Asn Arg Ser Lys Leu Pro Lys Ser Lys Cys Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Cys Xaa Glu Lys Glu Cys He Asp Pro Cys Met 195 200 205 Lys Tyr Arg Asp Trp He He Arg Ser Lys Phe Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys 260 265 270 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 277 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Cys Val Pro Pro Arg Arg 20 25 30 Gin Glu Leu Cys Leu Gly Asn He Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu Val Cys Lys 65 70 75 80 He He Asn Lys Thr Phe Ala Asp He Arg Asp He He Gly Gly Thr 85 90 95 Asp Tyr Trp Asn Asp Leu Ser Asn Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Lys Lys Asn Asp Lys Leu Phe 115 120 125 Arg Asp Glu Trp Trp Lys Val He Lys Lys Asp Val Trp Asn Val He 130 135 140 Ser Trp Phe Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 He Pro Gin Phe Phe Arg Trp Phe Ser Glu Trp Gly Asp Asp Tyr Cys 165 170 175 Gin Asp Lys Thr Lys Met He Glu Thr Leu Lys Val Glu Cys Xaa Xaa 180 185 190 Xaa Xaa Cys Xaa Asp Asp Asn Cys Lys Ser Lys Cys Asn Ser Tyr Lys 195 200 205 Glu Trp He Ser Lys Lys Lys Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Cys Xaa Xaa Cys 275 (2) INFORMATION FOR SEQ ID NO:28 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 282 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Cys Gly Pro Pro Arg Arg 20 25 30 Gin Gin Leu Cys Leu Gly Tyr He Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys He Cys Asn 65 70 75 80 Ala He Leu Gly Ser Tyr Ala Asp He Gly Asp He Val Arg Gly Leu 85 90 95 Asp Val Trp Arg Asp He Asn Thr Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Lys Gin Asn Asp Asn 115 120 125 Asn Glu Arg Asn Lys Trp Trp Glu Lys Gin Arg Asn Leu He Trp Ser 130 135 140 Ser Met Val Lys His He Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa He Pro Gin Phe Leu Arg Trp Leu Lys Glu Trp Gly 165 170 175 Asp Glu Phe Cys Glu Glu Met Gly Thr Glu Val Lys Gin Leu Glu Lys 180 185 190 He Cys Xaa Xaa Xaa Xaa Cys Xaa Glu Lys Lys Cys Lys Asn Ala Cys 195 200 205 Ser Ser Tyr Glu Lys Trp He Lys Glu Arg Lys Asn Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys 275 280 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 324 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Cys He Pro Pro Arg Arg Gin Lys 20 25 30 Leu Cys Leu His Tyr Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Phe Lys Arg Gin Met Phe 85 90 95 Tyr Thr Phe Ala Asp Tyr Arg Asp He Cys Leu Gly Thr Asp He Ser 100 105 110 Ser Lys Lys Asp Thr Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Lys He Ser Asn Ser He Arg Tyr Arg Lys Ser 130 135 140 Trp Trp Glu Thr Asn Gly Pro Val He Trp Glu Gly Met Leu Cys Ala 145 150 155 160 Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 165 170 175 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Pro Gin Phe Leu 195 200 205 Arg Trp Leu Thr Glu Trp Gly Glu Asn Phe Cys Lys Glu Gin Lys Lys 210 215 220 Glu Tyr Lys Val Leu Leu Ala Lys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Val Ala Cys Lys Asp Gin Cys 245 250 255 Lys Gin Tyr His Ser Trp He Gly He Trp He Asp Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 275 280 285 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 305 310 315 320 Xaa Xaa Xaa Cys (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 362 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Ala Cys Ala Pro Tyr Arg Arg Leu His Leu Cys Asp Tyr Asn Leu Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Leu Cys Thr Val Leu -δi- 50 55 60 Ala Arg Ser Phe Ala Asp He Gly Asp He Val Arg Gly Lys Asp Leu 65 70 75 80 Tyr Leu Gly Tyr Asp Asn Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Gly Gly Asp 115 120 125 Phe Phe Gin Leu Arg Glu Asp Trp Trp Thr Ser Asn Arg Glu Thr Val 130 135 140 Trp Lys Ala Leu He Cys His Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 165 170 175 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Pro Gin Tyr Leu 180 185 190 Arg Trp Phe Glu Glu Trp Ala Glu Asp Phe Cys Arg Lys Lys Lys Lys 195 200 205 Lys Leu Glu Asn Leu Gin Lys Gin Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys 210 215 220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 225 230 235 240 Thr Asn Cys Ser Val Trp Cys Arg Met Tyr Glu Thr Trp He Asp Asn 245 250 255 Gin Lys Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 275 280 285 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 305 310 315 320 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 340 345 350 Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys 355 360 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 411 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Ala Cys Ala Pro Tyr Arg Arg Leu His Val Cys Asp Gin Asn Leu Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin He Cys Thr 85 90 95 Met Leu Ala Arg Ser Phe Ala Asp He Gly Asp He Val Arg Gly Arg 100 105 110 Asp Leu Tyr Leu Gly Asn Pro Gin Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Asp Pro Glu Phe Phe Lys Leu Arg 145 150 155 160 Glu Asp Trp Trp Thr Ala Asn Arg Glu Thr Val Trp Lys Ala He Thr 165 170 175 Cys Asn Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Val Pro Gin Tyr Leu Arg Trp Phe Glu Glu Trp Ala 210 215 220 Glu Asp Phe Cys Arg Lys Lys Asn Lys Lys He Lys Asp Val Lys Arg 225 230 235 240 Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Cys He Ser Cys Leu Tyr Ala Cys Asn Pro Tyr 275 280 285 Val Asp Trp He Asn Asn Gin Lys Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 305 310 315 320 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 340 345 350 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa 355 360 365 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 370 375 380 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 385 390 395 400 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys 405 410 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 411 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Val Phe Leu Pro Pro Arg Arg Glu His Met Cys Thr Ser Asn 50 55 60 Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Met Cys Arg Ala Val Arg Tyr 115 120 125 Ser Phe Ala Asp Leu Gly Asp He He Arg Gly Arg Asp Met Trp Asp 130 135 140 Glu Asp Lys Ser Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 165 170 175 Xaa Xaa Xaa Xaa Xaa Lys Lys Pro Ala Tyr Lys Lys Leu Arg Ala Asp 180 185 190 Trp Trp Glu Ala Asn Arg His Gin Val Trp Arg Ala Met Lys Cys Ala 195 200 205 Thr Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa He Pro 210 215 220 Gin Arg Leu Arg Trp Met Thr Glu Trp Ala Glu Trp Tyr Cys Lys Ala 225 230 235 240 Gin Ser Gin Glu Tyr Asp Lys Leu Lys Lys He Cys Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Gly 260 265 270 Lys Cys Lys Ala Ala Cys Asp Lys Tyr Lys Glu Glu He Glu Lys Trp 275 280 285 Asn Glu Gin Trp Arg Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 305 310 315 320 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 340 345 350 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 355 360 365 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 370 375 380 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 385 390 395 400 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys 405 410 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 311 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Ala Cys Met Pro Pro Arg Arg Gin Lys Leu 20 25 30 Cys Leu Tyr Tyr He Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Phe Leu Arg Ser Met Met 85 90 95 Tyr Thr Phe Gly Asp Tyr Arg Asp He Cys Leu Asn Thr Asp He Ser 100 105 110 Lys Lys Gin Asn Asp Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Ser Lys Ser Pro Ser Gly Leu Ser Arg Gin Glu 130 135 140 Trp Trp Lys Thr Asn Gly Pro Glu He Trp Lys Gly Met Leu Cys Ala 145 150 155 160 Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 165 170 175 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Lys Pro Gin Phe Leu Arg Trp Met He Glu 195 200 205 Trp Gly Glu Glu Phe Cys Ala Glu Arg Gin Lys Lys Glu Asn He He 210 215 220 Lys Asp Ala Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa 225 230 235 240 Lys His Arg Cys Asn Gin Ala Cys Arg Ala Tyr Gin Glu Tyr Val Glu 245 250 255 Asn Lys Lys Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 275 280 285 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 290 295 300 Xaa Xaa Xaa Xaa Cys Xaa Cys 305 310 (2) INFORMATION FOR SEQ ID NO:34 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Pro Arg Arg Gin Xaa Leu Cys 1 5 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: CCRAGRAGRC AARAAYTATG 20 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: CCSMGSMGSC AGCAGYTSTG 20 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: Phe Ala Asp Xaa Xaa Asp He 1 5 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: TTTGC GAT WWSGWGATAT 20 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: TTCGCSGATW WCSGSGACAT 20 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Pro Gin Phe Xaa Arg Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: CCAWCKKARR AATTGWGG 18 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: CCASCKG AG A CTGSGG 18 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43 Glu Trp Gly Xaa Xaa Xaa Cys 1 5 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: CAA A TCWT CWCCCCATTC 20 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: CAGWASTCST CSCCCCACTC 20

Claims: WE CLAIM: 1. A composition comprising a nucleotide sequence of the DBL gene family, wherein said nucleotide sequence is selected from the group consisting of the var l, var-2, var-3 and var-7 genes. 2. The composition of Claim 1, wherein the nucleotide sequence of the varl, var-2, var-3 or var- 7 gene encodes a cysteine-rich domain homologous to a cysteine-rich domain of a Duffy Antigen Binding Protein (DABP) derived from Plasmodium vivax and a Sialic Acid Binding Protein (SABP) derived from Plasmodium falciparum. 3. The composition of Claim 1, wherein the nucleotide sequence of the var l, var-2, var-3 or var- 7 gene encodes a cysteine-rich interdomain region between a first domain and a second domain. 4. The composition of Claim 1, wherein the nucleotide sequence is derived from a coding region of SEQ ID N0:13 or SEQ ID N0:15. 5. A composition comprising a polypeptide encoded by a nucleotide sequence of the DBL gene family, wherein said polypeptide is encoded by a varl, var-2, var-3 or tw-7 gene. 6. The composition of claim 5, wherein the polypeptide comprises a sequence of amino acid residues homologous to cysteine-rich domains of a Duffy Antigen Binding Protein (DABP) derived from Plasmodium vivax and a Sialic Acid Binding Protein (SABP) derived from Plasmodium falciparum. 1. The composition of claim 5, wherein the polypeptide comprises a sequence of about 300 to 400 amino acid residues occuring in the cysteine-rich interdomain region between a first domain and a second domain of a polypeptide encoded by the var-1, var-2, var-3 or tw-7 gene. 8. The composition of claim 5, wherein the polypeptide comprises a sequence of amino acid residues of SEQ ID N0.14 or SEQ ID N0:16. 9. The composition of claim 5, wherein the polypeptide comprises a sequence of about 50 to about 325 amino acid residues of SEQ ID N0.14 or SEQ ID N0:16. 10. The composition of claim 5, wherein the polypeptide comprises a sequence of about 75 to about 300 amino acid residues of SEQ ID N0.14 or SEQ ID N0:16. 11. The composition of claim 5, wherein the polypeptide comprises a sequence of about 100 to about 250 amino acid residues of SEQ ID N0:14 or SEQ ID N0:16. 12. The composition of claim 5, further comprising a pharmaceutically acceptable carrier and an isolated Duffy Antigen Binding Protein (DABP) binding domain polypeptide, a Sialic Acid Binding Protein (SABP) binding domain polypeptide, or a combination thereof, in an amount sufficient to induce a protective immune response to Plasmodium merozoites in a mammal. 13. The composition of any of the preceding claims for use in inducing a protective immune response to Plasmodium merozoites in a mammal. 14. Use of the composition of any one of claims 1-12 in the preparation of a medicament for inducing a protective immune response to Plasmodium merozoites in a mammal. 15. A method of inducing a protective immune response to Plasmodium merozoites in a mammal, comprising administering to a mammal an immunologically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated cysteine-rich polypeptide encoded by a var gene selected from the group of genes consisting of varl, var-2, var-3 and var-7 genes. 16. The method of claim 15, further comprising administering to said mammal an immunologically effective amount of a Duffy Antigen Binding Protein (DABP) binding domain polypeptide, a Sialic Acid Binding Protein (SABP) binding domain polypeptide, or a combination thereof.

Inventors: CHITNIS CHETAN, MILLER LOUIS H, PETERSON DAVID S, SIM KIM LEE, SU XIN-ZHUAN, WELLEMS THOMAS E, CHITNIS, CHETAN, MILLER, LOUIS, H., PETERSON, DAVID, S., SIM, KIM, LEE, SU, XIN-ZHUAN, WELLEMS, THOMAS, E.
Applicants: US HEALTH, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, RE
Application year: 1996
Main classification: C07K14
IPC codes: A61K39, C07K14